Autophagy

Autophagy is an intracellular degradation system that delivers cytoplasmic constituents to the lysosome. Autophagy plays a wide variety of physiological and pathophysiological roles. Different selective forms of autophagy have been identified and characterized, leading to the specific degradation of organelles or pathogens. These selective pathways include the autophagic degradation of mitochondria (mitophagy), peroxisomes (pexophagy), endoplasmic reticulum (reticulophagy or ER-phagy), ribosomes (ribophagy), protein aggregates (aggrephagy), lipid droplets (lipophagy), spermatozoon-inherited organelles following fertilization (allophagy), secretory granules within pancreatic cells (zymophagy), or intracellular pathogens (xenophagy).

Autophagy consists of several sequential steps--sequestration, transport to lysosomes, degradation, and utilization of degradation products--and each step may exert different function. Autophagy signal transduction are mainly regulated by autophagy-related genes/proteins, Atgs. ATGs have unveiled much of the machinery of autophagosome formation. Furthermore, different non-ATG proteins are involved in the regulation and process of autophagy, e.g., mTOR, AMPK, AKT, AMBRA1, BCL2, DFCP1, or VPS34.

Autophagy and its dysregulation have been implicated in different human diseases or processes, such as cancer, neurodegeneration, immunity, or aging. Plenty of drugs and natural products are involved in autophagy modulation, either inducing or inhibiting autophagy, through multiple signaling pathways. Small molecules that can regulate autophagy seem to have great potential to modulate the clinical course of neurodegenerative diseases or promote chemotherapeutic response in tumor models. Besides, several clinical drugs and compounds in diabetes are also found to involve regulation of autophagy.

References:

[1] Glick D, et al. J Pathol. 2010 May;221(1):3-12.
[2]. Mizushima N. Genes Dev. 2007 Nov 15;21(22):2861-73.
[3]. Wesselborg S, et al. Cell Mol Life Sci. 2015 Dec;72(24):4721-57.

Target List in Autophagy

Autophagy



Autophagy is a conserved cellular degradation and recycling process in the lysosome. In mammalian cells, there are three primary types of autophagy: microautophagy, macroautophagy, and chaperone-mediated autophagy (CMA). Microphagy captures cargoes by means of invaginations or protrusions of the lysosomal membrane directly, CMA uses chaperones to identify cargo proteins and then unfolds and transfers them into the lysosomal, while macroautophagy sequesters cargo by autophagosomes-de novo synthesized of double-membrane vesicles-and subsequently transport it to the lysosome.

Macroautophagy is the best studied and it occurs at a low level constitutively and can also be further induced under stress conditions, such as nutrient or energy starvation with a salient feature of autophagy protein degradation. Stress-induced macrophagy plays an important role in protein catabolism with another key protein degradation pathway, the ubiquitin–proteasome system (UPS).

As the study progressed, autophagy gains its importance under basal, nutrient-rich conditions, and is now recognized as a critical housekeeping pathway in catabolism of diverse cellular constituents, such as protein aggregates (aggrephagy), lipid droplets (lipophagy), iron complex (Ferritinophagy) and carbohydrate. Except for macromolecules, autophagy can also target several organelles and structures, such as mitochondria (mitophagy), peroxisome (pexophagy), endoplasmic reticulum (reticulophagy or ER-phagy), ribosome (ribophagy), spermatozoon-inherited organelles following fertilization (allophagy), secretory granules within pancreatic cells (zymophagy) and intracellular pathogens (xenophagy).

Autophagy and its dysfunction are associated with a variety of human pathologies, including ageing, cancer, neurodegenerative disease, heart disease and metabolic diseases, such as diabetes. Plenty of drugs and natural products are involved in autophagy modulation through multiple signaling pathways. Small molecules that can regulate autophagy seem to have great potential to intervene such diseases in animal models or clinical courses.

(+)-JQ-1

(JQ1) Cat. No.: HY-13030

Bioactivity: (+)-JQ-1 is a **BET bromodomain** inhibitor, with **IC_{50}**s of 77 and 33 nM for the first and second bromodomain (**BRD4(1/2)**) [1]. (+)-JQ-1 also activates **autophagy** [2].

Purity: 99.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 5 g



(-)-Epicatechin gallate

(ECG; Epicatechin gallate; (-)-Epicatechin 3-O-gallate) Cat. No.: HY-N0002

Bioactivity: Epicatechin gallate inhibits cyclooxygenase-1 (**COX-1**) with an **IC_{50}** of 7.5 μM.

Purity: 98.57%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



(-)-Epigallocatechin

(EGC; Epigallocatechin; l-Epigallocatechin) Cat. No.: HY-N0225

Bioactivity: (-)-Epigallocatechin (EGCG) is the most abundant flavonoid in green tea, can bind to unfolded native polypeptides and prevent conversion to amyloid fibrils.

Purity: 99.16%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



(-)-Epigallocatechin Gallate

(EGCG; Epigallocatechol Gallate) Cat. No.: HY-13653

Bioactivity: (-)-Epigallocatechin Gallate is a tea flavonoid with potent antioxidant, antiinflammatory, and anticarcinogenic properties. (-)-Epigallocatechin Gallate is reported to inhibit **EGFR** signaling and thereby exert anticancer effects.

Purity: 99.91%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



(E)-Daporinad

(FK866; APO866) Cat. No.: HY-50876

Bioactivity: (E)-Daporinad (FK866) is an effective inhibitor of nicotinamide phosphoribosyltransferase (**NMPRTase**) with an **IC_{50}** of 0.09 nM.

Purity: 99.91%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



(R)-(-)-Gossypol

(AT-101; R-(-)-gossypol acetic acid) Cat. No.: HY-15464

Bioactivity: (R)-(-)-Gossypol (AT-101) is the levorotatory isomer of a natural product Gossypol. AT-101 is determined to bind to **Bcl-2**, **Mcl-1** and **Bcl-xL** proteins with **K_i**s of 260±30 nM, 170±10 nM, and 480±40 nM, respectively.

Purity: >98%
Clinical Data: Phase 2
Size: 10 mg, 50 mg



(R)-(-)-Gossypol acetic acid (AT-101 (acetic acid); (-)-Gossypol acetic acid; (R)-Gossypol acetic acid)

Cat. No.: HY-15464A

Bioactivity: (R)-(-)-Gossypol acetic acid (AT-101 (acetic acid)) is the levorotatory isomer of a natural product Gossypol. AT-101 is determined to bind to **Bcl-2**, **Mcl-1** and **Bcl-xL** proteins with **K_i**s of 260±30 nM, 170±10 nM, and 480±40 nM, respectively.

Purity: 97.40%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



2-Methoxyestradiol

(2-ME2; NSC-659853) Cat. No.: HY-12033

Bioactivity: 2-Methoxyestradiol is an **angiogenesis** inhibitor and **apoptosis** inducer with potent antineoplastic activity. 2-Methoxyestradiol also destablize **microtubules**.

Purity: 99.82%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



3,3'-Diindolylmethane

(DIM; Arundine; HB 236) Cat. No.: HY-15758

Bioactivity: 3,3'-Diindolylmethane is a strong, pure **androgen receptor** (AR) antagonist.

Purity: 98.74%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



3-Methyladenine

(3-MA) Cat. No.: HY-19312

Bioactivity: 3-Methyladenine is a **PI3K** inhibitor. 3-Methyladenine is a widely used inhibitor of **autophagy** via its inhibitory effect on class III PI3K.

Purity: 99.84%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 200 mg, 500 mg



3BDO

Cat. No.: HY-U00434

Bioactivity: 3BDO is a new **mTOR** activator which can also inhibit **autophagy**.

Purity: 99.67%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



5-Aminolevulinic acid hydrochloride

(ALA; 5-ALA)

Cat. No.: HY-N0305

Bioactivity: 5-Aminolevulinic acid HCl is an intermediate in heme biosynthesis in the body and the universal precursor of tetrapyrroles. Target: Others 5-Aminolevulinic acid is a non-fluorescent prodrug that leads to intracellular accumulation of fluorescent porphyrins in malignant gliomas-a...

Purity: 98.0%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 100 mg, 1 g, 5 g, 10 g



5-Azacytidine

(Ladakamycin; 5-AzaC; Azacitidine)

Cat. No.: HY-10586

Bioactivity: 5-Azacytidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping **DNA methyltransferases**.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



6-Mercaptopurine

(Mercaptopurine; 6-MP)

Cat. No.: HY-13677

Bioactivity: 6-Mercaptopurine is a purine analogue which acts as an antagonist of the **endogenous purines** and has been widely used as antileukemic agent and immunosuppressive drug.

Purity: 96.0%
Clinical Data: Launched
Size: 50 mg, 100 mg, 500 mg



6-Thioguanine

(Thioguanine2-Amino-6-purinethiol)

Cat. No.: HY-13765

Bioactivity: 6-Thioguanine (Thioguanine) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (**PLpros**) and also potently inhibits **USP2** activity, with **IC_{50}**s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



A-317491

Cat. No.: HY-15568

Bioactivity: A-317491 is a non-nucleotide P2X3 and P2X2/3 receptor antagonist, which inhibits calcium flux mediated by the receptors. IC50 value: Target: P2X2/3 It is known that P2X3 and P2X2/3 receptors stimulate the pronociceptive effects of ATP upon activation. Studies indicate that the P2X3 receptor...

Purity: 99.18%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



A-317491 sodium salt hydrate

Cat. No.: HY-15568A

Bioactivity: A-317491 is a non-nucleotide P2X3 and P2X2/3 receptor antagonist, which inhibits calcium flux mediated by the receptors. IC50 value: Target: P2X2/3 receptor It is known that P2X3 and P2X2/3 receptors stimulate the pronociceptive effects of ATP upon activation. Studies indicate that the P2X3...

Purity: 99.65%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg



A-867744

Cat. No.: HY-12149

Bioactivity: A-867744 is a positive allosteric modulator of α7 nAChRs (IC50 values are 0.98 and 1.12 μM for human and rat α7 receptor ACh-evoked currents respectively, in X. laevis oocytes). Displays no activity at 5-HT3A, α3β4 or α4β2 nAChRs. IC50 value: ~ 1 uM Target: α7 nAChR Target:

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



ABT-737

Cat. No.: HY-50907

Bioactivity: ABT-737 is a selective and BH3 mimetic **Bcl-xL**, **Bcl-2** and **Bcl-w** inhibitor with **EC_{50}**s of 78.7 nM, 30.3 nM and 197.8 nM, respectively.

Purity: 99.59%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



ABT-751

(E7010)

Cat. No.: HY-13270

Bioactivity: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively. IC50 Value: 1.5 μM(neuroblastoma); 3.4 μM(non-neuroblastoma) Target: Microtubule/Tubulin in vitro:...

Purity: 99.87%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Aceglutamide

(α-N-Acetyl-L-glutamine; N2-Acetylglutamine) **Cat. No.:** HY-B1065

Bioactivity: Aceglutamide is a psychostimulant and nootropic, used to improve memory and concentration.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g



Acetazolamide

Cat. No.: HY-B0782

Bioactivity: Acetazolamide is a **carbonic anhydrase** (**CA**) **IX** inhibitor with an **IC_{50}** of 30 nM for **hCA IX** [1]. Diuretic effects [4].

Purity: 99.87%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Acetylcholine chloride

(Ach; ACh chloride) **Cat. No.:** HY-B0282

Bioactivity: Acetylcholine (chloride) is a common **neurotransmitter** found in the central and peripheral nerve system.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Actinomycin D

(Dactinomycin; Actinomycin IV) **Cat. No.:** HY-17559

Bioactivity: Actinomycin D inhibits **DNA repair** with an **IC_{50}** of 0.42 μM.

Purity: 99.89%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



Adenosine

(Adenine riboside; D-Adenosine) **Cat. No.:** HY-B0228

Bioactivity: Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond. Target: Nucleoside antimetabolite/analog Adenosine plays an important role in biochemical processes, such as energy transfer — as adenosine...

Purity: 99.84%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Afatinib

(BIBW 2992) **Cat. No.:** HY-10261

Bioactivity: Afatinib (BIBW 2992) is an irreversible **EGFR** family inhibitor with **IC_{50}**s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^{wt}, EGFR ^{L858R}, EGFR $^{L858R/T790M}$ and HER2, respectively.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Afatinib dimaleate

(BIBW 2992MA2) **Cat. No.:** HY-10261A

Bioactivity: Afatinib dimaleate is an irreversible **EGFR** family inhibitor with **IC_{50}**s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^{wt}, EGFR ^{L858R}, EGFR $^{L858R/T790M}$ and HER2, respectively.

Purity: 99.31%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



AG-490

(Tyrphostin AG 490) **Cat. No.:** HY-12000

Bioactivity: AG-490 is a tyrosine kinase inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.

Purity: 99.84%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



AG1024

(Tyrphostin AG 1024) **Cat. No.:** HY-10253

Bioactivity: AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, less potent to IR with IC50 of 57 μM. IC50 value: 7 uM (IGF-1R autophosphorylation); 57 uM (IR) [1] Target: IGF-1R; IR in vitro: AG-1024 blocks the IGF-1 receptor and IR autophosphorylation with IC50 of 7 μM and 57 μM,...

Purity: 97.16%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



AICAR

(Acadesine; AICA Riboside) **Cat. No.:** HY-13417

Bioactivity: AICAR is a cell-permeable AMP-activated protein kinase (**AMPK**) activator.

Purity: 99.92%
Clinical Data: Phase 3
Size: 10mM x 1mL in Water, 50 mg, 100 mg, 200 mg, 500 mg



AICAR phosphate

(Acadesine phosphate; AICA Riboside phosphate) Cat. No.: HY-13417A

Bioactivity: AICAR phosphate is an activator of AMP-activated protein kinase (**AMPK**).

Purity: 98.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in Water, 50 mg, 100 mg, 200 mg, 500 mg



Alisertib

(MLN 8237) Cat. No.: HY-10971

Bioactivity: Alisertib (MLN 8237) is an oral active and selective **Aurora A kinase** inhibitor with an $\mathbf{IC_{50}}$ of 1.2 nM.

Purity: 99.84%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Aliskiren

(CGP 60536; CGP60536B; SPP 100) Cat. No.: HY-12176

Bioactivity: Aliskiren(CGP 60536) is a direct renin inhibitor with IC50 of 1.5 nM. IC50 value: 1.5 nM [1] Target: renin in vitro: Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core...

Purity: 99.57%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Aliskiren hemifumarate (CGP 60536 (hemifumarate); CGP60536B (hemifumarate); SPP 100 (hemifumarate))

Cat. No.: HY-12177

Bioactivity: Aliskiren hemifumarate(CGP 60536 hemifumarate) is a direct renin inhibitor with IC50 of 1.5 nM. IC50 value: 1.5 nM [1] Target: renin in vitro: Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site...

Purity: 99.47%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg



Alisol A

(Alisol-A) Cat. No.: HY-N0853

Bioactivity: Alisol A is a natural product.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



ALLO-1

Cat. No.: HY-121546

Bioactivity: ALLO-1, an autophagy receptor, is essential for autophagosome formation around paternal organelles and directly binds to the worm LC3 homologue LGG-1 through its LC3-interacting region (LIR) motif [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Aloe emodin

(Rhabarberone; 3-Hydroxymethylchrysazine) Cat. No.: HY-N0189

Bioactivity: Aloe emodin is a hydroxyanthraquinone present in Aloe vera leaves, has a specific in vitro and in vivo antitumor activity. IC50 value: Target: in vitro: aloe-emodin treatment led to the dissociation of heat shock protein 90 (HSP90) and ER α and increased ER α ubiquitination. Protein fractionation...

Purity: 97.70%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg



AM580

(CD336; NSC608001; Ro 40-6055) Cat. No.: HY-10475

Bioactivity: AM580 is a selective **RARα** agonist with $\mathbf{IC_{50}}$ and $\mathbf{EC_{50}}$ of 8 nM and 0.36 nM, respectively.

Purity: 99.41%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Amiodarone

Cat. No.: HY-14187

Bioactivity: Amiodarone is an antiarrhythmic drug for inhibition of ATP-sensitive potassium channel with an IC_{50} of 19.1 μM.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



Amiodarone hydrochloride

Cat. No.: HY-14188

Bioactivity: Amiodarone is an antiarrhythmic drug for inhibition of ATP-sensitive potassium channel with IC50 of 19.1 μM. IC50 Value: 1.5 uM (inhibit TBARS, LOOH and FPL formation)[1] in vitro: It was found that 10 uM amiodarone induces accumulation of ethidium bromide (5 ug/ml) in Saccharomyces cerevisiae...

Purity: 99.82%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Amsacrine
(m-AMSA; acridinyl anisidide) Cat. No.: HY-13551

Bioactivity: Amsacrine (m-AMSA) is an inhibitor of **topoisomerase II**, and acts as an antineoplastic agent which can intercalates into the DNA of tumor cells.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 500 mg



Amsacrine hydrochloride
(m-AMSA hydrochloride; acridinyl anisidide hydrochloride) Cat. No.: HY-13551A

Bioactivity: Amsacrine hydrochloride (mAMSA hydrochloride) is an inhibitor of **topoisomerase II**, and acts as an antineoplastic agent which can intercalates into the DNA of tumor cells.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Ancitabine hydrochloride (Cyclocytidine hydrochloride; Cyclo-CMP hydrochloride; Cyclo-C)
Cat. No.: HY-N0093

Bioactivity: Ancitabine (hydrochloride) is an important antileukemia drugs.

Purity: 98.59%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 200 mg, 1 g



Andrographolide
(Andrographis) Cat. No.: HY-N0191

Bioactivity: Andrographolide is a **NF-κB** inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on **p50** in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation.

Purity: 97.46%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Apatinib
(YN968D1) Cat. No.: HY-13342

Bioactivity: Apatinib is a highly selective **VEGFR2** inhibitor with an **IC_{50}** of 1 nM. Apatinib also potently suppresses the activities of Ret, c-Kit and c-Src with IC_{50}s of 13, 429 and 530 nM, respectively.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Apigenin (4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1)
Cat. No.: HY-N1201

Bioactivity: Apigenin is a competitive **CYP2C9** inhibitor with a **K_i** of 2 μM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Apocynin
(Acetovanillone) Cat. No.: HY-N0088

Bioactivity: Apocynin is a selective **NADPH-oxidase** inhibitor with an **IC_{50}** of 10 μM.

Purity: 99.97%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Arctigenin
((-)-Arctigenin) Cat. No.: HY-N0035

Bioactivity: Arctigenin is a lignan found in certain plants of the Asteraceae; it has shown antiviral and anticancer effects in glass; it is the aglycone of arctiin. IC50 value: Target: anticancer agent Arctiin and its aglucone, arctigenin from the fruits of Arctium lappa L. showed potent in vitro antiviral...

Purity: 99.63%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



AS-605240
Cat. No.: HY-10109

Bioactivity: AS-605240 is a specific and orally active inhibitor of the **PI3Kγ**, with an **IC_{50}** of 8 nM, and a **K_i** of 7.8 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



AS1842856
Cat. No.: HY-100596

Bioactivity: AS1842856, a specific **Foxo1** inhibitor (**IC_{50}**=30 nM), potently suppresses **autophagy** [1]. AS1842856 inhibits FoxO1 activity by suppressing the expression of SIRT1. AS1842856 only reduces the activity of FoxO1 by binding with it, without affect...

Purity: 98.09%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Aspirin

(ASA; Acetylsalicylic Acid) Cat. No.: HY-14654

Bioactivity: Aspirin is a non-selective and irreversible inhibitor of **COX-1** and **COX-2** with **IC_{50}**s of 5 and 210 μg/mL.

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



AT9283

Cat. No.: HY-50514

Bioactivity: AT9283 is a multitargeted kinase inhibitor which potently inhibits **aurora kinase A/B**, **JAK2/3** (**IC_{50}**=1.2 nM, 1.1 nM).

Purity: 99.13%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Atorvastatin hemicalcium salt

(CI-981; Atorvastatin hemicalcium) Cat. No.: HY-17379

Bioactivity: Atorvastatin hemicalcium salt is a potent **HMG-CoA reductase** inhibitor with an **IC_{50}** value of 8 nM.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Atropine sulfate monohydrate

(Atropine sulfate hydrate) Cat. No.: HY-B0394

Bioactivity: Atropine sulfate monohydrate is a competitive muscarinic acetylcholine receptor antagonist. Target: mAChR Atropine is a naturally occurring tropane alkaloid extracted from deadly nightshade (Atropa belladonna), Jimson weed (Datura stramonium), mandrake (Mandragora officinarum) and other...

Purity: 99.62%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Autophinib

Cat. No.: HY-101920

Bioactivity: Autophinib is a potent **autophagy** inhibitor, which can inhibit autophagy induced by starvation or rapamycin by targeting the lipid kinase VPS34 with **IC_{50}**s of 90, 40 and 19 nM, respectively.

Purity: 99.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Avermectin B1

(Abamectin; Avermectin B1a-Avermectin B1b mixt.) Cat. No.: HY-15311

Bioactivity: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. IC50 Value: N/A Target: Antiparasitic Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. These two components, B1a and B1b have very similar biological and...

Purity: 97.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 100 mg



AZ304

Cat. No.: HY-117273

Bioactivity: AZ304 is an ATP-competitive dual **BRAF** kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with **IC_{50}**s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such...

Purity: 99.39%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Azathramycin

(Azaerythromycin A; Desmethyl Azithromycin) Cat. No.: HY-17442

Bioactivity: Azathramycin is an antibiotic.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg



AZD 6482

(KIN 193) Cat. No.: HY-10344

Bioactivity: AZD 6482 is a potent and selective **p110β** inhibitor with **IC_{50}** of 0.69 nM.

Purity: 99.26%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

AZD-3463

(ALK/IGF1R inhibitor) Cat. No.: HY-15609

Bioactivity: AZD-3463 is an ALK/IGF1R inhibitor which overcomes multiple mechanisms of acquired resistance to crizotinib. IC50 Value: Target: ALK/IGF1R

Purity: 98.49%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



AZD-8055

Cat. No.: HY-10422

Bioactivity: AZD-8055 is a novel ATP-competitive inhibitor of **mTOR** kinase with an **IC_{50}** of 0.8 nM. AZD-8055 inhibits both **mTORC1** and **mTORC2**.

Purity: 98.60%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



AZD1208

Cat. No.: HY-15604

Bioactivity: AZD1208 is a novel, orally bioavailable, highly selective **PIM** kinases inhibitor.

Purity: 99.67%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Azithromycin

(CP 62993)

Cat. No.: HY-17506

Bioactivity: Azithromycin is a macrolide antibiotic useful for the treatment of a number of bacterial infections.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Azithromycin hydrate

(CP-62993 dihydrate)

Cat. No.: HY-17506A

Bioactivity: Azithromycin hydrate is a macrolide antibiotic useful for the treatment of a number of bacterial infections.

Purity: >98%
Clinical Data: Launched
Size: 50 mg, 100 mg



Bafetinib

(INNO-406; NS-187)

Cat. No.: HY-50868

Bioactivity: Bafetinib is a **Lyn and Bcr-Abl** tyrosine kinase inhibitor with potential antineoplastic activity.

Purity: 99.80%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Bafilomycin A1

((-)-Bafilomycin A1)

Cat. No.: HY-100558

Bioactivity: Bafilomycin A1, a macrolide antibiotic isolated from the Streptomyces species, is a specific inhibitor of **vacuolar-type H+ ATPase (V-ATPase)**. Bafilomycin A1 inhibits **autophagy** [1].

Purity: 99.0%
Clinical Data: No Development Reported
Size: 100u g



Baicalin

(Baicalein 7-O-β-D-glucuronide)

Cat. No.: HY-N0197

Bioactivity: Baicalin is a flavonoid glycoside isolated from Scutellaria baicalensis. Baicalin reduces the expression of **NF-κB**.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g, 5 g



Bardoxolone methyl

(NSC 713200; RTA 402; CDDO Methyl ester)

Cat. No.: HY-13324

Bioactivity: Bardoxolone methyl (NSC 713200; RTA 402; CDDO Methyl ester) is a synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities, acting as an activator of the **Nrf2** pathway and an inhibitor of the **NF-κB** pathway.

Purity: 99.72%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



BAY 11-7082

(BAY 11-7821)

Cat. No.: HY-13453

Bioactivity: BAY 11-7082 is a **NF-κB** inhibitor which decreases NF-κB by inhibiting TNF-α-induced phosphorylation of IκB-α. BAY 11-7082 inhibits ubiquitin-specific protease **USP7** and **USP21** with **IC_{50}**s of 0.19 μM and 0.96 μM, respectively.

Purity: 99.42%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Belinostat

(PXD101; PX105684)

Cat. No.: HY-10225

Bioactivity: Belinostat is a potent **HDAC** inhibitor with an **IC_{50}** of 27 nM in HeLa cell extracts.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Berbamine dihydrochloride

Cat. No.: HY-N0714A

Bioactivity: Berbamine dihydrochloride is an inhibitor of **NF-κB** activity with remarkable anti-myeloma efficacy.

Purity: 95.98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg



Berberine chloride

(Natural Yellow 18 (chloride))

Cat. No.: HY-18258

Bioactivity: Berberine chloride is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an **antibiotic**. Berberine chloride induces reactive oxygen species (**ROS**) generation and inhibits **DNA topoisomerase**. Antineoplastic properties [1].

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Berberine chloride hydrate

(Natural Yellow 18 (chloride hydrate))

Cat. No.: HY-17577

Bioactivity: Berberine chloride hydrate is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an **antibiotic**. Berberine chloride hydrate induces reactive oxygen species (**ROS**) generation and inhibits **DNA topoisomerase**. Antineoplastic properties [1].

Purity: 99.56%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g



Bergapten

(5-Methoxypsoralen)

Cat. No.: HY-N0370

Bioactivity: Bergapten is a natural anti-inflammatory and anti-tumor agent isolated from bergamot essential oil, other citrus essential oils and grapefruit juice. Bergapten is inhibitory towards mouse and human **CYP** isoforms.

Purity: 99.96%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Bergenin

(Cuscutin)

Cat. No.: HY-N0017

Bioactivity: Bergenin, a polyphenol, is a potent antinarcotic agent with antioxidant action. IC50 value: < 2.5 μM (antiplasmodial) [3] Target: In vitro: The naloxone-precipitated withdrawal symptom (jumping frequency) was significantly ameliorated (50% of control group) by administration of bergenin (20 mg/kg) in...

Purity: 99.50%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg



Betulinic acid

(Lupatic acid; Betulic acid)

Cat. No.: HY-10529

Bioactivity: Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic **topoisomerase I** inhibitor, with an **IC_{50}** of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties.

Purity: 98.18%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Bexarotene

(LGD1069)

Cat. No.: HY-14171

Bioactivity: Bexarotene (LGD1069) is a selective **retinoid X receptors (RXR)** agonist for the treatment of cutaneous T-cell lymphoma.

Purity: 99.81%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



BGT226

(NVP-BGT226)

Cat. No.: HY-13334A

Bioactivity: BGT226 (NVP-BGT226) is a **PI3K** (with **IC_{50}**s of 4 nM, 63 nM and 38 nM for **PI3Kα**, **PI3Kβ** and **PI3Kγ**)/ **mTOR** dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells [1] [2].

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



BGT226 maleate

(NVP-BGT226 (maleate))

Cat. No.: HY-13334

Bioactivity: BGT226 maleate (NVP-BGT226 maleate) is a **PI3K** (with **IC_{50}**s of 4 nM, 63 nM and 38 nM for **PI3Kα**, **PI3Kβ** and **PI3Kγ**) / **mTOR** dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells [1] [2].

Purity: 99.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



BI-D1870

Cat. No.: HY-10510

Bioactivity: BI-D1870 is an ATP-competitive inhibitor of **RSK** isoforms, with **IC_{50}**s of 31 nM/24 nM/18 nM/15 nM for RSK1/SK2/SK3/SK4, respectively.

Purity: 99.60%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg



Bicalutamide

Cat. No.: HY-14249

Bioactivity: Bicalutamide is a non-steroidal **androgen receptor** inhibitor.

Purity: 99.61%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg, 1 g, 5 g



Bicyclol

(SY801)

Cat. No.: HY-B0766

Bioactivity: Bicyclol(SY 801) is a anti-hepatitis drug. Target: HBV Oral administration of bicyclol normalized the elevated serum transaminases (ALT, AST) by approximately 50% in chronic viral hepatitis B and C, and also showed certain level of inhibiting HBV and HCV replication. No noticeable adverse reaction has...

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



BIIB021

(CNF2024)

Cat. No.: HY-10212

Bioactivity: BIIB021 is an orally available, fully synthetic inhibitor of **HSP90** with K_i and EC_{50} of 1.7 nM and 38 nM, respectively.

Purity: 99.93%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Bilobalide

((-)-Bilobalide)

Cat. No.: HY-N0076

Bioactivity: Bilobalide is a biologically active terpenic trilactone present in Ginkgo biloba. An increasing number of studies have demonstrated its neuroprotective effects. IC50 Value: 3.33 (pIC50 Value) [1] Target: neuroprotective in vitro: Inhibition by BB and GB was abolished in mutant receptors containing T6'S...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Binimetinib

(MEK162; ARRY-162; ARRY-438162)

Cat. No.: HY-15202

Bioactivity: Binimetinib (MEK162) is an oral and selective **MEK1/2** inhibitor with an IC_{50} of 12 nM.

Purity: 98.61%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Bisdemethoxycurcumin

(Curcumin III; Didemethoxycurcumin)

Cat. No.: HY-N0007

Bioactivity: Bisdemethoxycurcumin(Curcumin III; Didemethoxycurcumin) is a natural derivative of curcumin with anti-inflammatory and anti-cancer activities. IC50 value: Target: Anticancer natural compound in vitro: BDMC-induced apoptosis was mediated by a combinatory inhibition of cytoprotective proteins, such as...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

BIX-01294

Cat. No.: HY-10587

Bioactivity: BIX-01294 is an inhibitor of **G9a Histone Methyltransferase** with an IC_{50} of 1.9 μM. BIX-01294 also inhibits ATF3 expression.

Purity: 98.61%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Bortezomib (PS-341; Brotezamide; DPBA; LDP 341; MG 341; Radiciol; NSC 681239)

Cat. No.: HY-10227

Bioactivity: Bortezomib (PS-341) is a potent **20S proteasome** inhibitor with a K_i of 0.6 nM.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Bosutinib

(SKI-606)

Cat. No.: HY-10158

Bioactivity: Bosutinib is a dual **Src/Abl** inhibitor with IC_{50}s of 1.2 nM and 1 nM, respectively.

Purity: 99.83%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



BRD5631

Cat. No.: HY-125197

Bioactivity: BRD5631 is an **autophagy** enhancer, enhances **autophagy** through an mTOR-independent pathway. BRD5631 affects several cellular disease phenotypes previously linked to autophagy, including protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production [1].

Purity: >98%
Clinical Data: No Development Reported
Size:



Brefeldin A

(BFA; Cyanein; Decumbin) Cat. No.: HY-16592

Bioactivity: Brefeldin A is a specific inhibitor of **protein trafficking** which blocks the protein transport from the endoplasmic reticulum to the Golgi complex.

Purity: 99.79%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Brivanib

(BMS-540215) Cat. No.: HY-10337

Bioactivity: Brivanib is an ATP-competitive inhibitor against **VEGFR2** with **IC_{50}** of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β.

Purity: 99.37%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Brivanib alaninate

(BMS-582664) Cat. No.: HY-10336

Bioactivity: Brivanib alaninate is an ATP-competitive inhibitor against **VEGFR2** with an **IC_{50}** of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ.

Purity: 99.76%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Bromhexine hydrochloride

Cat. No.: HY-B0372A

Bioactivity: Bromhexine Hydrochloride is a medication prescribed for coughs which works by dissolving hard phlegm. Target: Others Bromhexine is a mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. In addition, bromhexine has antioxidant properties....

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 g



Bromocriptine mesylate

(CB-154) Cat. No.: HY-12705A

Bioactivity: Bromocriptine mesylate is a potent **dopamine D2/D3 receptor** agonist, which binds D2 dopamine receptor with **pK_i** of 8.05±0.2.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



Butein

(2′,3,4,4′-tetrahydroxy Chalcone) Cat. No.: HY-16558

Bioactivity: Butein, a plant polyphenol isolated from Rhus verniciflua, inhibit the activation of protein tyrosine kinase and EGFR. target: EGFR [1] In vitro: 1) Butein inhibited the activation of AKT, extracellular signal-regulated kinase (ERKs) and p38 kinases in the presence of cisplatin.[2] 2) FoxO3a and its...

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



C646

Cat. No.: HY-13823

Bioactivity: C646 is a selective and competitive **histone acetyltransferase p300** inhibitor with **K_i** of 400 nM, and is less potent for other acetyltransferases.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



CA-5f

Cat. No.: HY-112698

Bioactivity: CA-5f is a potent late-stage **macroautophagy/autophagy** inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II (a marker to monitor autophagy) and SQSTM1 protein both in A549 cells and HUVECs. Anti-tumor activity [1].

Purity: 99.12%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Cabazitaxel

(XRP6258; RPR-116258A; taxoid XRP6258) Cat. No.: HY-15459

Bioactivity: Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Cabergoline

(FCE-21336) Cat. No.: HY-15296

Bioactivity: Cabergoline is an ergot derived-dopamine D_2-like receptor agonist that has high affinity for **D_2**, **D_3**, and **5-HT_{2B}** receptors (**K_i**=0.7, 1.5, and 1.2, respectively).

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Calcineurin substrate

Cat. No.: HY-P0228

Bioactivity: Calcineurin substrate is a peptide from the regulatory RII subunit of cAMP-dependent protein kinase. It can be used in the calcineurin activity assay.

Purity: >98%
Clinical Data: No Development Reported
Size: 500u g, 1 mg, 5 mg

DLDVPIPGRFDRRVSVAAE

Capivasertib

(AZD5363)

Cat. No.: HY-15431

Bioactivity: Capivasertib (AZD5363) is a potent **pan-AKT** kinase inhibitor with **IC_{50}** of 3, 7 and 7 nM for **Akt1**, **Akt2** and **Akt3**, respectively.

Purity: 99.71%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Capsaicin

((E)-Capsaicin; 8-Methyl-N-vanillyl-trans-6-nonenamide)

Cat. No.: HY-10448

Bioactivity: Capsaicin is a **TRPV1** agonist with an **EC_{50}** of 0.29 μM in HEK293 cells.

Purity: 98.39%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Carbamazepine

(CBZ; NSC 169864)

Cat. No.: HY-B0246

Bioactivity: Carbamazepine, a sodium channel blocker, is an anticonvulsant drug. Target: Sodium channel Carbamazepine inhibits the binding of [3H]batrachotoxinin A 20-α-benzoate (BTX-B) to a receptor site of voltage-sensitive sodium channel with IC50 of 131 μM, to decrease the activation of sodium channel ion flux...

Purity: 99.35%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Carboplatin

(NSC 241240)

Cat. No.: HY-17393

Bioactivity: Carboplatin (NSC 241240) is a **DNA synthesis** inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent.

Purity: 99.93%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



Carfilzomib

(PR-171)

Cat. No.: HY-10455

Bioactivity: Carfilzomib is an irreversible **proteasome** inhibitor with an **IC_{50}** of 5 nM in ANBL-6 and RPMI 8226 cells.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Carvedilol

(BM 14190)

Cat. No.: HY-B0006

Bioactivity: Carvedilol(BM14190) is a non-selective beta blocker/alpha-1 blocker with an IC50 of 3.8 μM for inhibition of LDL oxidation. IC50 Value: 3.8 μM (inhibition of LDL oxidation) Target: beta Adrenergic Receptor Carvedilol is a nonselective-blocking agent and is used in the treatment of...

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



CCT128930

Cat. No.: HY-13260

Bioactivity: CCT128930 is a potent and selective inhibitor of **Akt2** (**IC_{50}** 6 nM) with 28-fold selectivity over the closely related PKA kinase (IC_{50} 168 nM), as well as 20-fold selectivity over p70S6K (IC_{50} 120 nM).

Purity: 99.15%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Cediranib

(AZD2171)

Cat. No.: HY-10205

Bioactivity: Cediranib (AZD2171) is a highly potent, orally available **VEGFR** tyrosine kinase inhibitor with **IC_{50}**s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

Purity: 99.58%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Cediranib maleate

(AZD-2171 maleate)

Cat. No.: HY-13049

Bioactivity: Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available **VEGFR** inhibitor with **IC_{50}**s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

Purity: 96.67%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



CGI-1746

Cat. No.: HY-11999

Bioactivity: CGI-1746 is a potent and highly selective inhibitor of the **Btk** with **IC_{50}** of 1.9 nM.

Purity: 97.40%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Chelerythrine Chloride

Cat. No.: HY-12048

Bioactivity: Chelerythrine Chloride is a potent, cell-permeable inhibitor of **protein kinase C**, with an **IC_{50}** of 660 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



CHIR-99021

(CT99021)

Cat. No.: HY-10182

Bioactivity: CHIR-99021 is a **GSK-3α/β** inhibitor with an **IC_{50}** of 10 and 6.7 nMshowing 500-fold selectivity over its closest homologs CDC2 and ERK2, as well as other protein kinases.

Purity: 98.68%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



CHIR-99021 monohydrochloride

(CT99021 monohydrochloride)

Cat. No.: HY-10182A

Bioactivity: CHIR-99021 monohydrochloride is a **GSK-3α/β** inhibitor with **IC_{50}** of 10 nM/6.7 nM; > 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases.

Purity: 99.93%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



CHIR-99021 trihydrochloride

(CT99021 trihydrochloride)

Cat. No.: HY-10182B

Bioactivity: CHIR-99021 trihydrochloride is a **GSK-3α/β** inhibitor with **IC_{50}** of 10 nM/6.7 nM; > 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases.

Purity: 97.93%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Chloroquine diphosphate

Cat. No.: HY-17589

Bioactivity: Chloroquine (diphosphate) is an antimalarial and anti-inflammatory drug widely used to treat malaria and rheumatoid arthritis. Chloroquine is an inhibitor of **autophagy** and **toll-like receptors (TLRs)**.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg



Chlorpromazine hydrochloride

Cat. No.: HY-B0407A

Bioactivity: Chlorpromazine Hydrochloride is an antagonist of the **dopamine D2**, **5HT2A**, **potassium channel** and **sodium channel**. Chlorpromazine binds with D2 and 5HT2A with **K_i**s of 363 nM and 8.3 nM, respectively.

Purity: 99.83%
Clinical Data: Launched
Size: 1 g, 5 g



Ciclopirox

(HOE296b)

Cat. No.: HY-B0450

Bioactivity: Ciclopirox (Penlac) is a synthetic antifungal agent. Target: Antifungal Ciclopirox is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. It is most useful against Tinea versicolor. The mechanism of action of ciclopirox is poorly understood [1]. However, loss of...

Purity: 98.76%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Cilengitide

(EMD 121974)

Cat. No.: HY-16141

Bioactivity: Cilengitide is a potent and selective **integrin** inhibitor for α $_v$β $_3$ and α $_v$β $_5$ receptor, with **IC_{50}**s of 4 and 79 nM, respectively.

Purity: 99.06%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Cilostazol

(OPC 13013; OPC 21)

Cat. No.: HY-17464

Bioactivity: Cilostazol(OPC 13013; OPC 21) is a potent inhibitor of PDE3A, the isoform of PDE 3 in the cardiovascular system (IC50=0.2 uM). IC50 Value: 0.2 uM [1] Target: PDE3A in vitro: Cilostazol caused a concentration-dependent increase in the cAMP level in rabbit and human platelets with similar potency. Furthermore,...

Purity: 99.34%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Cinobufagin
(Cinobufagine) **Cat. No.:** HY-N0421

Bioactivity: Cinobufagin, a kind of Chinese materia medica with antitumor effect, is widely used in clinical practice, especially in anti-liver cancer. IC50 value: Target: In vitro: Cinobufagin inhibited proliferation of cancer cells at doses of 0.1, 1, or 10 μM after 2–4 days of culture. Cytotoxicity of cinobufagin...
Purity: 98.05%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Cisatracurium besylate
(51W89) **Cat. No.:** HY-13596

Bioactivity: Cisatracurium Besylate (51W89) is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission.
Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 25 mg, 50 mg, 100 mg



Citalopram hydrobromide
((±)-Citalopram hydrobromide; Lu 10-171) **Cat. No.:** HY-B1287

Bioactivity: Citalopram hydrobromide is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class. It has US FDA approval to treat major depression.
Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Clarithromycin
Cat. No.: HY-17508

Bioactivity: Clarithromycin is a macrolide antibiotic and a CYP3A4 inhibitor. Target: Antibacterial; CYP3A4 Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias...
Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Clemastine fumarate
(HS-592 (fumarate); Meclastine (fumarate)) **Cat. No.:** HY-B0298A

Bioactivity: Clemastine (fumarate) (HS-592 (fumarate)) is a selective histamine H1 receptor antagonist with IC $_{50}$ of 3 nM.
Purity: 99.82%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Clioquinol
(Iodochlorhydroxyquin) **Cat. No.:** HY-14603

Bioactivity: Clioquinol(Iodochlorhydroxyquin) is an antifungal drug and antiprotozoal compound that shows effectivity for Alzheimer's disease treatment and induce cancer cell death.
Purity: 98.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Clofarabine
Cat. No.: HY-A0005

Bioactivity: Clofarabine(Clolar; Clofarex) inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase. IC50 Value: 65 nM Target: in vitro: Clofarabine is a second generation purine nucleoside analog with antineoplastic activity. It is phosphorylated intracellularly,...
Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Clotrimazole
Cat. No.: HY-10882

Bioactivity: Clotrimazole is an imidazole derivative, an antifungal compound and is a CYP (cytochrome P450) inhibitor. Target: Antifungal; CYP Clotrimazole (brand name Canesten or Lotrimin) is an antifungal medication commonly used in the treatment of fungal infections (of both humans and other animals) such as...
Purity: 99.62%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g



Colchicine
Cat. No.: HY-16569

Bioactivity: Colchicine is a **tubulin** inhibitor and a **microtubule** disrupting agent. Colchicine inhibits microtubule polymerization with an **IC$_{50}$** of 3 nM.
Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg



Colistin sulfate
(Polymyxin E Sulfate) **Cat. No.:** HY-A0089

Bioactivity: Colistin sulfate is a polypeptide antibiotic which inhibits **gram-negative bacteria** by binding to lipopolysaccharides and phospholipids in the outer cell membrane of gram-negative bacteria.
Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Cordycepin
(3'-Deoxyadenosine) Cat. No.: HY-N0262

Bioactivity: Cordycepin, which is a nucleoside derivative isolated from Cordyceps, inhibits IL-1β-induced **MMP-1** and **MMP-3** expression in rheumatoid arthritis synovial fibroblasts (RASFs) in a dose-dependent manner.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg



Corosolic acid
(Colosolic acid; Corsolic acid; Glucosol) Cat. No.: HY-N0280

Bioactivity: Corosolic acid isolated from the fruit of Cratoegus pinnatifida var. psilosa, was reported to have anticancer activity.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Corynoxine
Cat. No.: HY-N0901

Bioactivity: Corynoxine is an enantiomer of Corynoxine B; induces autophagy in different neuronal cell lines, including N2a and SHSY-5Y cells.

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Corynoxine B
Cat. No.: HY-N0901A

Bioactivity: Corynoxine B is an oxindole alkaloid isolated from Uncaria rhynchophylla (Miq.) Jacks (Gouteng in Chinese); a Beclin-1-dependent autophagy inducer.

Purity: 99.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Crenolanib
(CP-868596) Cat. No.: HY-13223

Bioactivity: Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases **FLT3** and **PDGFRα/β** with K_ds of 0.74 nM and 2.1 nM/3.2 nM, respectively.

Purity: 99.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Cresol (Cresol mixture of isomers; Hydroxytoluene; Tricresol; Methylphenol)
Cat. No.: HY-B0969

Bioactivity: Cresol is organic compoundis a widely occurring natural and manufactured group of aromatic organic compounds.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 g



Crizotinib
(PF-02341066) Cat. No.: HY-50878

Bioactivity: Crizotinib is a potent inhibitor of **c-Met** and **ALK** with an **IC_{50}** of 11 nM and 24 nM in cell-based assays, respectively.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Crizotinib hydrochloride
(PF-02341066 hydrochloride) Cat. No.: HY-50878A

Bioactivity: Crizotinib hydrochloride is a potent inhibitor of **c-Met** and **ALK** with **IC_{50}**s of 11 nM and 24 nM in cell-based assays, respectively.

Purity: 99.86%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Cryptotanshinone
(Cryptotanshinon; Tanshinone c) Cat. No.: HY-N0174

Bioactivity: Cryptotanshinone is a natural compound extracted from the root of Salvia miltiorrhiza Bunge that shows antitumor activities. Cryptotanshinone inhibits **STAT3** with an **IC_{50}** of 4.6 μM.

Purity: 98.51%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Cucurbitacin B
Cat. No.: HY-N0416

Bioactivity: Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids; could repress cancer cell progression. IC50 value: Target: anticancer natural compound in vitro: Cucurbitacin-B inhibited growth and modulated expression of cell-cycle regulators in SHSY5Y cells. At the...

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Cucurbitacin E

(α-Elaterin; α-Elaterine) **Cat. No.:** HY-N0417

Bioactivity: Cucurbitacin E is a natural compound which from the climbing stem of Cucumic melo L. Cucurbitacin E significantly suppresses the activity of the **cyclin B1**/ **CDC2** complex.

Purity: 99.30%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Curcumin

(Turmeric yellow; Natural Yellow 3; Diferuloylmethane) **Cat. No.:** HY-N0005

Bioactivity: Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (**HATs**) and also shows inhibitory effects on **NF-κB** and...

Purity: 99.66%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



CX546

Cat. No.: HY-12505

Bioactivity: CX546 is a selective positive AMPAR modulator; the prototypical ampakine agent. IC50 value: Target: AMPAR agonist in vitro: Treatments with the ampakine CX614 markedly and reversibly increased brain-derived neurotrophic factor (BDNF) mRNA and protein levels in cultured rat entorhinal/hippocampal...

Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



Cycloheximide

(Naramycin A; Actidione; CHX) **Cat. No.:** HY-12320

Bioactivity: Cycloheximide (Naramycin A) is an eukaryote **protein synthesis** inhibitor, with **IC_{50}**s of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively.

Purity: 99.45%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg



Cysteamine hydrochloride (β-Mercaptoethylamine Hydrochloride; 2-Aminoethanethiol Hydrochloride; ...)

Cat. No.: HY-77591

Bioactivity: Cysteamine Hydrochloride is an agent for the treatment of nephropathic cystinosis and an antioxidant. Target: Others Cysteamine has been shown to increase intracellular glutathione levels in cystinotic cells, thus restoring the altered redox state of the cells. Also increased rates of...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g



Cytarabine (Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C)

Cat. No.: HY-13605

Bioactivity: Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits **DNA polymerase**. Cytarabine inhibits **DNA synthesis** with an **IC_{50}** of 16 nM.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g



Cytarabine hydrochloride (Cytosine β-D-arabinofuranoside hydrochloride; Cytosine Arabinoside hydrochloride; ...)

Cat. No.: HY-13605A

Bioactivity: Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits **DNA polymerase**. Cytarabine inhibits **DNA synthesis** with an **IC_{50}** of 16 nM.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



D-Glutamine

Cat. No.: HY-100587

Bioactivity: D-Glutamine is a cell-permeable D type stereoisomer of Glutamine.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 50 mg, 100 mg



D4476

(Casein Kinase I Inhibitor) **Cat. No.:** HY-10324

Bioactivity: D4476 is a potent, selective and cell-permeable inhibitor of casein kinase 1(**CK1**) with an **IC_{50}** value of 0.3 μM in vitro.

Purity: 99.64%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Dacinostat

(NVP-LAQ824; LAQ824) **Cat. No.:** HY-13606

Bioactivity: Dacinostat is a potent **HDAC** inhibitor, with an **IC_{50}** of 32 nM; Dacinostat also inhibits **HDAC1** with an **IC_{50}** of 9 nM, and used in cancer research.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Dactolisib

(BEZ235; NVP-BEZ235) **Cat. No.:** HY-50673

Bioactivity: Dactolisib (BEZ235) is a dual pan-class I **PI3K** and **mTOR** kinase inhibitor with **IC_{50}**s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for **p110α/ p110γ/ p110δ/ p110β** and **mTOR**, respectively. Dactolisib (BEZ235) inhibits both **mTORC1** and **mTORC2**.

Purity: 99.13%
Clinical Data: Phase 2
Size: 50 mg, 100 mg, 200 mg, 500 mg



Dactolisib Tosylate

(BEZ235 (Tosylate); NVP-BEZ 235 (Tosylate)) **Cat. No.:** HY-15174

Bioactivity: Dactolisib (BEZ235) Tosylate is a dual **PI3K** and **mTOR** kinase inhibitor with **IC_{50}** values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib (BEZ235) Tosylate inhibits **mTORC1** and **mTORC2**.

Purity: 99.89%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Danshensu

(Dan shen suan A; Salvianic acid A) **Cat. No.:** HY-N1913

Bioactivity: Danshensu, an active ingredient of Salvia miltiorrhiza, shows wide cardiovascular benefit by activating **Nrf2** signaling pathway.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg



Danshensu sodium salt

(Sodium Danshensu; (±)-DanShenSu sodium sal) **Cat. No.:** HY-N0106

Bioactivity: Danshensu (sodium salt) is odium salt of danshensu from the widely used Chinese herb Danshen. It can inhibited phenylephrine- and CaCl2-induced vasoconstriction in Ca2+-free medium. In vitro: Sodium danshensu showed a biphasic effects on vessel tension. While low dosage of sodium danshensu...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg, 200 mg



Danthron

(Dantron; Chrysazin; 1,8-Dihydroxyanthraquinone) **Cat. No.:** HY-B0923

Bioactivity: Danthron is a natural product extracted from the traditional Chinese medicine rhubarb. Danthron functions in regulating glucose and lipid metabolism by activating **AMPK**.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Dantrolene sodium hemiheptahydrate

(Dantrolene sodium hydrate) **Cat. No.:** HY-12542A

Bioactivity: Dantrolene sodium hemiheptahydrate is a skeletal muscle relaxant which acts by blocking muscle contraction beyond the neuromuscular junction. Dantrolene sodium hemiheptahydrate is a inhibitor of calcium channel proteins, inhibiting the release of Ca2+ from the sarcoplasm.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Danusertib

(PHA-739358) **Cat. No.:** HY-10179

Bioactivity: Danusertib is a pyrrolo-pyrazole and **aurora kinase** inhibitor with **IC_{50}** of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

Purity: 99.44%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Daphnetin

(7,8-Dihydroxycoumarin) **Cat. No.:** HY-N0281

Bioactivity: Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative isolated from plants of the Genus Daphne, is a **protein kinase** inhibitor, with **IC_{50}s** of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively [1] [2]. Daphne...

Purity: 99.55%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



DAPT

(GSI-IX) **Cat. No.:** HY-13027

Bioactivity: DAPT is a **γ-secretase** inhibitor with **IC_{50}**s of 115 and 200 nM for total Aβ and Aβ42, respectively.

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Dasatinib

(BMS-354825) **Cat. No.:** HY-10181

Bioactivity: Dasatinib (BMS-354825) is a dual **Bcr-Abl** and **Src** family tyrosine kinase inhibitor with **IC_{50}**s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-Kit ^{D816V}, respectively.

Purity: 99.84%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Dasatinib hydrochloride
(BMS 354825 hydrochloride) Cat. No.: HY-10181A

Bioactivity: Dasatinib hydrochloride is a potent and dual **Abl^{WT}/ Src** inhibitor **IC_{50}** of 0.6 nM/0.8 nM respectively; also inhibits **c-Kit^{WT}/ c-Kit^{D816V}** with **IC_{50}** of 79 nM/37 nM.

Purity: 98.84%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Daunorubicin
(RP 13057; Daunomycin; Rubidomycin) Cat. No.: HY-13062A

Bioactivity: Daunorubicin (RP 13057, Daunomycin, Rubidomycin) is a **topoisomerase II** inhibitor with potent antineoplastic activities. Daunorubicin inhibites **DNA and RNA synthesis** in sensitive and resistant Ehrlich ascites tumor cells.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Daunorubicin Hydrochloride (RP 13057 (Hydrochloride); Daunomycin (Hydrochloride); Rubidomycin (Hydrochloride)) Cat. No.: HY-13062

Bioactivity: Daunorubicin Hydrochloride is a **topoisomerase II** inhibitor with potent antineoplastic activities. Daunorubicin Hydrochloride inhibites **DNA and RNA synthesis** in sensitive and resistant Ehrlich ascites tumor cells.

Purity: 99.27%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Daurisoline
((R,R)-Daurisoline) Cat. No.: HY-N0221

Bioactivity: Daurisoline is a **hERG** inhibitor and also an **autophagy** blocker.

Purity: 98.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



DBeQ
(JRF 12) Cat. No.: HY-15945

Bioactivity: DBeQ is a selective, potent, reversible, and ATP-competitive **p97** inhibitor, with an **IC_{50}** value of 1.5 μM and 1.6 μM for p97(wt) and p97(C522A), respectively; DBeQ also inhibits **Vps4** with an **IC_{50}** of 11.5 μM.

Purity: 98.84%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



DC661
Cat. No.: HY-111621

Bioactivity: DC661 is a potent palmitoyl-protein thioesterase 1 (**PPT1**) inhibitor, inhibits **autophagy**, and acts as an anti-lysosomal agent. Anti-cancer activity [1].

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Deferoxamine mesylate
(Desferrioxamine B mesylate; DFOM) Cat. No.: HY-B0988

Bioactivity: Deferoxamine mesylate is an iron chelator that binds free iron in a stable complex, preventing it from engaging in chemical reactions.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Deforolimus
(AP23573; MK-8669; Ridaforolimus) Cat. No.: HY-50908

Bioactivity: Deforolimus (AP23573; MK-8669) is a potent and selective **mTOR** inhibitor; inhibits ribosomal protein S6 phosphorylation with an **IC_{50}** of 0.2 nM in HT-1080 cells.

Purity: 98.46%
Clinical Data: Phase 3
Size: 10 mg, 50 mg



Degrasyn
(WP1130) Cat. No.: HY-13264

Bioactivity: Degrasyn (WP1130) is a cell-permeable **deubiquitinase (DUB)** inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. Degrasyn has been shown to downregulate the antiapoptotic proteins **Bcr-Abl** and **JAK2**.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Deguelin
((-)-Deguelin; (-)-cis-Deguelin) Cat. No.: HY-13425

Bioactivity: Deguelin, a naturally occurring rotenoid, is a potent **PI3K/AKT** inhibitor.

Purity: 99.56%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Demethoxycurcumin

(Curcumin II; Desmethoxycurcumin; Monodemethoxycurcumin) **Cat. No.:** HY-N0006

Bioactivity: Demethoxycurcumin(Curcumin II) is a major active curcuminoid; possess anti-inflammatory properties; also exert cytotoxic effects in human cancer cells via induction of apoptosis. IC50 value: Target: in vitro: DMC significantly decreased NO secretion by 35-41% in our inflamed cell model. Decrease in NO...

Purity: 99.09%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Dexamethasone

(Hexadecadrol; Prednisolone F) **Cat. No.:** HY-14648

Bioactivity: Dexamethasone is a **glucocorticoid receptor** agonist.

Purity: 99.86%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 1 g, 5 g



Dexamethasone acetate

(Dexamethasone 21-acetate) **Cat. No.:** HY-14648A

Bioactivity: Dexamethasone acetate is a **glucocorticoid receptor** agonist.

Purity: 97.68%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 1 g, 5 g



Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride)

Cat. No.: HY-17034A

Bioactivity: Dexmedetomidine Hydrochloride is an agonist of adrenergic alpha-2 receptor, which is used in veterinary medicine for its analgesic and sedative properties. Target: Adrenergic alpha-2 Receptor Dexmedetomidine, acting at alpha(2A) adrenoceptors, must be present during the encoding process to decrease...

Purity: 98.0%

Clinical Data: Launched

Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg



Diazoxide

(Sch-6783; SRG-95213) **Cat. No.:** HY-B1140

Bioactivity: Diazoxide is an ATP-sensitive **potassium channel** activator ; can be used to treat hyperinsulinism.

Purity: 99.99%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 100 mg



Dienogest

(STS 557) **Cat. No.:** HY-B0084

Bioactivity: Dienogest(STS-557) is a specific progesterone receptor agonist with potent oral endometrial activity and is used in the treatment of endometriosis. Target: progesterone receptor agonist Dienogest is an orally active synthetic progesterone (or progestin). It is available for use as an oral...

Purity: 99.70%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Dihydroartemisinin

(Dihydroqinghaosu; β-Dihydroartemisinin; Artenimol) **Cat. No.:** HY-N0176

Bioactivity: Dihydroartemisinin is a potent **anti-malaria** agent.

Purity: 99.03%

Clinical Data: Phase 4

Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Dihydromyricetin

(Ampeloptin; Ampelopsin) **Cat. No.:** HY-N0112

Bioactivity: Dihydromyricetin is a potent inhibitor with an **IC_{50}** of 48 μM on **dihydropyrimidinase**. Dihydromyricetin can activate autophagy through inhibiting **mTOR** signaling. Dihydromyricetin suppresses the formation of mTOR complexes (**mTORC1**/ **2**).

Purity: 99.54%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Dioscin

(Collettiside III; CCRIS 4123) **Cat. No.:** HY-N0124

Bioactivity: Dioscin(CCRIS 4123; Collettiside III) is a natural steroid saponin derived from several plants, showing potent anti-cancer effect against a variety of tumor cell lines. IC50 value: Target: Anticancer agent in vitro: dioscin (1, 2 and 4 μmol/L) could significantly inhibit the viability of LNCaP...

Purity: 98.0%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



DMH-1

Cat. No.: HY-12273

Bioactivity: DMH-1 is a potent and selective **BMP** inhibitor with **IC_{50}**s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.

Purity: 99.58%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



DMOG
(Dimethyloxallyl Glycine) Cat. No.: HY-15893

Bioactivity: DMOG (Dimethyloxallyl Glycine) is a cell-permeable and competitive inhibitor of **HIF-1α prolyl hydroxylase (HIF-PH)**.

Purity: 99.15%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Dorsomorphin
(BML-275; Compound C) Cat. No.: HY-13418A

Bioactivity: Dorsomorphin (BML-275; Compound C) is a potent and selective **AMPK** inhibitor, that is competitive with ATP, with K_i=109 nM in the absence of AMP [1]. Dorsomorphin inhibits BMP pathway by targeting the type I receptors **ALK2**, **ALK3**, ...

Purity: 99.65%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg



Dorsomorphin dihydrochloride
(BML-275 dihydrochloride; Compound C dihydrochloride) Cat. No.: HY-13418

Bioactivity: Dorsomorphin dihydrochloride (BML-275 dihydrochloride; Compound C dihydrochloride) is a potent, selective and ATP-competitive **AMPK** inhibitor, with a K_i of 109 nM [1]. Dorsomorphin dihydrochloride inhibits BMP pathway by target...

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg



Doxazosin mesylate
(UK 33274 mesylate) Cat. No.: HY-B0098A

Bioactivity: Doxazosin mesylate(UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. Target: α1-adrenergic receptor Doxazosin (mesylate) is the mesylate salt form of doxazosin, which is a long-lasting inhibitor of α1-adrenoceptors that is widely used to treat...

Purity: 98.60%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 500 mg, 1 g



Doxorubicin
(Hydroxydaunorubicin) Cat. No.: HY-15142A

Bioactivity: Doxorubicin is a cytotoxic anthracycline antibiotic for the treatment of multiple cancers. The possible mechanisms by which doxorubicin acts in the cancer cell are intercalation into DNA and disruption of **topoisomerase-II**-mediated DNA repair.

Purity: >98%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg



Doxorubicin hydrochloride
(Hydroxydaunorubicin (hydrochloride)) Cat. No.: HY-15142

Bioactivity: Doxorubicin hydrochloride is a cytotoxic anthracycline antibiotic for the treatment of multiple cancers. The possible mechanisms by which doxorubicin acts in the cancer cell are intercalation into DNA and disruption of **topoisomerase-II**-mediated DNA repair.

Purity: 99.47%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Dronedarone
(SR 33589) Cat. No.: HY-A0016

Bioactivity: Dronedarone (SR 33589) is a newer therapeutic agent with a structural resemblance to amiodarone and a better side effect profile; it is a multichannel blocker with antiadrenergic properties and has been evaluated in both rate and rhythm control strategies in the management of AF.

Purity: 99.49%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Dronedarone Hydrochloride
Cat. No.: HY-75839

Bioactivity: Dronedarone hydrochloride is a non-iodinated amiodarone derivative that inhibits **Na^+**, **K^+** and **Ca^{2+}** currents.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Dynasore
Cat. No.: HY-15304

Bioactivity: Dynasore is a cell-permeable **dynamin** inhibitor with an **IC_{50}** of 15 μM.

Purity: 99.61%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



E-64
(Proteinase inhibitor E 64) Cat. No.: HY-15282

Bioactivity: E-64 is a potent irreversible inhibitor against general **cysteine proteases** with **IC_{50}** of 9 nM for **papain**.

Purity: 99.62%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Ebselen

(SPI-1005; PZ-51; CCG-39161) Cat. No.: HY-13750

Bioactivity: Ebselen is a small-molecule capsid Inhibitor of HIV-1 replication. Target: Ebselen is an organoselenium compound, as an inhibitor of HIV-1 capsid CTD dimerization. Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process. [1]...

Purity: 99.58%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



Efavirenz

(DMP 266; EFV; L-743726) Cat. No.: HY-10572

Bioactivity: Efavirenz is a potent inhibitor of the wild-type **HIV-1 reverse transcriptase** with a K_i of 2.93 nM and exhibits an IC_{95} of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Elaiophylin

(Azalomycin B; Gopalamicin; Efomycin E) Cat. No.: HY-15184

Bioactivity: Elaiophylin (Azalomycin B; Gopalamicin; Efomycin E) is an **autophagy** inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg



Emetine dihydrochloride hydrate

Cat. No.: HY-B1479B

Bioactivity: Emetine dihydrochloride hydrate is an anti-protozoal drug previously used for intestinal and tissue amoebiasis.

Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



Emodin

(Frangula emodin) Cat. No.: HY-14393

Bioactivity: Emodin is a broad-spectrum anticancer agent. Emodin inhibits **casein kinase** II (CKII) activity with IC_{50} of 2 μM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



Enalaprilat dihydrate

(MK-422) Cat. No.: HY-B0231

Bioactivity: Enalaprilat (dihydrate) (MK-422) is an angiotensin-converting enzyme (ACE) inhibitor with IC_{50} of 1.94 nM.

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Entinostat

(MS-275; SNDX-275) Cat. No.: HY-12163

Bioactivity: Entinostat is an oral and selective class I **HDAC** inhibitor, with IC_{50}s of 243 nM, 453 nM, and 248 nM for **HDAC1**, **HDAC2**, and **HDAC3**, respectively.

Purity: 99.65%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Entrectinib

(NMS-E628; RXDX-101) Cat. No.: HY-12678

Bioactivity: Entrectinib is a potent and orally available **Trk**, **ROS1**, and **ALK** inhibitor; inhibits TrkA, TrkB, TrkC, ROS1 and ALK with IC_{50} values of 1, 3, 5, 12 and 7 nM, respectively.

Purity: 99.61%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Enzalutamide

(MDV3100) Cat. No.: HY-70002

Bioactivity: Enzalutamide (MDV3100) is an **androgen receptor (AR)** antagonist with an IC_{50} of 36 nM in LNCaP prostate cells.

Purity: 99.71%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g, 5 g



Enzastaurin

(LY317615) Cat. No.: HY-10342

Bioactivity: Enzastaurin is a potent and selective **PKCβ** inhibitor with an IC_{50} of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε.

Purity: 99.79%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Erlotinib
(CP-358774; NSC 718781; OSI-774)

Cat. No.: HY-50896

Bioactivity: Erlotinib is a medication for the treatment of non-small cell lung cancer. It inhibits purified **EGFR** kinase with an **IC_{50}** of 2 nM.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Erlotinib Hydrochloride (CP-358774 (Hydrochloride); NSC 718781 (Hydrochloride); OSI-774 (Hydrochloride))

Cat. No.: HY-12008

Bioactivity: Erlotinib Hydrochloride inhibits purified **EGFR** kinase with an **IC_{50}** of 2 nM.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Erlotinib mesylate (CP-358774 (mesylate); NSC 718781 (mesylate); OSI-774 (mesylate))

Cat. No.: HY-12008A

Bioactivity: Erlotinib mesylate inhibits purified **EGFR** kinase with an **IC_{50}** of 2 nM.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Erythromycin

Cat. No.: HY-B0220

Bioactivity: Erythromycin, an oral macrolide antibiotic produced by Streptomyces erythreus, reversibly binds to the 50S ribosome of bacteria, and inhibits protein synthesis. Target: Antibacterial Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g, 10 g



Erythromycin Ethylsuccinate
(Erythromycin ethyl succinate; EES)

Cat. No.: HY-B0957

Bioactivity: Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin.

Purity: 98.0%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 200 mg



Esmolol hydrochloride

Cat. No.: HY-B1392

Bioactivity: Esmolol Hydrochloride is a beta adrenergic receptor blocker. Target: Adrenergic receptor Esmolol Hydrochloride is the hydrochloride salt form of Esmolol, a short and rapid-acting beta adrenergic antagonist belonging to the class II anti-arrhythmic drugs and devoid of intrinsic sympathomimetic...

Purity: 99.77%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Esomeprazole Magnesium trihydrate
((S)-Omeprazole magnesium trihydrate)

Cat. No.: HY-17022

Bioactivity: Esomeprazole Magnesium trihydrate is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells. IC50 value: Target: proton pump Esomeprazole sodium (Nexium) is the S-isomer of omeprazole and acts as a proton pump inhibitor and gastric...

Purity: 95.0%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg



Etoposide
(VP-16; VP-16-213)

Cat. No.: HY-13629

Bioactivity: Etoposide (VP-16; VP-16-213), a chemotherapy medication used for the treatments of a number of types of cancer, inhibits **DNA synthesis** by forming a complex with topoisomerase II and DNA. Etoposide arrests cell cycle in G2 and induces apoptos...

Purity: 99.65%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Eupatilin

Cat. No.: HY-N0783

Bioactivity: Eupatilin, a lipophilic flavonoid isolated from Artemisia species, is a **PPARα** agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.

Purity: 99.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Everolimus
(RAD001; SDZ-RAD)

Cat. No.: HY-10218

Bioactivity: Everolimus (RAD001) is a potent **mTOR** inhibitor that binds to FKBP-12 to generate an immunosuppressive complex.

Purity: 98.79%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



Ezetimibe
(SCH 58235) Cat. No.: HY-17376

Bioactivity: Ezetimibe (SCH 58235) is a Niemann-Pick C1-like1 (**NPC1L1**) inhibitor, and is a potent **Nrf2** activator. Ezetimibe (SCH 58235) is a potent cholesterol absorption inhibitor.

Purity: 99.76%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Fasudil
(HA-1077; AT877) Cat. No.: HY-10341A

Bioactivity: Fasudil (HA-1077; AT877), a potent inhibitor of **ROCK** with a K_i of 0.33 μM for ROCK1, which is also a potent Ca^{2+} **channel** antagonist and vasodilator.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



Fasudil Hydrochloride
(HA-1077 (Hydrochloride); AT-877 (Hydrochloride)) Cat. No.: HY-10341

Bioactivity: Fasudil Hydrochloride (HA-1077 Hydrochloride; AT-877 Hydrochloride), a potent inhibitor of **ROCK** with a K_i of 0.33 μM for ROCK1, which is also a potent Ca^{2+} **channel** antagonist and vasodilator.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg



Felodipine
Cat. No.: HY-B0309

Bioactivity: Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker. Target: Calcium Channel Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their...

Purity: 99.75%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Fenofibrate
Cat. No.: HY-17356

Bioactivity: Fenofibrate is a **PPARα** agonist with an EC_{50} of 30 μM.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 g



Fenretinide
(4-HPR) Cat. No.: HY-15373

Bioactivity: Fenretinide is a synthetic retinoid deriverative, binding to the retinoic acid receptors (**RAR**) at concentrations necessary to induce cell death.

Purity: 99.41%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

FIPI
(5-Fluoro-2-indolyl deschlorohalopemide) Cat. No.: HY-12807

Bioactivity: FIPI is a derivative of halopemide which potently inhibits both **PLD1** and **PLD2** with IC_{50}s of 25 nM and 20 nM, respectively.

Purity: 99.49%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Flavopiridol
(L868275; HMR-1275; Alvocidib) Cat. No.: HY-10005

Bioactivity: Flavopiridol is a broad spectrum and competitive inhibitor of **CDKs**, inhibiting CDK1, CDK2, CDK4 with IC_{50}s of 30, 170, 100 nM, respectively.

Purity: 99.70%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg



Flavopiridol Hydrochloride (HL 275; NSC 649890; MDL 107826A; FLAVOPIRIDOL HCL; Alvocidib Hydrochloride)
Cat. No.: HY-10006

Bioactivity: Flavopiridol Hydrochloride is a broad inhibitor of **CDK**, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC_{50}s of 30, 170, 100 nM, respectively.

Purity: 99.00%
Clinical Data: Phase 2
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg



Flubendazole
Cat. No.: HY-B0294

Bioactivity: Flubendazole is a potent broad spectrum anthelmintic. Target: Antiparasitic Flubendazole is an anthelmintic. It is also available for human use to treat worm infections[1].

Purity: 99.09%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Fludrocortisone acetate

(9α-Fludrocortisone acetate; 9α-Fluorcortisol acetate) Cat. No.: HY-B1203A

Bioactivity: Fludrocortisone Acetate is a synthetic mineralocorticoid, used to control the amount of sodium and fluids in your body. It is used to treat Addison's disease by decreasing the amount of sodium that is lost (excreted) in your urinealso used to increase blood pressure.

Purity: 99.45%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Fluoxetine

(LY-110140 (free base)) Cat. No.: HY-B0102

Bioactivity: Fluoxetine (LY-110140 free base) is a selective serotonin reuptake inhibitor (**SSRI**) class used for antidepressant research.

Purity: >98%
Clinical Data: Launched
Size: 50 mg, 100 mg, 500 mg



Fluoxetine hydrochloride

(LY-110140) Cat. No.: HY-B0102A

Bioactivity: Fluoxetine hydrochloride is an antidepressant and a selective **serotonin reuptake** inhibitor.

Purity: 99.86%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



Fluvastatin sodium

(XU 62320 sodium) Cat. No.: HY-14664A

Bioactivity: Fluvastatin (XU 62320) sodium is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), used to treat hypercholesterolemia and to prevent cardiovascular disease.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 50 mg, 100 mg



FMK 9a

Cat. No.: HY-100522

Bioactivity: FMK 9a is an **autophagin-1** inhibitor with **IC_{50}** values of 80 and 73 μM in FRET and LRA assay.

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Forskolin

(Coleonol; Colforsin) Cat. No.: HY-15371

Bioactivity: Forskolin is a potent **adenylate cyclase** activator, with **IC_{50}** and **EC_{50}** of 41 nM and 0.5 μM for **type I adenylyl cyclase**, respectively.

Purity: 98.52%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Fulvestrant

(ICI 182780; ZD 9238; ZM 182780) Cat. No.: HY-13636

Bioactivity: Fulvestrant is a potent **Estrogen Receptor** antagonist with an **IC_{50}** of 9.4 nM.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Galangin

(Norizalpinin; 3,5,7-Trihydroxyflavone) Cat. No.: HY-N0382

Bioactivity: Galangin is an agonist/antagonist of the arylhydrocarbon receptor, and also shows inhibition of **CYP1A1** activity.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg, 100 mg



Gambogic Acid

(Beta-Guttiferrin) Cat. No.: HY-N0087

Bioactivity: Gambogic acid is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic acid inhibits **Bcl-X_L**, **Bcl-2**, **Bcl-W**, **Bcl-B**, **Bfl-1** and **Mcl-1** with **IC_{50}**s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM.

Purity: 95.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



GANT 61

(NSC 136476) Cat. No.: HY-13901

Bioactivity: GANT 61 is an inhibitor of **Gli1** and **Gli2** targeting the Hedgehog/GLI pathway.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



GDC-0349

Cat. No.: HY-15248

Bioactivity: GDC-0349 is a potent and selective ATP-competitive **mTOR** inhibitor with a K_i of 3.8 nM. GDC-0349 inhibits of both **mTORC1** and **mTORC2** complexes.

Purity: 98.20%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Gefitinib

(ZD1839)

Cat. No.: HY-50895

Bioactivity: Gefitinib (ZD1839) is a **EGFR tyrosine kinase** inhibitor, with IC_{50} of 2-37 nM in NR6wtEGFR cells.

Purity: 99.70%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g, 5 g



Gemcitabine

(NSC 613327; LY188011)

Cat. No.: HY-17026

Bioactivity: Gemcitabine (NSC 613327;LY188011) is a **DNA synthesis** inhibitor which inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC_{50}s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg, 1 g



Gemcitabine elaidate

(CP-4126; CO-101; Gemcitabine 5'-elaidate)

Cat. No.: HY-13538

Bioactivity: Gemcitabine elaidate(CP-4126; CO-101) is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. IC50 value: Target: Gemcitabine analog Upon hydrolysis intracellularly by esterases, the...

Purity: 99.24%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

Gemcitabine Hydrochloride

(LY 188011 hydrochloride)

Cat. No.: HY-B0003

Bioactivity: Gemcitabine hydrochloride is a **DNA synthesis** inhibitor with IC_{50}s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM in BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells, respectively.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 200 mg, 500 mg, 1 g



Genipin

((+)-Genipin)

Cat. No.: HY-17389

Bioactivity: Genipin is a natural water soluble crosslinking reagent.

Purity: 99.40%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Genistein

(NPI 031L)

Cat. No.: HY-14596

Bioactivity: Genistein, a soy isoflavone, is a multiple **tyrosine kinases** inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.

Purity: 99.68%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Genistin (Genistine; Genistoside; Genistein 7-O-β-D-glucopyranoside)

Cat. No.: HY-N0595

Bioactivity: Genistin is the major isoflavonoid of soybeans and soy products.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Ginsenoside Rb1

(Gypenoside III)

Cat. No.: HY-N0039

Bioactivity: Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits **Na^+, K^+-ATPase** activity with an IC_{50} of 6.3±1.0 μM. Ginsenoside also inhibits **IRAK-1** activation and phosphorylation of **NF-κB p65** .

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Ginsenoside Rh4

Cat. No.: HY-N0905

Bioactivity: Ginsenoside Rh4 is a rare saponin obtained from Panax notoginseng. Ginsenoside Rh4 activates **Bax**, **caspase 3**, **caspase 8**, and **caspase 9**. Ginsenoside Rh4 also induces **autophagy**.

Purity: 98.40%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Glaucocalyxin B

Cat. No.: HY-N2113

Bioactivity: Glaucocalyxin B is an ent kaurane diterpenoid isolated from the Chinese traditional medicine Rabdosia japonica with anticancer and antitumor activity; decreases the growth of HL-60 cells with an **IC_{50}** of approximately 5.86 μM at 24 h.

Purity: 99.39%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Glibenclamide

(Glyburide)

Cat. No.: HY-15206

Bioactivity: Glibenclamide is a selective inhibitor of **ATP-sensitive $^{K+}$ channel**.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Glucosamine hydrochloride (D-(+)-Glucosamine hydrochloride; Chitosamine hydrochloride)

Cat. No.: HY-N0733

Bioactivity: Glucosamine (hydrochloride) is a natural product. IC50 value: Target: In vitro: Glucosamine hydrochloride exhibited dose-dependent DPPH antioxidant activity [1]. Short-term (4 h) glucosamine hydrochloride treatment inhibited HIF-1α at the protein level, decreased phosphorylation of p70S6K and S6,...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 50 mg



GSK-690693

Cat. No.: HY-10249

Bioactivity: GSK-690693 is an ATP-competitive **pan-Akt** inhibitor with **IC_{50}**s of 2, 13, 9 nM for Akt1, Akt2 and Akt3, respectively.

Purity: 97.52%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



GSK2578215A

Cat. No.: HY-13237

Bioactivity: GSK2578215A is a potent and highly selective **LRRK2** inhibitor, which exhibits **IC_{50}**s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.

Purity: 99.86%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



GSK2606414

Cat. No.: HY-18072

Bioactivity: GSK2606414 is a cell-permeable and orally available **protein kinase R-like endoplasmic reticulum (ER) kinase (PERK)** inhibitor with an **IC_{50}** of 0.4 nM.

Purity: 99.38%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



GSK2656157

Cat. No.: HY-13820

Bioactivity: GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (**PERK**) with an **IC_{50}** of 0.9 nM.

Purity: 99.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



GSK343

Cat. No.: HY-13500

Bioactivity: GSK343 is a highly potent and selective **EZH2** inhibitor with an **IC_{50}** of 4 nM.

Purity: 98.49%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



GSK4112

(SR6452)

Cat. No.: HY-14414

Bioactivity: GSK4112 is a Rev-erbα agonist with EC50 of 0.4 μM, also is a small molecule chemical probe for the cell biology of the nuclear heme receptor Rev-erbα. IC50 value: 0.4 μM (EC50) Target: Rev-erbα in vitro: GSK4112 profiled as a Rev-erb agonist in cells to inhibit expression of the circadian target...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



GW 501516

(GW 1516; GSK-516)

Cat. No.: HY-10838

Bioactivity: GW 501516 is a **PPARδ** agonist with an **EC_{50}** of 1.1 nM.

Purity: 99.27%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



H 89

(Protein kinase inhibitor H-89) Cat. No.: HY-15979

Bioactivity: H-89 is a potent inhibitor of cyclic AMP-dependent protein kinase (**protein kinase A**) with **IC_{50}** of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg



H-89 dihydrochloride

(Protein kinase inhibitor H-89 dihydrochloride) Cat. No.: HY-15979A

Bioactivity: H-89 dihydrochloride is a potent inhibitor of protein kinase A (**PKA**) with an **IC_{50}** of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase.

Purity: 98.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Hemin

(Hemin chloride) Cat. No.: HY-19424

Bioactivity: Hemin is an iron-containing porphyrin. Hemin is an **Heme oxygenase (HO)-1** inducer.

Purity: 98.0%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Heparin

Cat. No.: HY-17567

Bioactivity: Heparin is a highly sulfated glycosaminoglycan,that is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule (50-400 U/Kg).

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Heparin Lithium salt

Cat. No.: HY-17567B

Bioactivity: Heparin Lithium salt is an anticoagulant which binds reversibly to **antithrombin III (ATIII)** (50-400 U/Kg).

Purity:
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Heparin sodium salt

(Sodium heparinate) Cat. No.: HY-17567A

Bioactivity: Heparin sodium salt is an anticoagulant which binds reversibly to **antithrombin III (ATIII)** and greatly accelerates the rate at which ATIII inactivates coagulation enzymes **thrombin factor IIa** and **factor Xa** (50-400 U/Kg).

Purity: 98.0%
Clinical Data: Launched
Size: 100 mg, 500 mg, 1 g



Hesperadin

Cat. No.: HY-12054

Bioactivity: Hesperadin is an ATP-competitive inhibitor of **aurora B** kinase with an **IC_{50}** of 250 nM.

Purity: 98.48%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Hesperidin

(Hesperetin 7-rutinoside) Cat. No.: HY-15337

Bioactivity: Hesperidin (HP) is a bioflavonoid that plays a role in plant defense and is abundant in citrus species, such as grapefruit, lemon and orange. Hesperidin is used effectively as a supplemental agent in complementary therapy protocols, since it possesses biological and pharmacological properties as an...

Purity: 97.00%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Hoechst 33342

(bisBenzimide H 33342; HOE 33342) Cat. No.: HY-15559

Bioactivity: Hoechst 33342 is a DNA minor groove binder used fluorochrome for visualizing cellular **DNA**.

Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg



Hoechst 33342 trihydrochloride (bisBenzimide H 33342 trihydrochloride; HOE 33342 trihydrochloride)

Cat. No.: HY-15559A

Bioactivity: Hoechst 33342 trihydrochloride is a membrane permeant blue fluorescent **DNA** stain.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



Honokiol

(NSC 293100) Cat. No.: HY-N0003

Bioactivity: Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of **Akt** and enhances the phosphorylation of **ERK1/ERK2**.

Purity: 99.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



Hydroxychloroquine sulfate

(HCQ sulfate) Cat. No.: HY-B1370

Bioactivity: Hydroxychloroquine sulfate is a synthetic **antimalarial** drug which can also inhibit **Toll-like receptor 7/9** (**TLR7/9**) signaling.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 50 mg



Hydroxyurea

(Hydroxycarbamide) Cat. No.: HY-B0313

Bioactivity: Hydroxyurea is a cell apoptosis inducer that inhibit **DNA** synthesis through inhibition of **ribonucleotide reductase**.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Icariin

(Ieariline) Cat. No.: HY-N0014

Bioactivity: Icariin is a flavonol glycoside. Icariin inhibits **PDE5** and **PDE4** activities with **IC_{50}**s of 432 nM and 73.50 μM, respectively. Icariin also is a **PPARα** activator.

Purity: 98.75%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Icaritin

(Anhydroicaritin) Cat. No.: HY-N0678

Bioactivity: Icaritin(Anhydroicaritin) is a component of Epimedium flavonoid isolated from Herba Epimedii; enhances osteoblastic differentiation of mesenchymal stem cells (MSCs) while it inhibits adipogenic differentiation of MSCs by inhibiting PPAR-g pathway. IC50 value: Target: in vitro: Icaritin was...

Purity: 98.81%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Idarubicin hydrochloride

(4-Demethoxydaunorubicin hydrochloride) Cat. No.: HY-17381

Bioactivity: Idarubicin hydrochloride is an anthracycline antileukemic drug. It inhibits the **topoisomerase II** interfering with the replication of DNA and RNA transcription.

Purity: 99.62%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Idelalisib

(CAL-101; GS-1101) Cat. No.: HY-13026

Bioactivity: Idelalisib (CAL-101) is a highly selective and orally bioavailable **p110δ** inhibitor with an **IC_{50}** of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



IITZ-01

Cat. No.: HY-112897

Bioactivity: IITZ-01 is a potent lysosomotropic **autophagy** inhibitor with single-agent antitumor activity, with an **IC_{50}** of 2.62 μM for PI3Kγ.

Purity: 99.80%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Imatinib

(STI571; CGP-57148B) Cat. No.: HY-15463

Bioactivity: Imatinib (STI571) is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (**IC_{50}**=100 nM) tyrosine kinases.

Purity: 99.80%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg, 1 g, 5 g



Imatinib Mesylate

(STI571 (Mesylate); CGP-57148B (Mesylate)) Cat. No.: HY-50946

Bioactivity: Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (**IC_{50}**=100 nM) tyrosine kinases.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg, 1 g, 5 g



Imiquimod
(R 837) Cat. No.: HY-B0180

Bioactivity: Imiquimod (R 837) is an immune response modifier that acts as a **toll-like receptor 7** agonist.

Purity: 99.37%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Imiquimod hydrochloride
(R 837 hydrochloride) Cat. No.: HY-B0180A

Bioactivity: Imiquimod hydrochloride is an immune response modifier that acts as a **toll-like receptor 7**agonist.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



Imiquimod maleate
(R 837 maleate) Cat. No.: HY-B0180B

Bioactivity: Imiquimod maleate is an immune response modifier that acts as a **toll-like receptor 7**agonist.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



Indomethacin
(Indometacin) Cat. No.: HY-14397

Bioactivity: Indomethacin is a potent and nonselective inhibitor of **COX1** and **COX2**, with **IC_{50}**s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Iohexol
Cat. No.: HY-B0594

Bioactivity: Iohexol is a contrast agent. Target: Others Iohexol is a contrast agent. The osmolality of iohexol ranges from 322 mOsm/kg-approximately 1.1 times that of blood plasma-to 844 mOsm/kg, almost three times that of blood. Despite this difference, iohexol is still considered a low-osmolality...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Ipsalazide
Cat. No.: HY-101744

Bioactivity: Ipsalazide is a novel sulfasalazine analog designed to release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Irinotecan
((+)-Irinotecan; CPT-11) Cat. No.: HY-16562

Bioactivity: Irinotecan is a water soluble **topoisomerase I** inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex.

Purity: 99.84%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Irinotecan hydrochloride
(CPT-11 hydrochloride; Camptothecin 11 hydrochloride) Cat. No.: HY-16562A

Bioactivity: Irinotecan hydrochloride is a water soluble **topoisomerase I** inhibitor mainly used to treat colon cancer and rectal cancer.

Purity: 99.75%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Irinotecan hydrochloride trihydrate
Cat. No.: HY-16568

Bioactivity: Irinotecan hydrochloride trihydrate is a water soluble **topoisomerase I** inhibitor with antitumor activity.

Purity: 99.78%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Isoalantolactone
((+)-Isoalantolactone; Isohelenin) Cat. No.: HY-N0780

Bioactivity: Isoalantolactone is an **apoptosis** inducer, which also acts as an alkylating agent.

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Isobavachalcone

(Corylifolinin; Isobacachalcone) Cat. No.: HY-13065

Bioactivity: Isobavachalcone(Corylifolinin) is a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. IC50 value: Target: Isobavachalcone inhibits platelet aggregation. Inhibitor of Epstein-Barr virus early antigen (EBV-EA) induction. Isobavachalcone exhibits potent inhibitory effect...

Purity: 99.21%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



Isoliquiritigenin

(GU17; ISL; Isoliquiritigen) Cat. No.: HY-N0102

Bioactivity: Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza glabra, which inhibits **aldose reductase** with an $\mathbf{IC_{50}}$ of 320 nM.

Purity: 98.24%

Clinical Data: Phase 1

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Isoniazid

(INH; Isonicotinic acid hydrazide; Isonicotinic hydrazide) Cat. No.: HY-B0329

Bioactivity: Isoniazid is an antibacterial agent used primarily as a tuberculostatic. Target: Antibacterial Isoniazid is a prodrug and must be activated by a bacterial catalase-peroxidase enzyme that in M. tuberculosis is called KatG [1]. KatG couples the isonicotinic acyl with NADH to form isonicotinic...

Purity: 99.0%

Clinical Data: Launched

Size: 10mM x 1mL in Water, 100 mg



Isosorbide

(D-Isosorbide; Dianhydro-D-glucitol) Cat. No.: HY-B1469

Bioactivity: Isosorbide is used as a diuretic used mainly to treat hydrocephalus and is also used to treat glaucoma.

Purity: 98.0%

Clinical Data: Launched

Size: 10mM x 1mL in Water, 5 g



Isosorbide mononitrate

(Isosorbide-5-mononitrate) Cat. No.: HY-B0642

Bioactivity: Isosorbide mononitrate(Isosorbide-5-mononitrate) is a nitrate-class compound used for angina pectoris; acts by dilating the blood vessels so as to reduce the blood pressure.

Purity: 98.0%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 1 g, 5 g



Isradipine

(PN 200-110) Cat. No.: HY-B0233

Bioactivity: Isradipine(Dynacirc) is a calcium channel blocker with an IC50 of 34±8 μM. Target: Calcium Channel Isradipine(Dynacirc) is a calcium channel blocker with an IC50 of 34±8 μM.It is usually prescribed for the treatment of high blood pressure in order to reduce the risk of stroke and heart attack[1]. Isradipine...

Purity: 99.24%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Itraconazole

(R51211) Cat. No.: HY-17514

Bioactivity: Itraconazole is a triazole antifungal agent. IC50 Value: N/A Target: antifungal in vitro: Itraconazole is pharmacologically distinct from other azole antifungal agents in that it is the only inhibitor in this class that has been shown to inhibit both the hedgehog signaling pathway and angiogenesis[1, 2]....

Purity: 99.55%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



IU1

Cat. No.: HY-13817

Bioactivity: IU1 is a special **Usp14** inhibitor with $\mathbf{IC_{50}}$ of 4-5 μM.

Purity: 98.0%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Ivermectin

(MK-933) Cat. No.: HY-15310

Bioactivity: Ivermectin (MK-933) is a widely used antiparasitic agent in human and veterinary medicine. It is a positive allosteric effector of $\mathbf{P2X_4}$ and the α7 neuronal nicotinic acetylcholine receptor (**nAChRs**).

Purity: 98.0%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 500 mg, 1 g



Ixazomib

(MLN2238) Cat. No.: HY-10453

Bioactivity: Ixazomib (MLN2238) is a selective, potent, and reversible **proteasome** inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an $\mathbf{IC_{50}}$ of 3.4 nM ($\mathbf{K_i}$ of 0.93 nM).

Purity: 98.0%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Ixazomib citrate
(MLN9708) Cat. No.: HY-10452

Bioactivity: Ixazomib citrate (MLN9708) is a reversible inhibitor of the chymotrypsin-like proteolytic β5 site of the **20S proteasome** with an $\mathbf{IC_{50}}$ of 3.4 nM and a $\mathbf{K_i}$ of 0.93 nM.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



JPH203
(KYT-0353) Cat. No.: HY-100868

Bioactivity: JPH203 is a potent and selective L-type amino acid transporter 1 (**LAT-1**) inhibitor.

Purity: 98.67%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



JPH203 Dihydrochloride
Cat. No.: HY-U00445

Bioactivity: JPH203 Dihydrochloride is a tyrosine analog, acts as a selective inhibitor of L-type amino acid transporter 1 (**LAT1**), and is used in cancer research.

Purity: 98.35%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Kaempferide
(Kaempferol 4'-O-methyl ether) Cat. No.: HY-15449

Bioactivity: Kaempferide is an O-methylated flavonol, a type of chemical compound. It can be found in Kaempferia galanga (aromatic ginger). The enzyme kaempferol 4'-O-methyltransferase uses S-adenosyl-L-methionine and kaempferol to produce S-adenosyl-L-homocysteine and kaempferide. P-glycoproteins.

Purity: 98.50%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Kaempferol
(Robigenin; Kempferol) Cat. No.: HY-14590

Bioactivity: Kaempferol inhibits **estrogen receptor α** expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK.

Purity: 99.47%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Ketanserin
(R41468) Cat. No.: HY-10562

Bioactivity: Ketanserin is a selective **5-HT receptor** antagonist. Ketanserin also blocks hERG current ($\mathbf{I_{hERG}}$) in a concentration-dependent manner ($\mathbf{IC_{50}}$=0.11 μM).

Purity: 98.86%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Ketanserin tartrate
(R41468 tartrate) Cat. No.: HY-10562A

Bioactivity: Ketanserin tartrate is a selective **5-HT receptor** antagonist. Ketanserin tartrate also blocks hERG current ($\mathbf{I_{hERG}}$) in a concentration-dependent manner ($\mathbf{IC_{50}}$=0.11 μM).

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



KU-55933
Cat. No.: HY-12016

Bioactivity: KU-55933 is a potent **ATM** inhibitor with an $\mathbf{IC_{50}}$ and $\mathbf{K_i}$ of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



L-779450
Cat. No.: HY-12787

Bioactivity: L-779450 is a potent and selective **B-Raf** kinase inhibitor with a K_d of 2.4 nM.

Purity: 98.75%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Lamotrigine
(LTG; BW430C) Cat. No.: HY-B0495

Bioactivity: Lamotrigine(BW430C) is a novel anticonvulsant drug for inhibition of 5-HT and sodium channel Target: Sodium Channel Lamotrigine stabilises presynaptic neuronal membranes by blockade of voltage-dependent sodium channels, thus preventing the release of excitatory neurotransmitters, particularly...

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Lanatoside C

Cat. No.: HY-B1030

Bioactivity: Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Target: in vitro: Dose-dependent reduction in dengue viral RNA and viral...

Purity: 98.10%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg



Lapatinib

(GW572016)

Cat. No.: HY-50898

Bioactivity: Lapatinib (GW572016) is a potent **EGFR** and **ErbB2** inhibitor with **IC_{50}**s of 10.2 and 9.8 nM, respectively.

Purity: 99.83%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g



Lapatinib ditosylate

(GW-572016 ditosylate)

Cat. No.: HY-50898A

Bioactivity: Lapatinib ditosylate is a potent **EGFR** and **ErbB2** inhibitor with **IC_{50}** of 10.2 and 9.8 nM, respectively.

Purity: 98.58%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g



Lasalocid

(Antibiotic X-537A; Lasalocid-A; X-537A; Ionophore X-537A)

Cat. No.: HY-B1071

Bioactivity: Lasalocid is an antibacterial agent and a coccidiostat, used in the feed additives

Purity: 98.03%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



Lasalocid sodium

(Sodium lasalocid)

Cat. No.: HY-B1071A

Bioactivity: In vitro: Lasalocid sodium treatment led to an increase in cell wall thickness, whilst the quantity and sugar composition of the cell wall remained unchanged in BY-2 cells. Lasalocid sodium treatment enhances enzymatic saccharification efficiency in both BY-2 cells and Arabidopsis plants. [1]

Purity: 97.17%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg



Latrepirdine dihydrochloride

(Dimebolin dihydrochloride)

Cat. No.: HY-14537

Bioactivity: Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and **amyloid-β** (**Aβ**) secretion.

Purity: 99.75%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



Leonurine

(SCM-198)

Cat. No.: HY-N0741

Bioactivity: Leonurine is an alkaloid isolated from Herba leonuri, with anti-oxidative and anti-inflammatory.

Purity: 99.45%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Leonurine hydrochloride

(SCM-198 hydrochloride)

Cat. No.: HY-N0741A

Bioactivity: Leonurine hydrochloride is an alkaloid isolated from Herba leonuri, with anti-oxidative and anti-inflammatory.

Purity: 99.32%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Letrozole

(CGS 20267)

Cat. No.: HY-14248

Bioactivity: Letrozole is an **aromatase** inhibitor with an **IC_{50}** of 1-13 nM.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Levobupivacaine hydrochloride

((S)-(-)-Bupivacaine monohydrochloride)

Cat. No.: HY-B0653A

Bioactivity: Levobupivacaine hydrochloride is a local anaesthetic compound belonging to the amino amide group; long-acting local anesthetic.

Purity: 99.85%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Levosimendan
(OR1855; OR1259) **Cat. No.:** HY-14286

Bioactivity: Levosimendan (OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Licochalcone A
(Licochalcone-A) **Cat. No.:** HY-N0372

Bioactivity: Licochalcone A, a flavonoid isolated from the famous Chinese medicinal herb Glycyrrhiza uralensis Fisch, presents obvious anti-cancer effects. The IC50 value is 0.97 μM for UGT1A1.

Purity: 99.72%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Ligustilide
Cat. No.: HY-N0401

Bioactivity: Ligustilide is an effective constituent extracted from Angelica sinensis. IC50 value: Target: In vitro: To investigate the neuroprotective of ligustilide (LIG) against glutamate-induced apoptosis of PC12 cells, cell viability were examined by MTT assay. Pretreatment with ligustilide (1, 5, 15...

Purity: 98.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Linagliptin
(BI 1356) **Cat. No.:** HY-10284

Bioactivity: Linagliptin is a highly potent, selective **DPP-4** inhibitor with **IC_{50}** of 1 nM.

Purity: 99.80%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg, 1 g



Linifanib
(ABT-869; AL-39324) **Cat. No.:** HY-50751

Bioactivity: Linifanib (ABT-869) is a multi-targeted inhibitor of **VEGF** and **PDGFR** receptor family with **IC_{50}**s of 3, 4, 66, 4 nM for KDR, Flt-1, PDGFRβ and FLT3, respectively.

Purity: 99.60%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Lithocholic acid
(3α-Hydroxy-5β-cholanic acid) **Cat. No.:** HY-B0172

Bioactivity: Lithocholic acid is a toxic secondary bile acid, causes intrahepatic cholestasis, has tumor-promoting activity. Target: Others Lithocholic acid has been used in a study to assess cholestasis and its action on several organs and tissues in rats. It has also been used in a study to...

Purity: 98.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Lomustine
(CCNU; NSC 79037) **Cat. No.:** HY-13669

Bioactivity: Lomustine (CCNU) is a **DNA alkylating** agent, with antitumor activity.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg



Lonafarnib
(Sch66336) **Cat. No.:** HY-15136

Bioactivity: Lonafarnib is an orally bioavailable farnesyl protein transferase (**FPTase**) inhibitor for H-ras, K-ras and N-ras with **IC_{50}** of 1.9 nM, 5.2 nM and 2.8 nM, respectively.

Purity: 98.67%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Loperamide hydrochloride
(R-18553 (hydrochloride)) **Cat. No.:** HY-B0418A

Bioactivity: Loperamide (hydrochloride) (R-18553 (hydrochloride)) is an **opioid receptor** agonist for the treatment of diarrhea.

Purity: 99.69%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Losmapimod
(GSK-AHAB; GW856553X; SB856553) **Cat. No.:** HY-10402

Bioactivity: Losmapimod is a selective, potent, and orally active **p38 MAPK** inhibitor with **pK_i**s of 8.1 and 7.6 for p38α and p38β, respectively.

Purity: 97.08%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Lucanthone

Cat. No.: HY-B2098

Bioactivity: Lucanthone is an endonuclease inhibitor of Apurinic endonuclease-1 (**APE-1**).

Purity: 98.47%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg



Lumefantrine

(Benflumetol)

Cat. No.: HY-B0803

Bioactivity: Lumefantrine is an antimalarial drug, used in combination with Artemether. The artemether-lumefantrine (AL) as the first- and second-line anti-malarial drugs.

Purity: 97.29%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 500 mg



Luminespib

(NVP-AUY922; AUY922; VER-52296)

Cat. No.: HY-10215

Bioactivity: Luminespib (NVP-AUY922) is a potent **HSP90** inhibitor with **IC_{50}**s of 7.8 and 21 nM for HSP90α and HSP90β, respectively.

Purity: 99.14%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 100 mg, 200 mg, 500 mg



Luteolin

(Luteolol; Digitoflavone; Luteoline)

Cat. No.: HY-N0162

Bioactivity: Luteolin (Luteolol) is a falconoid compound, which exhibits anticancer properties.

Purity: 98.14%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 500 mg



LV-320

Cat. No.: HY-112711

Bioactivity: LV-320 is a potent **ATG4B** inhibitor with an **IC_{50}** of 24.5μM.

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



LX2343

Cat. No.: HY-111383

Bioactivity: LX2343 is a **BACE1** enzyme inhibitor with an **IC_{50}** value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive **PI3K** inhibitor with an **IC_{50}** of 15.99±3.23 μM. LX2343 stimulates **autophagy** in its promotion of **Aβ** clearance.

Purity: 99.86%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



LY2109761

Cat. No.: HY-12075

Bioactivity: LY2109761 is an orally active, selective **TGF-β receptor type I/II** inhibitor with **K_i**s of 38 nM and 300 nM, respectively.

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



LY294002

(NSC 697286; SF 1101)

Cat. No.: HY-10108

Bioactivity: LY294002 is a broad-spectrum inhibitor of **PI3K** with **IC_{50}**s of 0.5, 0.57, and 0.97 μM for **PI3Kα**, **PI3Kδ** and **PI3Kβ**, respectively [1]. LY294002 also inhibits **CK2** with an **IC_{50}** of 98 nM [2].

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



LY3009120

(DP-4978)

Cat. No.: HY-12558

Bioactivity: LY3009120 is a pan **RAF** inhibitor which inhibits BRAF ^{V600E}, BRAF ^{WT} and CRAF ^{WT} with **IC_{50}**s of 5.8, 9.1 and 15 nM, respectively.

Purity: 98.66%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



LY3023414

Cat. No.: HY-12513

Bioactivity: LY3023414 potently and selectively inhibits **class I PI3K** isoforms, **DNA-PK**, and **mTORC1/2** with **IC_{50}**s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. LY3023414 potently inhibits **mTORC1/ 2** at low nanomolar...

Purity: 99.77%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Lycorine hydrochloride

Cat. No.: HY-N0289

Bioactivity: Lycorine (hydrochloride) is VE-cadherin inhibitor,and has IC50 of 1.2μM in Hey1B cell. IC50: 1.2μM (Hey1B cell)[2] In vitro:Lycorine (hydrochloride) executed an anti-melanoma vasculogenic effect by inhibiting VE-cadherin gene expression in C8161 cells and caused a decrease in cell surface exposure...

Purity: >98%

Clinical Data: No Development Reported

Size: 10 mg, 25 mg, 50 mg, 100 mg



LYN-1604

(LYN1604; LYN 1604)

Cat. No.: HY-101923

Bioactivity: LYN-1604 is a potent UNC-51-like kinase 1 (**ULK1**) agonist with an **EC_{50}** of 18.94 nM.

Purity: >98%

Clinical Data: No Development Reported

Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



LYN-1604 hydrochloride

Cat. No.: HY-101923A

Bioactivity: LYN-1604 hydrochloride is a potent **ULK1** activator with an **EC_{50}** of 18.94 nM.

Purity: 99.80%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Lys01 trihydrochloride

(Lys05)

Cat. No.: HY-12855A

Bioactivity: Lys01 trihydrochloride (Lys05) is a novel **lysosomal autophagy** inhibitor with **IC_{50}** values of 3.6, 3.8, 6 and 7.9 μM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay.

Purity: 98.0%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Magnolol

Cat. No.: HY-N0163

Bioactivity: Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both **RXRα** and **PPARγ**, with **EC_{50}** values of 10.4 μM and 17.7 μM, respectively.

Purity: 99.72%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg



Maprotiline hydrochloride

Cat. No.: HY-B0444

Bioactivity: Maprotiline HCl is a selective noradrenalin re-uptake inhibitor and a tetracyclic antidepressant. Target: Others Maprotiline (sold as Deprilept, Ludiomil, Psymion) is a tetracyclic antidepressant (TeCA). However, Maprotiline's fourth ring is spurious, as formed by a bridge across the...

Purity: 99.97%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO,
100 mg, 500 mg



Matrine

(Matridin-15-one; Vegard; α-Matrine)

Cat. No.: HY-N0164

Bioactivity: Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus. It has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor and u-receptor agonist.

Purity: 98.0%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
100 mg, 200 mg, 500 mg



Mefloquine hydrochloride

(Mefloquin hydrochloride)

Cat. No.: HY-17437A

Bioactivity: Mefloquine hydrochloride is a quinoline antimalarial drug that is structurally related to the antiarrhythmic agent quinidine. IC50 Value: 1 microM (for K+ channel) [1] Target: Antiparasitic Mefloquine is widely used in both the treatment and prophylaxis of Plasmodium falciparum malaria. MQ can...

Purity: 99.96%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO,
100 mg, 500 mg



Megestrol Acetate

Cat. No.: HY-13676

Bioactivity: Megestrol Acetate is a synthetic progesteronal agent with an IC50 of 260 μM for the inhibition of HegG2. Target: Progesterone Receptor Megestrol acetate, also known as 17α-acetoxy-6-dehydro-6-methylprogesterone, and sometimes abbreviated as MGA or MA, is a steroidal progestin and...

Purity: 98.0%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO,
1 g, 5 g



Melatonin

(N-Acetyl-5-methoxytryptamine)

Cat. No.: HY-B0075

Bioactivity: Melatonin is a hormone made by the pineal gland that can activates **melatonin receptor**. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties.

Purity: 98.95%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO,
1 g, 5 g



Meloxicam

Cat. No.: HY-B0261

Bioactivity: Meloxicam is a non-steroidal antiinflammatory agent, inhibits **COX** activity, with **IC_{50}**s of 0.49 μM and 36.6 μM for COX-2 and COX-1, respectively.

Purity: 98.07%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Memantine hydrochloride

(D-145 (hydrochloride))

Cat. No.: HY-B0365A

Bioactivity: Memantine (hydrochloride) (D-145 (hydrochloride)), an amantadine derivative with low to moderate-affinity for NMDA receptors, inhibit CYP2B6 and CYP2D6 with K_i of 0.51 nM and 94.9 μM, respectively.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Meprednisone

Cat. No.: HY-B0243

Bioactivity: Meprednisone is a glucocorticoid and a methylated derivative of prednisone. Target: Glucocorticoid Receptor Meprednisone is a glucocorticoid and a methylated derivative of prednisone. The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in...

Purity: 99.36%
Clinical Data: Launched
Size: 10 mg, 100 mg



Metformin hydrochloride

(1,1-Dimethylbiguanide hydrochloride)

Cat. No.: HY-17471A

Bioactivity: Metformin (hydrochloride) is an FDA approved first-line drug for the treatment of type 2 diabetes. Metformin decreases hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory-chain complex 1.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 g, 50 g



Methylprednisolone

(U 7532)

Cat. No.: HY-B0260

Bioactivity: Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Target: Glucocorticoid Receptor Methylprednisolone is typically used for its anti-inflammatory effects. Common uses include arthritis therapy and short-term treatment of bronchial...

Purity: 99.67%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Metyrapone

(Su-4885)

Cat. No.: HY-B1232

Bioactivity: Metyrapone is an inhibitor of cytochrome P450-mediated ω/ω-1 hydroxylase activity and CYP11B1. Target: CYP11B1 Metyrapone is a drug used in the diagnosis of adrenal insufficiency and occasionally in the treatment of Cushing's syndrome (hypercortisolism). Metyrapone blocks cortisol synthesis by...

Purity: 99.83%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 500 mg



Mevastatin

(Compactin; ML236B)

Cat. No.: HY-17408

Bioactivity: Mevastatin (Compactin; ML236B) inhibits HMGCR (HMG-CoA reductase) (Ki for acid form is 1 nM) which in turn inhibits isoprenoid biosynthesis and therefore blocks protein isoprenylation and reduces plasma cholesterol levels in humans. IC50 value: 1 nM (Ki) Target: HMGCR Mevastatin induces...

Purity: 98.45%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



MG-132

Cat. No.: HY-13259

Bioactivity: MG-132 is a potent, reversible, and cell-permeable **20S proteasome** inhibitor which inhibits proteasomal chymotrypsin-like peptidase activity with an **IC_{50}** of 24.2 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



MHY1485

Cat. No.: HY-B0795

Bioactivity: MHY1485 is a cell-permeable **mTOR** activator. MHY1485 has an inhibitory effect on the autophagic process by inhibition of fusion between autophagosomes and lysosomes.

Purity: 99.05%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Mifepristone

(RU486; RU 38486)

Cat. No.: HY-13683

Bioactivity: Mifepristone is a **progesterone receptor** (**PR**) and **glucocorticoid receptor** (**GR**) antagonist with **IC_{50}**s of 0.2 nM and 2.6 nM in in vitro assay.

Purity: 98.17%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Milciclib
(PHA-848125) Cat. No.: HY-10424

Bioactivity: Milciclib (PHA-848125) is a potent, dual inhibitor of **CDK** and **Tropomyosin receptor kinase (TRK)**, with **IC_{50}**s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.
Purity: 98.61%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Mitomycin C
(Ametycine) Cat. No.: HY-13316

Bioactivity: Mitomycin C is an antitumor drug and antibiotic that shows extraordinary ability to inhibit **DNA synthesis**. Mitomycin C is a DNA cross-linking agent, which induces DNA damaging.
Purity: 99.45%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



MK 2206 dihydrochloride
Cat. No.: HY-10358

Bioactivity: MK 2206 dihydrochloride is an orally active allosteric **Akt** inhibitor with **IC_{50}**s of 5, 12 and 65 nM for **Akt1**, **Akt2** and **Akt3**, respectively.
Purity: 99.47%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



MK-5108
(VX-689) Cat. No.: HY-13252

Bioactivity: MK-5108 is a highly potent and specific inhibitor of **Aurora A kinase** with an **IC_{50}** value of 0.064 nM.
Purity: 99.11%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Mocetinostat
(MGCD0103) Cat. No.: HY-12164

Bioactivity: Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective **HDAC (Class I/IV)** inhibitor with **IC_{50}**s of 0.15, 0.29, 1.66 and 0.59 μM for **HDAC1**, **HDAC2**, **HDAC3** and **HDAC11**, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.
Purity: 99.81%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Momelotinib
(CYT387) Cat. No.: HY-10961

Bioactivity: Momelotinib (CYT387) is an ATP-competitive inhibitor of **JAK1/JAK2** with **IC_{50}**a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.
Purity: 98.11%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Momelotinib Mesylate
(CYT387 (Mesylate)) Cat. No.: HY-10963

Bioactivity: Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of **JAK1/JAK2** with **IC_{50}** of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.
Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg



Momelotinib sulfate
(CYT387 (sulfate salt)) Cat. No.: HY-10962

Bioactivity: Momelotinib sulfate (CYT387 sulfate) is an ATP-competitive inhibitor of **JAK1/JAK2** with **IC_{50}** of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC_{50}=155 nM).
Purity: 96.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Montelukast sodium
(MK0476) Cat. No.: HY-13315

Bioactivity: Montelukast (sodium) (MK0476) is a potent, selective **$CysLT_1$** receptor antagonist.
Purity: 99.82%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 50 mg, 100 mg, 500 mg



MRT67307
Cat. No.: HY-13018

Bioactivity: MRT67307 is a dual inhibitor of the **IKKε** and **TBK-1** with **IC_{50}**s of 160 and 19 nM, respectively. MRT67307 also inhibits ULK1 and ULK2 with IC_{50}s of 45 and 38 nM, respectively.
Purity: 99.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Myricetin
(Cannabiscetin) Cat. No.: HY-15097

Bioactivity: Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.

Purity: 99.41%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Naproxen
((S)-Naproxen) Cat. No.: HY-15030

Bioactivity: Naproxen is a **COX-1** and **COX-2** inhibitor with **IC_{50}**s of 8.72 and 5.15 μM, respectively in cell assay.

Purity: 99.66%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 g



Naproxen sodium
Cat. No.: HY-15030A

Bioactivity: Naproxen sodium is a **COX-1** and **COX-2** inhibitor with **IC_{50}**s of 8.72 and 5.15 μM, respectively in cell assay.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 g



Naringin
(Naringoside) Cat. No.: HY-N0153

Bioactivity: Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities.

Purity: 99.79%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 200 mg, 10 g



Necrostatin-1
(Nec-1) Cat. No.: HY-15760

Bioactivity: Necrostatin-1 (Nec-1) is a potent, selective and cell-permeable **necroptosis** inhibitor with an **EC_{50}** of 490 nM in Jurkat cells. It acts by inhibiting the death domain kinase RIP (**RIP1**) in the necroptosis pathway.

Purity: 99.20%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Neferine
((-)-Neferine) Cat. No.: HY-N0441

Bioactivity: Neferine is a major bisbenzylisoquinline alkaloid. Neferine strongly inhibits **NF-κB** activation.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Niacin
(Nicotinic acid; Vitamin B3) Cat. No.: HY-B0143

Bioactivity: Niacin (Vitamin B3) is a water-soluble vitamin and is part of the vitamin B group. Target: Others Niacin (also known as vitamin B3 and nicotinic acid) is an organic compound with the formula C6H5NO2 and, depending on the definition used, one of the 20 to 80 essential human nutrients. Not enough niacin in...

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 1 g, 5 g

Nicardipine Hydrochloride
(YC-93 Hydrochloride) Cat. No.: HY-12515A

Bioactivity: Nicardipine Hydrochloride (YC-93 Hydrochloride) is a calcium channel blocker that has been widely used to control blood pressure in severe hypertension following events such as ischemic stroke, traumatic brain injury, and intracerebral hemorrhage.

Purity: 99.85%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Nifedipine
(BAY-a-1040) Cat. No.: HY-B0284

Bioactivity: Nifedipine (BAY-a-1040) is a potent **calcium channel** blocker and drug of choice for cardiac insufficiencies.

Purity: 97.64%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g, 10 g



Nilotinib
(AMN107) Cat. No.: HY-10159

Bioactivity: Nilotinib is an orally available **Bcr-Abl** tyrosine kinase inhibitor with antineoplastic activity.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Nilotinib monohydrochloride monohydrate

(AMN107 (monohydrochloride monohydrate)) Cat. No.: HY-10159A

Bioactivity: Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly more potent against **BCR-ABL** than Imatinib, and is active against many Imatinib-resistant BCR-ABL mutants.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Nimodipine

(BAY-e 9736) Cat. No.: HY-B0265

Bioactivity: Nimodipine(Nimotop) is a dihydropyridine derivative and an analogue of the calcium channel blocker nifedipine, with antihypertensive activity.Nimodipine decreases intracellular free Ca2+,Beclin-1 and autophagy. Target: Calcium Channel Nimodipine is main use is in the prevention of cerebral...

Purity: 99.87%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Nitazoxanide

(NTZ; NSC 697855) Cat. No.: HY-B0217

Bioactivity: Nitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. (IC50 for canine influenza virus ranges from 0.17 to 0.21 μM). Target: Others Nitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. In vitro studies...

Purity: 95.24%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Nitrendipine

(BAY-E-5009) Cat. No.: HY-B0424

Bioactivity: Nitrendipine is a calcium channel blocker with marked vasodilator action. Target: Calcium Channel Nitrendipine is a dihydropyridine calcium channel blocker. It is used in the treatment of primary hypertension to decrease blood pressure. Nitrendipine blocked Ca2+ currents very potently, with...

Purity: 99.29%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Nitroprusside disodium dihydrate (Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate)

Cat. No.: HY-A0119

Bioactivity: Nitroprusside disodium dihydrate is a potent vasodilator working through releasing NO spontaneously in blood. Target: Others Nitroprusside disodium dihydrate is a potent vasodilator. Sodium nitroprusside has potent vasodilating effects in arterioles and venules. Sodium Nitroprusside breaks...

Purity: >98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 g



Nitroxoline

(8-Hydroxy-5-nitroquinoline; 5-Nitro-8-quinolinol) Cat. No.: HY-B1159

Bioactivity: Nitroxoline is an antibiotic that has proven to be very effective at combating biofilm infections. Nitroxoline functions by chelating Fe2+ and Zn2+ ions from the biofilm matrix.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g



Nobiletin

Cat. No.: HY-N0155

Bioactivity: Nobiletin is a citrus flavonoid with anti-inflammatory, anti-cancer, cholesterol lowering, memory protection activities.

Purity: 99.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Nocodazole

(Oncodazole; R17934) Cat. No.: HY-13520

Bioactivity: Nocodazole is a rapidly-reversible inhibitor of **microtubule**. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits **Bcr-Abl**, activates **CRISPR/Cas9**.

Purity: 98.68%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Nordihydroguaiaretic acid

(NDGA) Cat. No.: HY-N0198

Bioactivity: Nordihydroguaiaretic acid is a **5-lipoxygenase** (**5LOX**) (**IC_{50}**=8±3 μM) and tyrosine kinase inhibitor.

Purity: 99.78%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Norepinephrine

(Levarterenol; L-Noradrenaline) Cat. No.: HY-13715

Bioactivity: Norepinephrine (Levarterenol; L-Noradrenaline) is a **$β_1$**-selective **adrenergic receptor** agonist with **EC_{50}** of 5.37 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg



Norepinephrine bitartrate monohydrate (Levarterenol (bitartrate monohydrate); ...)

Cat. No.: HY-13715B

Bioactivity: Norepinephrine bitartrate monohydrate (Levarterenol bitartrate monohydrate; L-Noradrenaline bitartrate monohydrate) is a β_1-selective **adrenergic receptor** agonist with EC_{50} of 5.37 μM.

Purity: 99.75%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 500 mg, 1 g, 5 g



Norepinephrine hydrochloride (Levarterenol (hydrochloride); L-Noradrenaline (hydrochloride))

Cat. No.: HY-13715A

Bioactivity: Norepinephrine hydrochloride (Levarterenol hydrochloride; L-Noradrenaline hydrochloride) is a β_1-selective **adrenergic receptor** agonist with EC_{50} of 5.37 μM.

Purity: >98%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g



Nortriptyline hydrochloride (Desmethylamitriptyline hydrochloride)

Cat. No.: HY-B1417

Bioactivity: Nortriptyline hydrochloride is a tricyclic antidepressant used to relieve the symptoms of depression.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg



Noscapine ((S,R)-Noscapine)

Cat. No.: HY-13716

Bioactivity: Noscapine is an orally administrable drug used worldwide for cough suppression, primarily mediated by its σ-receptor agonist activity, and possess anticancer activity. Target: σ-receptor in vitro: Noscapine is a phthalideisoquinoline alkaloid from opium, is a recently discovered anticancer drug...

Purity: 97.80%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Novobiocin Sodium (Albamycin; Cathomycin)

Cat. No.: HY-B0425A

Bioactivity: Novobiocin Sodium is an antibiotic compound derived from Streptomyces niveus. Target: Antibacterial Novobiocin, also known as albamycin or cathomycin, is an aminocoumarin antibiotic that is produced by the actinomycete Streptomyces niveus, which has recently been identified as a subjective...

Purity: 95.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



NS1643

Cat. No.: HY-16916

Bioactivity: NS1643 is a potent human ether-a-go-go related gene (hERG) KV11.1 channel activator (EC50 = 10.5 μM). IC50 value: Target: HERG activator in vitro: NS1643 enhanced the magnitude of wild-type hERG current in a concentration- and voltage-dependent manner with an EC(50) of 10.4 microM at -10...

Purity: 96.85%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



NSC 185058

Cat. No.: HY-125169

Bioactivity: NSC 185058 is an inhibitor of **ATG4B**, a major **cysteine protease**. NSC185058 markedly attenuates **autophagic** activity [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Nutlin 3a (Nutlin-3a chiral)

Cat. No.: HY-10029

Bioactivity: Nutlin 3a is an active enantiomer of Nutlin-3, acts as a murine double minute (**MDM2**) antagonist that inhibits **MDM2-p53** interactions and stabilizes the p53 protein, and thereby induces cell cycle arrest and apoptosis.

Purity: 98.11%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



NVP-AEW541 (AEW541)

Cat. No.: HY-50866

Bioactivity: NVP-AEW541 is a potent inhibitor of **IGF-1R** with IC_{50} of 0.15 μM, also inhibits **InsR**, with IC_{50} of 0.14 μM.

Purity: 98.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Obatoclax (Obatoclax Mesylate; GX15-070)

Cat. No.: HY-10969

Bioactivity: Obatoclax is an inhibitor of the **BCL-2** family proteins. It binds to **BCL-2** with a K_i of 220 nM.

Purity: 99.20%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Olanzapine
(LY170053) Cat. No.: HY-14541

Bioactivity: Olanzapine(LY170053) is a high affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist. IC50 Value: Target: 5-HT Receptor Olanzapine is a thienobenzodiazepine that blocks especially the serontonin (5-hydroxytryptamine [5-HT]) 5-HT2A and the dopamine D2 receptors (Ki values are 4 and 11 nM...

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



Olaparib
(AZD2281; KU0059436) Cat. No.: HY-10162

Bioactivity: Olaparib (AZD2281;KU0059436) is a potent and oral **PARP** inhibitor with **IC_{50}**s of 5 and 1 nM for **PARP1** and **PARP2**, respectively.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g



Oleanolic Acid
(Oleanic acid; Caryophyllin) Cat. No.: HY-N0156

Bioactivity: Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.

Purity: 98.0%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg

Omeprazole
(H 16868) Cat. No.: HY-B0113

Bioactivity: Omeprazole (H 16868) is a proton pump inhibitor used in the treatment of dyspepsia.

Purity: 97.06%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Omipalisib
(GSK2126458; GSK458) Cat. No.: HY-10297

Bioactivity: Omipalisib (GSK2126458) is a highly selective and potent inhibitor of **PI3K** with **K_i**s of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively.

Purity: 99.31%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Oprozomib
(ONX 0912; PR-047) Cat. No.: HY-12113

Bioactivity: Oprozomib (ONX 0912; PR047) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. IC50 value: 36 nM/82 nM(20S proteasome β5/LMP7) [1] Target: 20S proteasome The anti-MM activity of Oprozomib is associated with activation of caspase-8,...

Purity: 99.60%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Oroxylin A
(Baicalein 6-methyl ether; 6-Methoxybaicalein) Cat. No.: HY-N0560

Bioactivity: Oroxylin A is a natural active flavonoid with strong anticancer effects. IC50 value: Target: In vitro: Oroxylin A suppressed the MDM2-mediated degradation of p53 via downregulating MDM2 transcription in wt-p53 cancer cells [1]. Oroxylin A remarkably reduced the generation of lactate and...

Purity: 99.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



OSI-027
Cat. No.: HY-10423

Bioactivity: OSI-027 is an ATP-competitive **mTOR** kinase activity inhibitor with an **IC_{50}** of 4 nM. OSI-027 targets both **mTORC1** and **mTORC2** with **IC_{50}**s of 22 nM and 65 nM, respectively.

Purity: 98.60%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Ouabain Octahydrate
(Acocantherine; G-Strophanthin) Cat. No.: HY-B0542

Bioactivity: Ouabain Octahydrate is an inhibitor of **Na^+/K^+-ATPase**, used for the treatment of congestive heart failure.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Oxaliplatin
Cat. No.: HY-17371

Bioactivity: Oxaliplatin is a **DNA synthesis** inhibitor. It causes DNA crosslinking damage, prevents DNA replication and transcription and causes cell death.

Purity: 99.86%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg



Oxidopamine hydrobromide

(6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide)Cat. No.: HY-B1081A

Bioactivity: Oxidopamine (hydrobromide), an antagonist of the **neurotransmitter dopamine**, is a widely used neurotoxin that selectively destroys dopaminergic neurons.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Oxyphenisatin acetate

Cat. No.: HY-101714

Bioactivity: Oxyphenisatin acetate, the pro-drug of oxyphenisatin, is used to be a laxative.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Oxyresveratrol

(trans-Oxyresveratrol) Cat. No.: HY-N1430

Bioactivity: Oxyresveratrol is neuroprotective and inhibits the apoptotic cell death in transient cerebral ischemia. It effectively scavenges H2O2, NO (IC50 = 45.3 μM), and the artificial free radical 2,2-diphenyl-l-picrylhydrazyl (IC50 = 28.9 μM) In vitro: 1)oxyresveratrol exhibited more than 50% inhibition at...

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g



PAC-1

(Procaspase activating compound 1) Cat. No.: HY-13523

Bioactivity: PAC-1 is an activator of **procaspase-3** induces apoptosis in cancer cells with $\mathbf{EC_{50}}$ of 2.08 μM.

Purity: 95.98%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Paclitaxel

(Taxol) Cat. No.: HY-B0015

Bioactivity: Paclitaxel (Taxol), a naturally occurring antineoplastic agent, stabilizes **tubulin polymerization**, resulting in arrest at the G2/M phase of the cell cycle and apoptotic cell death [1] [2].

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



Panobinostat

(LBH589; NVP-LBH589) Cat. No.: HY-10224

Bioactivity: Panobinostat is a non-selective histone deacetylase (**HDAC**) inhibitor.

Purity: 98.42%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Pantoprazole sodium

(BY1023 (sodium); SKF96022 (sodium)) Cat. No.: HY-17507A

Bioactivity: Pantoprazole sodium salt(SKF96022; Protonix) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. IC50 value: Target: proton pump inhibitor

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Paroxetine hydrochloride

(BRL29060 hydrochloride; BRL29060A) Cat. No.: HY-B0492

Bioactivity: Paroxetine hydrochloride is a potent selective **serotonin-reuptake** inhibitor, commonly prescribed as an antidepressant and has GRK2 inhibitory ability with $\mathbf{IC_{50}}$ of 14μM.

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Paroxetine hydrochloride hemihydrate (BRL29060 hydrochloride hemihydrate; BRL29060A hemihydrate)

Cat. No.: HY-B0492A

Bioactivity: Paroxetine hydrochloride hemihydrate is a potent selective **serotonin-reuptake** inhibitor, commonly prescribed as an antidepressant and has GRK2 inhibitory ability with $\mathbf{IC_{50}}$ of 14μM.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg



Parthenolide

((-)-Parthenolide) Cat. No.: HY-N0141

Bioactivity: Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting **NF-κB** activation; also inhibits **HDAC1** protein without affecting other class I/II HDACs.

Purity: 99.88%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



Pazopanib
(GW786034) Cat. No.: HY-10208

Bioactivity: Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with **IC_{50}**s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Purity: 99.68%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Pazopanib Hydrochloride
(GW786034 (Hydrochloride)) Cat. No.: HY-12009

Bioactivity: Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an **IC_{50}** of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



PD 169316
Cat. No.: HY-10578

Bioactivity: PD 169316 is a potent, cell-permeable and selective **p38 MAP kinase** inhibitor, with **IC_{50}** of 89 nM.

Purity: 98.33%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg

PD-166866
Cat. No.: HY-101296

Bioactivity: PD166866 is a selective **FGFR1** tyrosine kinase inhibitor with an **IC_{50}** of 52.4 nM.

Purity: 99.68%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



PD0325901
(PD325901) Cat. No.: HY-10254

Bioactivity: PD0325901 is a selective and cell permeable **MEK** inhibitor with an **IC_{50}** of 0.33 nM.

Purity: 99.95%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



PD146176
(NSC168807) Cat. No.: HY-103157

Bioactivity: PD146176 (NSC168807) is a **15-Lipoxygenase (15-LO)** inhibitor, which inhibits rabbit reticulocyte 15-LO with a **K_i** of 197 nM. PD146176 (NSC168807) has a dramatic effect in reducing atherogenesis [1].

Purity: 99.0%
Clinical Data: No Development Reported
Size: 5 mg



PD168393
Cat. No.: HY-13896

Bioactivity: PD168393 is an potent, cell-permeable, irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773, inactive against insulin, PDGFR, FGFR and PKC. target: EGFR IC 50: 0.7 nM [1] (1) PD 168393 inhibite EGFr autophosphorylation in A431 human epidermoid carcinoma cells with >9-fold...

Purity: 98.87%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg



PD98059
Cat. No.: HY-12028

Bioactivity: PD98059 is a potent, selective and cell-permeable **MEK1** and **MEK2** inhibitor with **IC_{50}**s of 4 μM and 50 μM respectively.

Purity: 99.33%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Peiminine
(Verticinone; Raddeanine) Cat. No.: HY-N0213

Bioactivity: Peiminine(Verticinone; Raddeanine) is a natural compound with anti-inflammatory activity. IC50 value: Target: Peiminine and DXS significantly reduced alveolar inflammation and pulmonary interstitial inflammation in rats with bleomycin-induced lung injury. peiminine inhibits lung inflammation and pulmonary...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Pemetrexed
(LY231514) Cat. No.: HY-10820

Bioactivity: Pemetrexed is a novel **antifolate**, the **K_i** values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (**TS**), dihydrofolate reductase (**DHFR**), and glycinamide ribonucleotide formyltransferase (**GARFT**), respectively.

Purity: 99.30%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Pemetrexed disodium

(LY231514 disodium) Cat. No.: HY-10820A

Bioactivity: Pemetrexed disodium is a novel **antifolate** that inhibits the folatedependent enzymes **thymidylate synthase**, **dihydrofolate reductase**, and **glycinamide ribonucleotide formyltransferase** with K_is of 1.3, 7.2, and 65 nM, respectively.

Purity: 99.77%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 50 mg, 100 mg, 200 mg



Pemetrexed disodium hemipenta hydrate

(LY231514 (disodium hemipenta hydrate)) Cat. No.: HY-13781

Bioactivity: Pemetrexed disodium hemipenta hydrate is a novel **antifolate**, the K_i values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (**TS**), dihydrofolate reductase (**DHFR**), and glycinamide ribonucleotide formyltransferase (**GARFT**), respectively.

Purity: 99.78%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Penfluridol

(R-16341) Cat. No.: HY-B1077

Bioactivity: Penfluridol is a highly potent, first generation diphenylbutylpiperidine antipsychotic.

Purity: 99.84%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Pentoxifylline

(BL-191; PTX; Oxpentifylline) Cat. No.: HY-B0715

Bioactivity: Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor. Target: PDE Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate...

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g



Pepstatin

(Pepstatin A) Cat. No.: HY-P0018

Bioactivity: Pepstatin is a specific **aspartic protease** inhibitor produced by actinomycetes, with IC_{50}s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease,...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



Perifosine

(KRX-0401; NSC 639966; D21266) Cat. No.: HY-50909

Bioactivity: Perifosine is an oral **Akt** inhibitor which inhibits proliferation of different tumor cell lines with IC_{50}s of 0.6-8.9 μM.

Purity: 98.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg

PF-04691502

Cat. No.: HY-15177

Bioactivity: PF-04691502 is a potent and selective inhibitor of **PI3K** and **mTOR**. PF-04691502 binds to human PI3Kα, β, δ, γ and mTOR with K_is of 1.8, 2.1, 1.6, 1.9 and 16 nM, respectively.

Purity: 99.49%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PF-4708671

Cat. No.: HY-15773

Bioactivity: PF-4708671 is a potent cell-permeable **S6K1** inhibitor with a K_i of 20 nM and IC_{50} of 160 nM.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



PFI-1

Cat. No.: HY-16586

Bioactivity: PFI-1 is a selective **BET** (bromodomain-containing protein) inhibitor for BRD4 with IC_{50} of 0.22 μM in a cell-free assay.

Purity: 99.80%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



PFK-015

Cat. No.: HY-12204

Bioactivity: PFK-015 is an effective inhibitor of PFKFB3 with IC50 of 110 nM (recombinant PFKFB3) and inhibits PFKFB3 activity in cancer cells with IC50 of 20 nM. IC50 value: 110 nM (recombinant PFKFB3)[1] Target: PFKFB3 PFK-015 possesses compelling in vitro properties, has satisfactory PK properties in rodents,...

Purity: 98.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PFK-158

Cat. No.: HY-12203

Bioactivity: PFK-158 is a potent and selective inhibitor of PFKFB3 that is currently being investigated in a phase I study in patients with advanced solid malignancies. Target: PFKFB3 in vitro: PFK-158 is the first 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3)...

Purity: 98.85%

Clinical Data: Phase 1

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PHA-665752

Cat. No.: HY-11107

Bioactivity: PHA-665752 is a potent, selective and ATP-competitive **c-Met** inhibitor with an **IC_{50}** of 9 nM.

Purity: 96.50%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Phenformin hydrochloride

(Phenethylbiguanide hydrochloride)

Cat. No.: HY-16397A

Bioactivity: Phenformin (hydrochloride) is a hydrochloride salt of phenformin that is an anti-diabetic drug from the biguanide class, can activate **AMPK** activity.

Purity: 98.0%

Clinical Data: Phase 1

Size: 10mM x 1mL in DMSO, 1 g, 5 g



PI-103

Cat. No.: HY-10115

Bioactivity: PI-103 is a potent **PI3K** and **mTOR** inhibitor with **IC_{50}**s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for **p110α**, **p110β**, **p110δ**, **p110γ**, **mTORC1**, and **mTORC2**. PI-103 also inhibits **DNA-PK** with an **IC50** of 2 nM.

Purity: 99.86%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PI-103 Hydrochloride

Cat. No.: HY-10115A

Bioactivity: PI-103 Hydrochloride is a dual **PI3K** and **mTOR** inhibitor with **IC_{50}**s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for **p110α**, **p110β**, **p110δ**, **p110γ**, **mTORC1**, and **mTORC2**. PI-103 also inhibits **DNA-PK** with an **IC50** of 2 nM.

Purity: 99.78%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Piceatannol

(Astringenin; trans-Piceatannol)

Cat. No.: HY-13518

Bioactivity: Piceatannol is a selective inhibitor of protein tyrosine kinase Syk. It could inhibit ICa,L, Ito, IKr, Ca2+ transients and Na+-Ca2+ exchange except IK1. Shows multiple biological activities such as anti-inflammatory, antiproliferative and immunomodulatory effects. In vitro: The treatment of human...

Purity: 98.10%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg, 100 mg



Pictilisib

(GDC-0941)

Cat. No.: HY-50094

Bioactivity: Pictilisib (GDC-0941) is a potent inhibitor of **PI3Kα/δ** with an **IC_{50}** of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

Purity: 99.62%

Clinical Data: Phase 2

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Pictilisib dimethanesulfonate

(GDC-0941 (dimethanesulfonate) ; GDC-0941 (2 MeSO3H salt))

Cat. No.: HY-20180

Bioactivity: Pictilisib dimethanesulfonate (GDC-0941 dimethanesulfonate) is a potent inhibitor of **PI3Kα/δ** with **IC_{50}** of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

Purity: 99.12%

Clinical Data: Phase 2

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Pifithrin-μ

(PFTμ; 2-Phenylethynesulfonamide)

Cat. No.: HY-10940

Bioactivity: Pifithrin-μ is an inhibitor of **p53** and **HSP70**, with antitumor and neuroprotective activity.

Purity: 98.31%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 10 mg



Pinocembrin

((+)-Pinocoembrin; Dihydrochrysin; Galangin flavanone)

Cat. No.: HY-N0575

Bioactivity: Pinocembrin ((+)-Pinocoembrin) is a flavonoid found in propolis, acts as a competitive inhibitor of **histidine decarboxylase**, and is an effective anti-allergic agent, with antioxidant, antimicrobial and anti-inflammatory properties [1].

Purity: 99.26%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



Piperine

(Bioperine; 1-Piperoylpiperidine) **Cat. No.:** HY-N0144

Bioactivity: Piperine, a natural alkaloid isolated from Piper nigrum L, inhibits **P-glycoprotein** and **CYP3A4** activities with an **IC_{50}** value of 61.94±0.054 μg/mL in HeLa cell.

Purity: 98.76%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 200 mg, 1 g, 5 g



Piperlongumine

(Piplartine) **Cat. No.:** HY-N2329

Bioactivity: Piperlongumine is a natural alkaloid isolated from Piper longum Linn [1], possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities [2]. Piperlongumine induces ROS, ...

Purity: 99.19%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg



Pirarubicin

(THP) **Cat. No.:** HY-13725

Bioactivity: Pirarubicin is an anthracycline antibiotics, acts as a **topoisomerase II** inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.

Purity: 99.02%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg



Pirarubicin Hydrochloride

(THP Hydrochloride) **Cat. No.:** HY-13725A

Bioactivity: Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a **topoisomerase II** inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.

Purity: 96.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Pitavastatin Calcium

(Pitavastatin (hemicalcium); NK-104 (hemicalcium)) **Cat. No.:** HY-B0144

Bioactivity: Pitavastatin Calcium is a potent **hydroxymethylglutaryl-CoA (HMG-CoA) reductase** inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an **IC_{50}** of 5.8 nM in HepG2 cells.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Polydatin

(Piceid) **Cat. No.:** HY-N0120A

Bioactivity: Polydatin (Piceid), extracted from the roots of Polygonum cuspidatum Sieb, a widely used traditional Chinese remedies, possesses anti-inflammatory activity in several experimental models.

Purity: 98.42%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Ponatinib

(AP24534) **Cat. No.:** HY-12047

Bioactivity: Ponatinib is a potent, orally available multi-targeted kinase inhibitor with **IC_{50}**s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.

Purity: 98.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



PR-619

Cat. No.: HY-13814

Bioactivity: PR-619 is a broad-range **DUB** inhibitor with **EC_{50}** of 3.93, 4.9, 6.86, 7.2, and 8.61 μM for **USP4**, **USP8**, **USP7**, **USP2**, and **USP5**, respectively.

Purity: 98.81%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Pramipexole dihydrochloride

Cat. No.: HY-17355

Bioactivity: Pramipexole 2Hcl is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively. IC50 Value: 3.9 nM(D2S); 2.2 nM(D2L); 0.5 nM(D3); 5.1 nM(D4) Target: Dopamine Receptor Pramipexole dihydrochloride is a dopamine receptor agonist...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 mg, 50 mg



Prazosin hydrochloride

Cat. No.: HY-B0193A

Bioactivity: Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder. It is an alpha-adrenergic...

Purity: 99.73%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Pregnenolone

(Arthenolone; 3β-Hydroxy-5-pregnen-20-one) Cat. No.: HY-B0151

Bioactivity: Pregnenolone acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor**, reduces several effects of tetrahydrocannabinol (THC).

Purity: 98.0%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 1 g, 5 g

Pregnenolone monosulfate

(Pregn-5-en-20-on-3β-yl sulfuric acid) Cat. No.: HY-B1739

Bioactivity: Pregnenolone monosulfate acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor**, reduces several effects of tetrahydrocannabinol (THC).

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg



PRIMA-1

(NSC-281668) Cat. No.: HY-19980A

Bioactivity: PRIMA-1 (NSC-281668) is a mutant **p53** reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



PRIMA-1Met

(APR-246) Cat. No.: HY-19980

Bioactivity: PRIMA-1MET restores wild-type conformation and function to mutant **p53**, and triggers apoptosis in tumor cells. PRIMA-1MET also targets the selenoprotein thioredoxin reductase 1 (**TrxR1**), a key regulator of cellular redox balance.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Procainamide hydrochloride

Cat. No.: HY-A0084

Bioactivity: Procainamide hydrochloride is an anti-arrhythmic agent and is used to treat cardiac arrhythmia; induces rapid block of the batrachotoxin(BTX)-activated sodium channels of the heart muscle and acts as antagonist to long gating closures.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Proflavine hemisulfate

(Proflavin hemisulfate; 3,6-Diaminoacridine hemisulfate) Cat. No.: HY-B0883

Bioactivity: Proflavine hemisulfate is an Acridine derivative, which is a slow-acting disinfectant with bacteriostatic action against many Gram-positive bacteria but less effective against Gram-negative organisms.

Purity: 99.13%
Clinical Data: Phase 2
Size: 10mM x 1mL in Water, 100 mg



Propranolol hydrochloride

Cat. No.: HY-B0573

Bioactivity: Propranolol hydrochloride is a nonselective β-adrenergic receptor (**βAR**) antagonist with an **IC_{50}** of 12 nM.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g



PTC-209

Cat. No.: HY-15888

Bioactivity: PTC-209 is a specific **BMI-1** inhibitor with an **IC_{50}** of 0.5 μM.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PTC-209 hydrobromide

Cat. No.: HY-15888A

Bioactivity: PTC-209 hydrobromide is a specific **BMI-1** inhibitor with **IC_{50}** of 0.5 μM in both GEMS reporter and ELISA assays.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



Pterostilbene

Cat. No.: HY-N0828

Bioactivity: Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium [1]. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties [1] [4]. Pterostilbene blocks ...

Purity: 99.79%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 25 mg



Purmorphamine
(Shh Signaling Antagonist VI) Cat. No.: HY-15108

Bioactivity: Purmorphamine is a **smoothened receptor** agonist with an **EC_{50}** of 1 μM.

Purity: 99.89%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Purvalanol A
(NG-60) Cat. No.: HY-18299A

Bioactivity: Purvalanol A is a potent **CDK** inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with **IC_{50}**s of 4, 70, 35, 850, 75 nM, resepctively.

Purity: 98.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PX-478
Cat. No.: HY-10231

Bioactivity: PX-478 is an antitumor inhibitor of hypoxia-inducible factor-1α (**HIF-1α**).

Purity: 98.0%
Clinical Data: Phase 1
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg



Pyrazinamide
(Pyrazinecarboxamide; Pyrazinoic acid amide) Cat. No.: HY-B0271

Bioactivity: Pyrazinamide is a pyrazine that is used therapeutically as an antitubercular agent. Target: Antibacterial Pyrazinamide is a prodrug that stops the growth of Mycobacterium tuberculosis. Pyrazinoic acid was thought to inhibit the enzyme fatty acid synthase (FAS) I, which is required by the bacterium to...

Purity: 99.37%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 g, 50 g



Pyriproxyfen
(S-31183) Cat. No.: HY-B2031

Bioactivity: Pyriproxyfen is a juvenile hormone analog, preventing larvae from developing into adulthood and thus rendering them unable to reproduce. Pyriproxyfen is a pyridine-based pesticide which is found to be effective against a variety of arthropoda.

Purity: 99.74%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 g



Quercetin
Cat. No.: HY-18085

Bioactivity: Quercetin, a natural flavonoid, is a stimulator of recombinant **SIRT1** and also a **PI3K** inhibitor with **IC_{50}** of 2.4±0.6 μM, 3.0±0.0 μM and 5.4±0.3 μM for PI3K γ, PI3K δ and PI3K β, respectively.

Purity: 98.0%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Quercitrin
(Quercetin 3-rhamnoside) Cat. No.: HY-N0418

Bioactivity: Quercitrin is a natural compound found in Tartary buckwheat with a potential anti-inflammation effect that is used to treat heart and vascular conditions. IC50 value: Target: In vitro: There were significant increases in caspase-3 activity, loss of MMP, and increases in the apoptotic cell population in...

Purity: 99.12%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Quinacrine dihydrochloride
(Mepacrine dihydrochloride; SN-390) Cat. No.: HY-13735A

Bioactivity: Quinacrine is a fluorescent probe for the conformational transitions of the cholinergic receptor protein. Quinacrine shows activity in the low μM range with a mean IC50 of 2.30 μM In the patient AML cells. IC50 value: 2.30 μM (for AML cells) Target: in vitro: Quinacrine is a fluorescent probe for the...

Purity: 98.05%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Quizartinib
(AC220) Cat. No.: HY-13001

Bioactivity: Quizartinib (AC220) is a potent **Flt3** tyrosine kinase inhibitor with a **K_d** of 1.6±0.7 nM.

Purity: 99.34%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Rabusertib
(LY2603618; IC-83) Cat. No.: HY-14720

Bioactivity: Rabusertib (LY2603618) is a potent and selective inhibitor of **Chk1** with an **IC_{50}** of 7 nM.

Purity: 99.69%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



RAF265

(CHIR-265) Cat. No.: HY-10248

Bioactivity: RAF265 is a potent **RAF/ VEGFR2** inhibitor.

Purity: 99.72%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Raloxifene hydrochloride

(LY156758 hydrochloride; LY139481 hydrochloride) Cat. No.: HY-13738A

Bioactivity: Raloxifene hydrochloride(LY156758 hydrochloride) is a second generation selective estrogen receptor antagonist. Target: Estrogen receptor Approved: September 14, 2007 Raloxifene activates TGF beta 3 promoter as a full agonist at nanomolar concentrations, and raloxifene inhibits the estrogen response...

Purity: 99.64%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



Ranolazine dihydrochloride

(CVT 303 (dihydrochloride); RS 43285) Cat. No.: HY-17401

Bioactivity: Ranolazine dihydrochloride (RS-43285) is an antianginal agent with antiarrhythmic properties that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current), without affecting heart rate or blood pressure (BP). IC50 value: Target: sodium-dependent calcium...

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 200 mg, 500 mg, 1 g, 5 g



Rapamycin

(Sirolimus; AY 22989) Cat. No.: HY-10219

Bioactivity: Rapamycin (Sirolimus; AY 22989) is a potent and specific **mTOR** inhibitor with an **IC_{50}** of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of **mTORC1** [1]. Rapamycin is...

Purity: 99.93%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g, 5 g



Rasagiline mesylate

(AGN1135 (mesylate); TVP1012 (mesylate)) Cat. No.: HY-14605

Bioactivity: Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. Target: Monoamine Oxidase (MAO)-B Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as...

Purity: 97.56%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 50 mg, 100 mg



Regorafenib

(BAY 73-4506) Cat. No.: HY-10331

Bioactivity: Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1**, respectively.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Regorafenib Hydrochloride

(BAY73-4506 hydrochloride) Cat. No.: HY-13308

Bioactivity: Regorafenib Hydrochloride is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

Purity: 99.58%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Regorafenib monohydrate

(BAY 73-4506 monohydrate) Cat. No.: HY-10331A

Bioactivity: Regorafenib monohydrate is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Resatorvid

(TAK-242; CLI-095) Cat. No.: HY-11109

Bioactivity: Resatorvid (TAK-242) is a potent **TLR4** signaling inhibitor which selectively inhibits the TLR4-mediated production of cytokines and nitric oxide.

Purity: 99.95%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Reserpine

Cat. No.: HY-N0480

Bioactivity: Reserpine is an inhibitor of the **vesicular monoamine transporter 2** (**VMAT2**).

Purity: 99.83%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Reversine

Cat. No.: HY-14711

Bioactivity: Reversine is a novel class of ATP-competitive **Aurora kinase** inhibitor with **IC_{50}**s of 400, 500 and 400 nM for **Aurora A**, **Aurora B** and **Aurora C**, respectively.

Purity: 99.25%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Rhein

(Rheic Acid; Rhubarb yellow; Monorhein)

Cat. No.: HY-N0105

Bioactivity: Rhein is a lipophilic anthraquinone extensively found in medicinal herbs, and has many pharmacological effects, including epatoprotective, nephroprotective, anti-inflammatory, antioxidant, anticancer, and antimicrobial activities. IC50 value: Target: In vitro: Rhein (0.1 and 1...

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



RITA

(NSC 652287)

Cat. No.: HY-13424

Bioactivity: RITA is an inhibitor of **p53-HDM-2 interaction**, binds to p53dN, with a **K_d** of 1.5 nM, and also induces **DNA-DNA cross-links**.

Purity: 99.57%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

ROC-325

Cat. No.: HY-103706

Bioactivity: ROC-325 is a novel inhibitor of **autophagy**.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Rosiglitazone

(BRL49653)

Cat. No.: HY-17386

Bioactivity: Rosiglitazone (BRL49653) is a selective **PPARγ** agonist with **EC_{50}**s of 30 nM, 100 nM and 60 nM for **PPARγ1**, **PPARγ2**, and **PPARγ**, respectively.

Purity: 99.21%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 200 mg



Rosiglitazone maleate

(BRL 49653C)

Cat. No.: HY-14600

Bioactivity: Rosiglitazone maleate is a potent and selective activator of **PPARγ**, with **EC_{50}**s of 30 nM, 100 nM and 60 nM for **PPARγ1**, **PPARγ2**, and **PPARγ**, respectively, and a **K_d** of appr 40 nM for **PPARγ**; Rosiglitazone maleate is also an modulator of **...**

Purity: 99.25%
Clinical Data: Launched
Size: 100 mg, 500 mg



Rosuvastatin Calcium

(Rosuvastatin hemicalcium; ZD 4522 Calcium)

Cat. No.: HY-17504

Bioactivity: Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM. IC50 Value: 11 nM [1] Target: HMG-CoA reductase in vitro: Rosuvastatin is relatively hydrophilic and is highly selective for hepatic cells; its uptake is mediated by the liver-specific organic anion...

Purity: 97.73%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Rotenone

Cat. No.: HY-B1756

Bioactivity: Rotenone is an **mitochondrial electron transport chain complex I** inhibitor.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Rottlerin

(Mallotoxin; NSC 56346; NSC 94525)

Cat. No.: HY-18980

Bioactivity: Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific **PKC** inhibitor, with **IC_{50}** values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream...

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg



Rupatadine Fumarate

(UR-12592 (Fumarate))

Cat. No.: HY-13511A

Bioactivity: Rupatadine Fumarate (UR-12592 Fumarate) is a potent dual PAF/H1 antagonist with Ki of 0.55/0.1 uM(rabbit platelet membranes/guinea pig cerebellum membranes). IC50 value: Target: PAF/H1 antagonist in vitro: Rupatadine competitively inhibited histamine-induced guinea pig ileum contraction (pA2...

Purity: 99.34%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Rutin

(Rutoside; Quercetin 3-O-rutinoside) Cat. No.: HY-N0148

Bioactivity: Rutin, a naturally occurring flavonoid glycoside, has antioxidant, anti-inflammatory, anti-allergic, anti-angiogenic and antiviral properties.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g, 10 g



Ruxolitinib

(INCB018424) Cat. No.: HY-50856

Bioactivity: Ruxolitinib is a potent and selective **JAK1/2** inhibitor with **IC_{50}**s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Ruxolitinib phosphate

(INCB018424 phosphate) Cat. No.: HY-50858

Bioactivity: Ruxolitinib phosphate is a potent **JAK1/2** inhibitor with **IC_{50}**s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Ruxolitinib S enantiomer

(S-Ruxolitinib; INCB18424) Cat. No.: HY-50856A

Bioactivity: Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective **JAK1/2** inhibitor to enter the clinic with **IC_{50}** of 3.3 nM/2.8 nM in cell-free assays.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



Ruxolitinib sulfate

(INCB018424 sulfate) Cat. No.: HY-50859

Bioactivity: Ruxolitinib sulfate is the first potent, selective **JAK1/2** inhibitor to enter the clinic with **IC_{50}**s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



S130

Cat. No.: HY-112818

Bioactivity: S130 is a high affinity, selective inhibitor of **ATG4B** (a major cysteine protease) with an **IC_{50}** of 3.24 μM. S130 suppresses autophagy flux [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 100 mg, 500 mg



Salbutamol hemisulfate

(Albuterol (hemisulfate); AH-3365 (hemisulfate)) Cat. No.: HY-B0436

Bioactivity: Salbutamol Hemisulfate is a short-acting β2 adrenergic receptor agonist Target: β2 Adrenergic Receptor Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. All the effects of R,S-salbutamol on guinea-pig skeletal muscles are due to the...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Salicylic acid

(2-Hydroxybenzoic acid) Cat. No.: HY-B0167

Bioactivity: Salicylic acid inhibits cyclo-oxygenase-2 (**COX-2**) activity independently of transcription factor (NF-κB) activation.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 g, 50 g



Salinomycin

(Procoxacin) Cat. No.: HY-15597

Bioactivity: Salinomycin is an anticoccidial drug with potent **anti-bacterial** activity and an novel anticancer agent targeting human cancer stem cells.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Salirasib (S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS)

Cat. No.: HY-14754

Bioactivity: Salirasib is a **Ras** inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.

Purity: 98.72%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Salubrinal

Cat. No.: HY-15486

Bioactivity: Salubrinal is a cell-permeable and selective inhibitor of **eIF2α dephosphorylation**.

Purity: 99.58%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Salvianolic acid B

(Dan Shen Suan B; Lithospermic acid B)

Cat. No.: HY-N1362

Bioactivity: Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication. IC50 value: Target: In vitro:...

Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



Sanguinarine

(Pseudochelerythrine; Sanguinarin)

Cat. No.: HY-N0052

Bioactivity: Sanguinarine, a benzophenanthridine alkaloid derived from the root of Sanguinaria Canadensis, can stimulate **apoptosis** via activating the production of reactive oxygen species (ROS). Sanguinarine-induced apoptosis is associated with the activation of JNK and NF-κB.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Sanguinarine chloride

(Pseudochelerythrine chloride; Sanguinarium chloride)

Cat. No.: HY-N0052A

Bioactivity: Sanguinarine chloride, a benzophenanthridine alkaloid derived from the root of Sanguinaria Canadensis, can stimulate **apoptosis** via activating the production of reactive oxygen species (ROS). Sanguinarine-induced apoptosis is associated with the activation of JNK and NF-κB.

Purity: 99.80%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Sapanisertib

(INK-128; MLN0128)

Cat. No.: HY-13328

Bioactivity: Sapanisertib (INK-128) is an orally available, ATP-dependent **mTOR1/2** inhibitor with an **IC_{50}** of 1 nM for mTOR kinase.

Purity: 99.06%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Saquinavir Mesylate

(Ro 31-8959/003)

Cat. No.: HY-17003

Bioactivity: Saquinavir mesylate is an HIV Protease Inhibitor used in antiretroviral therapy. IC50 Value: Target: HIV Protease Saquinavir is a protease inhibitor. Proteases are enzymes that cleave protein molecules into smaller fragments. HIV protease is vital for both viral replication within the cell and...

Purity: 99.79%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



SAR405

Cat. No.: HY-12481

Bioactivity: SAR405 is a **PIK3C3/ Vps34** inhibitor with an **IC_{50}** of 1.2 nM.

SAR405 prevents autophagy and synergizes with MTOR inhibition in tumor cells.

Purity: 99.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg



Saracatinib

(AZD0530)

Cat. No.: HY-10234

Bioactivity: Saracatinib (AZD0530) is a potent **Src** family inhibitor with **IC_{50}**s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk and shows high selectivity over other tyrosine kinases.

Purity: 99.88%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



SB 202190

Cat. No.: HY-10295

Bioactivity: SB 202190 is a cell-permeable **p38 MAP kinase** inhibitor with **IC_{50}**s of 50 nM and 100 nM for p38 and p38β2, respectively.

Purity: 99.89%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



SB 203580

(RWJ 64809)

Cat. No.: HY-10256

Bioactivity: SB 203580 (RWJ 64809) is a widely used **p38 MAPK** inhibitor with an **IC_{50}** of 0.3-0.5 μM. SB 203580 (RWJ 64809) shows more than 100-fold selectivity over Akt (PKB), LCK, and GSK-3β.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



SB 203580 hydrochloride

(RWJ 64809 hydrochloride) Cat. No.: HY-10256A

Bioactivity: SB 203580 hydrochloride (RWJ 64809 hydrochloride) is a widely used **p38 MAPK** inhibitor with an **IC_{50}** of 0.3-0.5 μM. SB 203580 hydrochloride shows more than 100-fold selectivity over Akt (PKB), LCK, and GSK-3β.

Purity: 99.71%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



SB 216763

Cat. No.: HY-12012

Bioactivity: SB 216763 is potent, selective and ATP-competitive **GSK-3** inhibitor with **IC_{50}**s of 34.3 nM for both GSK-3α and GSK-3β.

Purity: 96.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



SBC-115076

Cat. No.: HY-12402

Bioactivity: SBC-115076 is an anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds, for the treatment and/or prevention of cardiovascular diseases. Target: PCSK9 in vivo: SBC-115076 lowers cholesterol levels in mice that are fed high fat diet.

Purity: 98.25%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



SBE13

Cat. No.: HY-15158A

Bioactivity: SBE13 is a potent and selective **Plk1** inhibitor, with an **IC_{50}** of 200 pM; SBE13 poorly inhibits Plk2 (IC_{50}>66 μM) or Plk3 (IC_{50}=875 nM).

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



SBE13 Hydrochloride

Cat. No.: HY-15158

Bioactivity: SBE13 Hydrochloride is a potent and selective **Plk1** inhibitor, with an **IC_{50}** of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC_{50}>66 μM) or Plk3 (IC_{50}=875 nM).

Purity: 98.61%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Schisandrin (Schizandrol; Schizandrol-A; Wuweizi alcohol-A; Wuweizichun-A)

Cat. No.: HY-N0691

Bioactivity: Schisandrin has various therapeutic effects on a range of medical conditions such as anti-asthmatic, anti-cancer, and anti-inflammatory effects. IC50 value: Target: in vitro: Sch inhibited the pro-fibrotic activity of TGF-β1 in AML12 cells; thus, it suppressed the accumulation of ECM proteins. Also,...

Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



Schisandrin A

(Schizandrin-A; Wuweizisu-A; Deoxyschizandrin) Cat. No.: HY-N0693

Bioactivity: Schisandrin A inhibits **CYP3A** activity with an **IC_{50}** of 6.60 μM and **K_i** of 5.83 μM, respectively.

Purity: 99.67%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg



Schisandrin B

(Schizandrin-B; Wuweizisu-B; gamma-Schisandrin) Cat. No.: HY-N0089

Bioactivity: Schisandrin B(Wuweizisu-B) is a dibenzocyclooctadiene derivative isolated from Fructus Schisandrae, has been shown to produce antioxidant effect on rodent liver and heart. IC50 value: Target: in vitro: Schisandrin B exhibits anti-inflammatory activity through modulation of the...

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Schisandrol B

(Gomisin-A; TJN-101; Wuweizi alcohol-B) Cat. No.: HY-N0692

Bioactivity: Schisandrol B (Gomisin-A;TJN-101;Wuweizi alcohol-B) is one of its major active constituents of traditional hepato-protective Chinese medicine, Schisandra sphenanthera.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg



Scriptaid

(Scriptide; GCK1026) Cat. No.: HY-15489

Bioactivity: Scriptaid is a potent **histone deacetylase (HDAC)** inhibitor, used in cancer research.

Purity: 99.12%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Scutellarein

(6-Hydroxyapigenin; 4',5,6,7-Tetrahydroxyflavone) Cat. No.: HY-N0752

Bioactivity: Scutellarin, a main active ingredient extracted from Erigeron breviscapus (Vant.) Hand-Mazz., has been wildly used to treat acute cerebral infarction and paralysis induced by cerebrovascular diseases.

Purity: 99.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg



Selenomethionine

(Seleno-DL-methionine; DL-Selenomethionine) Cat. No.: HY-B1000

Bioactivity: Selenomethionine is a naturally occurring amino acid containing selenium, is a common natural food source of selenium.

Purity: 98.0%
Clinical Data: Phase 4
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Sertindole

(Lu 23-174) Cat. No.: HY-14543

Bioactivity: Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Target: Multi-target In vitro studies showed that sertindole exerts a potent antagonism at serotonin 5-HT2A, 5-HT2C, dopamine D2, and αl adrenergic receptors. Sertindole offers an alternative treatment option for...

Purity: 96.14%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



SGI-1776

Cat. No.: HY-13287

Bioactivity: SGI-1776 is an inhibitor of **Pim** kinases, with **IC_{50}**s of 7 nM, 363 nM, and 69 nM for Pim-1, -2 and -3, respectively.

Purity: 99.94%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Shogaol

([6]-Shogaol; 6-Shogaol) Cat. No.: HY-14616

Bioactivity: 6-shogaol, an active compound isolated from Ginger (Zingiber officinale Rosc), exhibits a variety of biological activities including anticancer, anti-inflammation, and anti-oxidation.

Purity: 99.84%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



Sildenafil

(UK-92480) Cat. No.: HY-15025

Bioactivity: Sildenafil is a potent phosphodiesterase type 5 (**PDE5**) inhibitor with **IC_{50}** of 5.22 nM.

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



Sildenafil citrate

(UK-92480 citrate) Cat. No.: HY-15025A

Bioactivity: Sildenafil citrate is a potent phosphodiesterase type 5 (**PDE5**) inhibitor with **IC_{50}** of 5.22 nM.

Purity: 99.84%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Silibinin

(Silybin; Silibinin A; Silymarin I) Cat. No.: HY-13748

Bioactivity: Silibinin, an effective anti-cancer and chemopreventive agent, has been shown to exert multiple effects on cancer cells, including inhibition of both cell proliferation and migration. IC50 value: Target: anticancer in vitro: silibinin significantly induced the expression of the non-steroidal...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Silmitasertib

(CX-4945) Cat. No.: HY-50855

Bioactivity: Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent **CK2** inhibitor, with **IC_{50}** values of 1 nM against CK2α and CK2α'.

Purity: 99.92%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Silmitasertib sodium salt

(CX-4945 (sodium salt)) Cat. No.: HY-50855B

Bioactivity: Silmitasertib sodium salt is an orally bioavailable, highly selective and potent **CK2** inhibitor, with **IC_{50}** values of 1 nM against CK2α and CK2α'.

Purity: 99.98%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Silvestrol

((-)-Silvestrol) **Cat. No.:** HY-13251

Bioactivity: Silvestrol is a eukaryotic translation initiation factor 4A (**eIF4A**) inhibitor isolated from the fruits and twigs of Aglaia foveolata.

Purity: 98.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 2 mg



Simvastatin

(MK 733) **Cat. No.:** HY-17502

Bioactivity: Simvastatin (MK 733) is a competitive inhibitor of **HMG-CoA reductase** with a K_i of 0.2 nM.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Sinomenine hydrochloride

(Cucoline hydrochloride) **Cat. No.:** HY-15122A

Bioactivity: Sinomenine hydrochloride is a blocker of the **NF-κB** activation and also an activator of **μ-opioid receptor**.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



Sirtinol

Cat. No.: HY-13515

Bioactivity: Sirtinol is a **sirtuin** inhibitor, with IC_{50}s of 48 μM, 57.7 μM and 131 μM for ySir2, hSIRT2 and hSIRT2, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Sitagliptin

(MK0431) **Cat. No.:** HY-13749

Bioactivity: Sitagliptin is a potent inhibitor of **DPP4** with IC_{50} of 19 nM in Caco-2 cell extracts.

Purity: 99.72%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg



Sitagliptin phosphate

(MK0431 phosphate) **Cat. No.:** HY-13749A

Bioactivity: Sitagliptin phosphate is a potent inhibitor of **DPP4** with IC_{50} of 19 nM in Caco-2 cell extracts.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg



Sitagliptin phosphate monohydrate

(MK-0431 phosphate monohydrate) **Cat. No.:** HY-13749B

Bioactivity: Sitagliptin phosphate monohydrate is a potent inhibitor of **DPP4** with IC_{50} of 19 nM in Caco-2 cell extracts.

Purity: 99.78%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 200 mg



SKF-96365 hydrochloride

Cat. No.: HY-100001

Bioactivity: SKF-96365 hydrochloride is a non-selective **TRP Channel** blocker.

Purity: 99.44%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



SLLN-15

Cat. No.: HY-125465

Bioactivity: SLLN-15 is an oral active, selective and potent enhancer of **autophagy** that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



SMER18

Cat. No.: HY-18672

Bioactivity: SMER18 is a small molecule enhancer of rapamycin which act as a mTOR-independent autophagy inducer.

Purity: 98.47%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



SMER28

Cat. No.: HY-100200

Bioactivity: SMER28 is a positive regulator of **autophagy** acting via an mTOR-independent mechanism. SMER28 prevents the accumulation of amyloid beta peptide.

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



SN-38

(NK012)

Cat. No.: HY-13704

Bioactivity: SN-38 (NK012) is an active metabolite of the **Topoisomerase I** inhibitor Irinotecan. SN-38 (NK012) inhibits **DNA** and **RNA synthesis** with **IC_{50}**s of 0.077 and 1.3 μM, respectively.

Purity: 99.46%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Sodium Butyrate

(Butanoic acid sodium salt)

Cat. No.: HY-B0350A

Bioactivity: Butyric acid is a **histone deacetylase (HDAC)** inhibitor, with anti-tumor effects in several cancers.

Purity: 98.00%
Clinical Data: Phase 3
Size: 10mM x 1mL in Water, 1 g, 5 g, 500 g



Sodium phenylbutyrate

(Sodium 4-phenylbutyrate; TriButyrate)

Cat. No.: HY-15654

Bioactivity: Sodium phenylbutyrate is an inhibitor of **HDAC** and endoplasmic reticulum **(ER)** stress, used in cancer and infection research.

Purity: 99.75%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 200 mg



Sodium Salicylate (Salicylic acid sodium salt; 2-Hydroxybenzoic acid sodium salt)

Cat. No.: HY-B0167A

Bioactivity: Sodium Salicylate inhibits cyclo-oxygenase-2 (**COX-2**) activity independently of transcription factor (NF-κB) activation.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 g, 50 g



Sofalcone

Cat. No.: HY-B2184

Bioactivity: Sofalcone, a gastric **antiulcer** agent in clinical use, is known to induce the expression of **Heme oxygenase-1** (**HO-1**) in gastric epithelium.

Purity: 98.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g, 5 g



Sorafenib

(Bay 43-9006)

Cat. No.: HY-10201

Bioactivity: Sorafenib (Bay 43-9006) is a potent multikinase inhibitor with **IC_{50}**s of 6 nM, 20 nM, and 22 nM for **Raf-1**, **B-Raf**, and **VEGFR-3**, respectively.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Sorafenib Tosylate

(Bay 43-9006 (Tosylate))

Cat. No.: HY-10201A

Bioactivity: Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent multikinase inhibitor, with **IC_{50}**s of 6 nM, 20 nM, and 22 nM for **Raf-1**, **B-Raf**, and **VEGFR-3**, respectively.

Purity: 99.53%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg

SP600125

Cat. No.: HY-12041

Bioactivity: SP600125 is a reversible and ATP-competitive **JNK** inhibitor with **IC_{50}**s of 40, 40 and 90 nM for **JNK1**, **JNK2** and **JNK3**, respectively.

Purity: 98.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Spautin-1

Cat. No.: HY-12990

Bioactivity: Spautin-1 is a specific and potent **autophagy** inhibitor which inhibits ubiquitin-specific peptidases, USP10 and USP13 with **IC_{50}**s of 0.6-0.7 μM.

Purity: 97.60%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Spironolactone
(SC9420)

Cat. No.: HY-B0561

Bioactivity: Spironolactone is a potent antagonist of the androgen receptor. Target: Androgen Receptor Spironolactone is a potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive...

Purity: 96.17%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



SR-3677

Cat. No.: HY-13300

Bioactivity: SR-3677 is a potent and selective **ROCK-II** inhibitor with an **IC_{50}** of ~3 nM.

Purity: 99.46%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



SR9009

Cat. No.: HY-16989

Bioactivity: SR9009 is a **REV-ERBα/β** agonist with **IC_{50}**s of 670 nM and 800 nM for REV-ERBα and REV-ERBβ, respectively.

Purity: 99.58%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



SR9011

Cat. No.: HY-16988

Bioactivity: SR9011 is a **REV-ERBα/ β** agonist with **IC_{50}**s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



SR9011 hydrochloride

Cat. No.: HY-16988A

Bioactivity: SR9011 hydrochloride is a **REV-ERBα/ β** agonist with **IC_{50}**s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively.

Purity: 97.83%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



SRT 1720 Hydrochloride

Cat. No.: HY-15145

Bioactivity: SRT 1720 Hydrochloride is a selective activator of **SIRT1** with an **$EC_{1.5}$** of 0.16 μM, and shows less potent activities on SIRT2 and SIRT3 with $EC_{1.5}$s of 37 μM and 300 μM, respectively.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



Stavudine
(d4T)

Cat. No.: HY-B0116

Bioactivity: Stavudine is a nucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. Target: HIV RT; NRTIs Stavudine is a dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. Stavudine is an analog of thymidine. It is...

Purity: 99.12%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



STF-31

Cat. No.: HY-18728

Bioactivity: STF-31 is an inhibitor of glucose transporter 1 (GLUT1, IC50 = 1 μM). IC50 value: 1 μM Target: GLUT1 in vitro: STF 31 is a glucose uptake inhibitor in RCC (renal cell carcinoma) 4 cells. By limiting glucose uptake in cancer cells, the immense energy requirements for the cancer cell is not met and the...

Purity: 96.62%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



STF-62247
(STF62247; STF 62247)

Cat. No.: HY-100746

Bioactivity: STF-62247 is TGN inhibitor with IC50 of 0.625μM and 16μM in RCC4 and RCC4/VHL cells,respectively.It specifically induces autophagic cell death in cells that have lost VHL, an essential mutation in the development of RCC. IC50: 0.625/16μM in RCC4 and RCC4/VHL cells,respectively.[1] In vitro:...

Purity: 98.09%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg



Streptozocin
(Streptozotocin; U 9889)

Cat. No.: HY-13753

Bioactivity: Streptozocin is a potent **DNA-methylating** agent, with **IC_{50}**s of 11.7, 904 and 1024 μg/mL in HL60, K562 and C1498 cells respectively.

Purity: 99.58%
Clinical Data: Launched
Size: 100 mg, 500 mg



SU11274

(PKI-SU11274) Cat. No.: HY-12014

Bioactivity: SU11274 is a selective **Met** inhibitor with **IC_{50}** of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.

Purity: 98.09%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



SU9516

Cat. No.: HY-18629

Bioactivity: SU9516 is a potent **CDK2** inhibitor, with an **IC_{50}** of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with **IC_{50}**s of 40, 200 nM, respectively.

Purity: 99.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Sulfabenzamide

(N-Sulfanilylbenzamide) Cat. No.: HY-B0960

Bioactivity: Sulfabenzamide is a intermediate in the synthesis of organic and pharmaceutical.

Purity: 99.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 500 mg



Sulfasalazine

(NSC 667219) Cat. No.: HY-14655

Bioactivity: Sulfasalazine is a drug for the treatment of rheumatoid arthritis and ulcerative colitis. Sulfasalazine is reported to suppress **NF-κB** activity.

Purity: 99.42%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Sulindac

(MK-231) Cat. No.: HY-B0008

Bioactivity: Sulindac (MK-231) is a non-steroidal antiinflammatory agent, acts as a **COX-2** inhibitor, and inhibits overexpression of COX-2.

Purity: 99.46%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Sunitinib

(SU 11248) Cat. No.: HY-10255A

Bioactivity: Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with **IC_{50}**s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.

Purity: 99.66%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Tacrolimus

(FK506; Fujimycin; FR900506) Cat. No.: HY-13756

Bioactivity: Tacrolimus (FK506; Fujimycin) is a macrocyclic lactone with potent immunosuppressive properties. Tacrolimus binds to **FK506 binding protein (FKBP)** to form a complex and inhibits **calcineurin phosphatase**.

Purity: 98.46%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Tacrolimus monohydrate (FK506 (monohydrate); Fujimycin (monohydrate); FR900506 (monohydrate))

Cat. No.: HY-13756A

Bioactivity: Tacrolimus monohydrate (FK506 monohydrate; Fujimycin monohydrate) binds to **FK506 binding protein** (**FKBP**). This complex inhibits calcineurin phosphatase (PP2B). Tacrolimus monohydrate is a mTOR-independent **autophagy** inducer.

Purity: 98.46%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Tamoxifen

(ICI47699; Z-Tamoxifen; trans-Tamoxifen) Cat. No.: HY-13757A

Bioactivity: Tamoxifen is a selective estrogen receptor modulator (**SERM**) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.

Purity: 99.76%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 500 mg, 1 g, 5 g



Tamoxifen Citrate

(ICI 46474) Cat. No.: HY-13757

Bioactivity: Tamoxifen Citrate is a selective estrogen receptor modulator (**SERM**).

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 500 mg, 1 g, 5 g



Tanespimycin

(17-AAG; NSC 330507; CP 127374) Cat. No.: HY-10211

Bioactivity: Tanespimycin (17-AAG) is a potent **HSP90** inhibitor with an **IC_{50}** of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90.

Purity: 99.03%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 100 mg, 200 mg



Taurine

(2-Aminoethanesulfonic acid) Cat. No.: HY-B0351

Bioactivity: Taurine is an organic acid widely distributed in animal tissues. Target: Others Taurine is a major constituent of bile and can be found in the large intestine and accounts for approximately 0.1% of total human body weight [1]. Taurine is present in high concentration in algae and in the animals...

Purity: 98.0%
Clinical Data: Phase 4
Size: 10mM x 1mL in Water, 1 g, 5 g

Taxifolin

((+)-Dihydroquercetin; (+)-Taxifolin) Cat. No.: HY-N0136

Bioactivity: Taxifolin ((+)-Dihydroquercetin) exhibits important anti-**tyrosinase** activity. Taxifolin exhibits significant inhibitory activity against **collagenase** with an **IC_{50}** value of 193.3 μM.

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg



TBHQ

(tert-Butylhydroquinone) Cat. No.: HY-100489

Bioactivity: TBHQ is an antioxidant that activates **Nrf2**.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 g



Telaglenastat

(CB-839) Cat. No.: HY-12248

Bioactivity: Telaglenastat (CB-839) is a potent and selective inhibitor of glutaminase with an **IC_{50}** of less than 50 nM.

Purity: 99.92%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Telmisartan

(BIBR 277) Cat. No.: HY-13955

Bioactivity: Telmisartan is a potent, long lasting antagonist of **angiotensin II type 1 receptor (AT1)**, selectively inhibiting the binding of ^{125}I-AngII to AT1 receptors with **IC_{50}** of 9.2 nM.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g



Temozolomide

(NSC 362856; CCRG 81045; TMZ) Cat. No.: HY-17364

Bioactivity: Temozolomide (NSC 362856; CCRG 81045) is an oral **DNA alkylating** agent used to treat some brain cancers.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Tempol

(4-Hydroxy-TEMPO) Cat. No.: HY-100561

Bioactivity: Tempol is a general superoxide dismutase (SOD)-mimetic drug that efficiently neutralizes reactive oxygen species (ROS).

Purity: 99.69%
Clinical Data: Phase 2
Size: 10mM x 1mL in Water, 200 mg, 1 g



Temsirolimus

(CCI-779) Cat. No.: HY-50910

Bioactivity: Temsirolimus is an inhibitor of **mTOR** with an **IC_{50}** of 1.76 μM.

Purity: 99.25%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 100 mg



Tenovin-1

Cat. No.: HY-13423

Bioactivity: Tenovin-1 is an inhibitor of **sirtuin 1** and **sirtuin 2**, an activator of **p53** and may have potential in the management of cancer.

Purity: 99.39%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Tenovin-6

Cat. No.: HY-15510

Bioactivity: Tenovin-6 is an inhibitor of **SIRT1** and **SIRT2**, slightly inhibits **HDAC8**, and is also a potent activator of **p53**, with **IC_{50}**s of 21 μM, 10 μM, and 67 μM for SirT1, SirT2, and SirT3, respectively.

Purity: 98.24%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Tenovin-6 Hydrochloride

Cat. No.: HY-15510B

Bioactivity: Tenovin-6 Hydrochloride is an inhibitor of **SIRT1** and **SIRT2**, slightly inhibits **HDAC8**, and is also a potent activator of **p53**, with **IC_{50}**s of 21 μM, 10 μM, and 67 μM for SirT1, SirT2, and SirT3, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Tepotinib

(EMD-1214063)

Cat. No.: HY-14721

Bioactivity: Tepotinib (EMD-1214063) is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

Purity: 99.80%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Tetrahydrocurcumin

(HZIV 81-2)

Cat. No.: HY-N0893

Bioactivity: Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit **CYP2C9** and **CYP3A4**.

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg

TG101209

Cat. No.: HY-10410

Bioactivity: TG101209 is a selective **JAK2** inhibitor with **IC_{50}** of 6 nM, less potent to **Flt3** and **RET** with **IC_{50}** of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

Purity: 98.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Thalidomide

Cat. No.: HY-14658

Bioactivity: Thalidomide is initially promoted as a sedative, inhibits ereblon (CRBN), a part of the **cullin-4 E3 ubiquitin ligase** complex CUL4-RBX1-DDB1, with a **K_d** of 250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg



Theophylline

(1,3-Dimethylxanthine; Theo-24)

Cat. No.: HY-B0809

Bioactivity: Theophylline is a nonselective **phosphodiesterase (PDE)** inhibitor, **adenosine receptor** blocker, and **histone deacetylase (HDAC)** activator.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 g



Thiamet G

Cat. No.: HY-12588

Bioactivity: Thiamet G is a potent and selective inhibitor of **O-GlcNAcase (OGA)**, which acts to remove O-GlcNAc from modified proteins, with **K_i** of 20 nM for human OGA.

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



Thioridazine hydrochloride

Cat. No.: HY-B0965

Bioactivity: Thioridazine is an antipsychotic drug, used in the treatment of schizophrenia and psychosis, shows D4 selectivity or serotonin antagonism.

Purity: 99.93%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Tigecycline

(GAR-936)

Cat. No.: HY-B0117

Bioactivity: Tigecycline (GAR-936) is a broad-spectrum glycylcycline antibiotic. The mean inhibitory concentration (MIC) of Tigecycline for E. coli (MG1655 strain) is approximately 125 ng/mL [1]. MIC $_{50}$ and MIC $_{90}$ are 1 and 2 mg/L for Acipetobacter baumannii (A. baumannii), respectively...

Purity: 99.88%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Tigecycline hydrochloride

(GAR-936 hydrochloride) **Cat. No.:** HY-B0117A

Bioactivity: Tigecycline hydrochloride (GAR-936 hydrochloride) is a broad-spectrum glycylcycline antibiotic. The mean inhibitory concentration (MIC) of Tigecycline for E. coli (MG1655 strain) is approximately 125 ng/mL [1]. MIC $_{50}$ and MIC $_{90}$ are 1 and 2 mg/L for Acinetobacter baumannii (A. baumannii),...

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Tigecycline mesylate

(GAR-936 mesylate) **Cat. No.:** HY-B0117B

Bioactivity: Tigecycline mesylate (GAR-936 mesylate) is a broad-spectrum glycylcycline antibiotic. The mean inhibitory concentration (MIC) of Tigecycline for E. coli (MG1655 strain) is approximately 125 ng/mL [1]. MIC $_{50}$ and MIC $_{90}$ are 1 and 2 mg/L for Acinetobacter baumannii (A. baumannii),...

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Tigecycline tetramesylate

(GAR-936 tetramesylate) **Cat. No.:** HY-B0117C

Bioactivity: Tigecycline tetramesylate (GAR-936 tetramesylate) is a broad-spectrum glycylcycline antibiotic. The mean inhibitory concentration (MIC) of Tigecycline for E. coli (MG1655 strain) is approximately 125 ng/mL [1]. MIC $_{50}$ and MIC $_{90}$ are 1 and 2 mg/L for Acinetobacter baumannii (A. baumannii),...

Purity: 95.36%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Tizoxanide

(TIZ) **Cat. No.:** HY-12687

Bioactivity: Tizoxanide is the active metabolite of Nitazoxanide, which is a thiazolide anti-infective compound against anaerobic bacteria, protozoa, and a range of viruses. IC50 value: Target: Antiviral agent in vitro: Tizoxanide inhibited virus replication of all CIVs with 50% and 90% inhibitory...

Purity: 99.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Tolbutamide

Cat. No.: HY-B0401

Bioactivity: Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic drug. Target: Potassium Channel Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). Tolbutamide act by stimulating β cells of the pancreas to...

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Tolvaptan

(OPC-41061) **Cat. No.:** HY-17000

Bioactivity: Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation. IC50 value: 1.28 uM (inhibition of AVP-induced platelet aggregation) Target: vasopressin receptor 2 Tolvaptan (OPC-41061) is a...

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Topotecan

(SKF 104864A; NSC 609669) **Cat. No.:** HY-13768

Bioactivity: Topotecan (SKF 104864A; NSC 609669) is a **Topoisomerase I** inhibitor. The **IC_{50}** values of Topotecan at 24 h are 2.73±0.25 μM of U251 cells, 2.95±0.23 μM of U87 cells, 5.46±0.41 μM of GSCs-U251 and 5.95±0.24 μM of GSCs-U87.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Topotecan Hydrochloride

(SKF 104864A (Hydrochloride); NSC 609669 (Hydrochloride)) **Cat. No.:** HY-13768A

Bioactivity: Topotecan Hydrochloride (SKF 104864A Hydrochloride; NSC 609669 Hydrochloride) is a **Topoisomerase I** inhibitor with potent antineoplastic activities.

Purity: 99.20%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Torin 1

Cat. No.: HY-13003

Bioactivity: Torin 1 is a potent inhibitor of **mTOR** with an **IC_{50}** of 3 nM. Torin 1 inhibits both **mTORC1/ 2** complexes with **IC_{50}** values between 2 and 10 nM.

Purity: 99.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



Torin 2

Cat. No.: HY-13002

Bioactivity: Torin 2 is an **mTOR** inhibitor with **EC_{50}** of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC $_{50}$: 200 nM). Torin 2 also inhibits **DNA-PK** with an **IC_{50}** of 0.5 nM in the cell free assay. Tori...

Purity: 99.93%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Torkinib
(PP 242) Cat. No.: HY-10474

Bioactivity: Torkinib (PP 242) is a selective and ATP-competitive **mTOR** inhibitor with an **IC_{50}** of 8 nM. PP242 inhibits both **mTORC1** and **mTORC2** with **IC_{50}**s of 30 nM and 58 nM, respectively.

Purity: 95.47%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Tozasertib
(VX 680; MK-0457) Cat. No.: HY-10161

Bioactivity: Tozasertib (VX 680; MK-0457) is an inhibitor of **Aurora A/B/C kinases** with **K_i**s of 0.6, 18, 4.6 nM, respectively.

Purity: 99.85%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 250 mg



TPEN
(TPEDA) Cat. No.: HY-100202

Bioactivity: TPEN is a specific cell-permeable heavy metal chelator.

Purity: 98.44%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



Trametinib
(GSK1120212; JTP-74057) Cat. No.: HY-10999

Bioactivity: Trametinib is a potent **MEK** inhibitor that inhibits MEK1 and MEK2 with **IC_{50}**s of about 2 nM. Due to the poor solubility of Trametinib, **Trametinib DMSO solvate (Cat. No.: HY-10999A)** is recommeded.

Purity: 99.37%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Triclosan
Cat. No.: HY-B1119

Bioactivity: Triclosan is an antibacterial and antifungal agent found in consumer products, including soaps, detergents, toys, and surgical cleaning treatments.

Purity: 97.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Trifluoperazine dihydrochloride
(TFP; SKF5019) Cat. No.: HY-B0532A

Bioactivity: Trifluoperazine Dihydrochloride is a potent dopamine D2 receptor inhibitor used as an antipsychotic and an antiemetic. Target: Dopamine D2 Receptor Trifluoperazine Dihydrochloride is a potent dopamine D2 receptor inhibitor used as an antipsychotic and an antiemetic. Trifluoperazine inhibited in...

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Triflupromazine hydrochloride
Cat. No.: HY-B0909

Bioactivity: Triflupromazine hydrochloride is an antipsychotic medication, which are Dopamine D1/D2 receptor antagonists.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg



Trimetazidine dihydrochloride
Cat. No.: HY-B0968

Bioactivity: Trimetazidine dihydrochloride is a drug for angina pectoris. Trimetazidine is the first cytoprotective anti-ischemic agent , which improves myocardial glucose utilization through inhibition of fatty acid metabolism.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Tripterin
(Celastrol) Cat. No.: HY-13067

Bioactivity: Tripterin (Celastrol) is a **proteasome** inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified **20S proteasome** with **IC_{50}** of 2.5 μM.

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Troglitazone
(CS-045) Cat. No.: HY-50935

Bioactivity: Troglitazone is a **PPARγ** agonist, with **EC_{50}**s of 550 nM and 780 nM for human and murinePPARγ receptor, respectively.

Purity: 99.53%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Tubastatin A Hydrochloride

(Tubastatin A HCl; TSA HCl) **Cat. No.:** HY-13271

Bioactivity: Tubastatin A (Hydrochloride) is a potent and selective **HDAC6** inhibitor with **IC_{50}** of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more).

Purity: 98.31%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Tubastatin-A

Cat. No.: HY-13271A

Bioactivity: Tubastatin-A is a potent and selective **HDAC6** inhibitor with **IC_{50}** of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more).

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



TWS119

Cat. No.: HY-10590

Bioactivity: TWS119 is a specific inhibitor of **GSK-3β**, with an **IC_{50}** of 30 nM, and activates the wnt/β-catenin pathway.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



U0126

(U0126-EtOH) **Cat. No.:** HY-12031

Bioactivity: U0126 is a potent and non-ATP competitive **MEK1** and **MEK2** inhibitor, with **IC_{50}**s of 70 nM and 60 nM, respectively.

Purity: 98.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



UBCS039

Cat. No.: HY-115453

Bioactivity: UBCS039 is the first synthetic, specific **Sirtuin 6 (SIRT6)** activator, inducing autophagy in human tumor cells, with an **EC_{50}** of 38 μM [1].

Purity: 98.55%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



UNBS5162

Cat. No.: HY-16509

Bioactivity: UNBS5162 is a pan-antagonist of **CXCL chemokine** expression, with anti-tumor activity.

Purity: 99.75%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



UNC0638

Cat. No.: HY-15273

Bioactivity: UNC0638 selectively inhibits **G9a** and **GLP histone methyltransferase** activity with **IC_{50}**s of less than 15 nM and 19 nM, respectively.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



UNC1999

Cat. No.: HY-15646

Bioactivity: UNC1999 is a SAM-competitive, potent and selective inhibitor of **EZH1/2** with **IC_{50}**s of 10 nM and 45 nM, repectively.

Purity: 99.47%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



URB-597

(KDS-4103) **Cat. No.:** HY-10864

Bioactivity: URB597 is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. IC50 value: 4.6 nM [1] Target: FAAH in vitro: URB597 binds in the hydrophobic pocket and catalytic core of FAAH that connects the active site residues to the membrane surface...

Purity: 98.71%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



URMC-099

Cat. No.: HY-12599

Bioactivity: URMC-099 is an orally bioavailable and potent mixed lineage kinase type 3 (**MLK3**) (**IC_{50}**=14 nM) inhibitor with with excellent blood-brain barrier penetration properties.

Purity: 99.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Urolithin A

Cat. No.: HY-100599

Bioactivity: Urolithin A is an intestinal metabolite of ellagic acid with antioxidant and antiproliferative effects; inhibits T24 and Caco-2 cell growth with **IC_{50}** values of 43.9 and 49 μM, respectively.

Purity: 98.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Ursolic acid

(Prunol; Urson; Malol)

Cat. No.: HY-N0140

Bioactivity: Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.

Purity: 99.27%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Valproic acid

(VPA; 2-Propylpentanoic Acid)

Cat. No.: HY-10585

Bioactivity: Valproic acid is an **HDAC** inhibitor, with **IC_{50}** in the range of 0.5 and 2 mM, also inhibits **HDAC1** (**IC_{50}**, 400 μM), and induces proteasomal degradation of **HDAC2**; Valproic acid sodium salt is used in the treatment of epilepsy, bipo...

Purity: 98.67%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g, 25 g



Valproic acid sodium salt

(Sodium Valproate)

Cat. No.: HY-10585A

Bioactivity: Valproic acid sodium salt is an anticonvulsants used to treat epilepsy, bipolar disorder and migraines. Valproic acid inhibits **histone deacetylase 1 (HDAC1)** with an **IC_{50}** of 0.4 mM.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 1 g, 5 g, 25 g



Vancomycin hydrochloride

Cat. No.: HY-17362

Bioactivity: Vancomycin hydrochloride is an antibiotic for the treatment of **bacterial** infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis.

Purity: 98.83%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 250 mg, 1 g, 5 g



Vandetanib

(ZD6474)

Cat. No.: HY-10260

Bioactivity: Vandetanib is a potent inhibitor of **VEGFR2** with an **IC_{50}** of 40 nM.

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 25 mg, 50 mg, 100 mg, 500 mg



Vandetanib hydrochloride

(ZD6474 hydrochloride)

Cat. No.: HY-10260B

Bioactivity: Vandetanib hydrochloride is a potent inhibitor of **VEGFR2** with **IC_{50}** of 40 nM.

Purity: >98%
Clinical Data: Launched
Size: 25 mg, 100 mg, 200 mg



Vandetanib trifluoroacetate

(ZD6474 trifluoroacetate)

Cat. No.: HY-10260A

Bioactivity: Vandetanib trifluoroacetate is a potent inhibitor of **VEGFR2** with **IC_{50}** of 40 nM.

Purity: >98%
Clinical Data: Launched
Size: 25 mg, 100 mg, 200 mg



Veliparib

(ABT-888)

Cat. No.: HY-10129

Bioactivity: Veliparib is a potent **PARP** inhibitor, inhibiting **PARP1** and **PARP2** with **K_i**s of 5.2 and 2.9 nM, respectively.

Purity: 98.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Veliparib dihydrochloride

(ABT-888 dihydrochloride)

Cat. No.: HY-10130

Bioactivity: Veliparib (dihydrochloride) is a potent inhibitor of **PARP1** and **PARP2** with **K_i**s of 5.2 nM and 2.9 nM in cell-free assays, respectively.

Purity: 99.62%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Vemurafenib
(PLX4032; RG7204; RO5185426) Cat. No.: HY-12057

Bioactivity: Vemurafenib (PLX4032; RG7204) is a novel and potent inhibitor of **B-RAF** kinase, with **IC_{50}**s of 31 and 48 nM for RAF ^{V600E} and c-RAF-1, respectively.

Purity: 99.73%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Venetoclax
(ABT-199; GDC-0199) Cat. No.: HY-15531

Bioactivity: Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable **Bcl-2** inhibitor with a **K_i** of less than 0.01 nM.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



VER-155008
Cat. No.: HY-10941

Bioactivity: VER-155008 is an inhibitor of **Hsp70**, with **IC_{50}**s of 0.5 μM, 2.6 μM, and 2.6 μM for **Hsp70**, Hsc70 and Grp7, respectively, and with a **K_d** of 0.3 μM for **Hsp70**.

Purity: 99.64%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Verteporfin
(CL 318952) Cat. No.: HY-B0146

Bioactivity: Verteporfin is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a **YAP** inhibitor which disrupts YAP-TEAD interactions.

Purity: 99.58%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Vinblastine sulfate
(Vincaleukoblastine sulfate salt) Cat. No.: HY-13780

Bioactivity: Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR with an **IC_{50}** of 8.9 μM.

Purity: 99.87%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Vinorelbine
(KW-2307 base) Cat. No.: HY-12053

Bioactivity: Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC_{50} of 1.25 nM.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg



Vinorelbine ditartrate
(KW-2307; Nor-5'-anhydrovinblastine ditartrate) Cat. No.: HY-12053A

Bioactivity: Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC_{50} of 1.25 nM.

Purity: 99.58%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Vismodegib
(GDC-0449) Cat. No.: HY-10440

Bioactivity: Vismodegib (GDC-0449) is an orally active **hedgehog** pathway inhibitor with an **IC_{50}** of 3 nM. It also inhibits P-gp, ABCG2 with IC_{50} values of 3.0 μM and 1.4 μM, respectively.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Vistusertib
(AZD2014) Cat. No.: HY-15247

Bioactivity: Vistusertib (AZD2014) is an ATP competitive **mTOR** inhibitor with an **IC_{50}** of 2.81 nM. AZD2014 inhibits both **mTORC1** and **mTORC2** complexes.

Purity: 98.80%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Vorinostat
(SAHA) Cat. No.: HY-10221

Bioactivity: Vorinostat is a potent and orally available inhibitor of **HDAC1**, **HDAC2** and **HDAC3 (Class I)**, **HDAC7 (Class II)** and **HDAC11 (Class IV)**, with **ID_{50}** values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively.

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 250 mg, 500 mg, 1 g, 5 g

Vps34-PIK-III

Cat. No.: HY-12794

Bioactivity: Vps34-PIK-III is a potent and selective inhibitor of **VPS34** with an **IC_{50}** of 18 nM.

Purity: 99.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Wogonin

Cat. No.: HY-N0400

Bioactivity: Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of **CDK8** and **Wnt**, and exhibits anti-inflammatory and anti-tumor effects.

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



WYE-354

Cat. No.: HY-12034

Bioactivity: WYE-354 is an ATP-competitive **mTOR** inhibitor with an **IC_{50}** of 5 nM. WYE-354 also inhibits **PI3Kα** and **PI3Kγ** with **IC_{50}**s of 1.89 μM and 7.37 μM, respectively. WYE-354 inhibits both **mTORC1** and **mTORC2**.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



XCT790

Cat. No.: HY-10426

Bioactivity: XCT-790 is a potent, selective and inverse agonist of estrogen-related receptor alpha(ERRα); induces cell death in chemotherapeutic resistant cancer cells. IC50 value: Target: ERRα ERRalpha inverse agonist XCT-790 induced cell death in HepG2 hepatocarcinoma and its multi-drug resistance (MDR)...

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



XL388

Cat. No.: HY-13806

Bioactivity: XL388 is a highly potent and ATP-competitive **mTOR** inhibitor with an **IC_{50}** of 9.9 nM. XL388 simultaneously inhibits both **mTORC1** and **mTORC2**.

Purity: 98.46%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



XRK3F2

Cat. No.: HY-112904

Bioactivity: XRK3F2 is an inhibitor of **p62 (Sequestosome-1)-ZZ/** domain.

Purity: 99.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Xylitol

(Xylite)

Cat. No.: HY-N0538

Bioactivity: Xylitol is a chemical categorized as a polyalcohol or sugar alcohol. Target: Others Xylitol is a chemical categorized as a polyalcohol or sugar alcohol (alditol). Xylitol has the formula (CHOH)3(CH2OH)2 and is an achiral isomer of pentane-1,2,3,4,5-pentol. Xylitol is used as a diabetic...

Purity: 98.0%
Clinical Data: Phase 4
Size: 10mM x 1mL in Water, 1 g, 5 g



Yangonin

Cat. No.: HY-N0919

Bioactivity: Yangonin exhibits affinity for the human recombinant cannabinoid **CB1 receptor** with an **IC_{50}** and a **K_i** of 1.79 ± 0.53 μM and 0.72±0.21 μM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



YM-155

(Sepantronium bromide)

Cat. No.: HY-10194

Bioactivity: YM-155 is a **survivin** inhibitor with an **IC_{50}** of 0.54 nM.

Purity: 98.91%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



YM-155 hydrochloride

Cat. No.: HY-10194A

Bioactivity: YM-155 hydrochloride is a novel **survivin** suppressant with an **IC_{50}** of 0.54 nM for the inhibition of survivin promoter activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



YM-201636

Cat. No.: HY-13228

Bioactivity: YM-201636 is a potent and selective **PIKfyve** inhibitor with an **IC_{50}** of 33 nM. YM-201636 also inhibits p110α with IC_{50} of 3.3 μM.

Purity: 98.22%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Zebularine

(NSC309132; 4-Deoxyuridine)

Cat. No.: HY-13420

Bioactivity: Zebularine (NSC309132; 4-Deoxyuridine) is a **DNA methyltransferase** inhibitor. Zebularine also inhibits **cytidine deaminase** with a **K_i** of 0.95 μM.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Zoledronic Acid

(Zoledronate; CGP 42446; CGP42446A; ZOL 446)

Cat. No.: HY-13777

Bioactivity: Zoledronic Acid is a third-generation, nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption, and also has antitumor activity.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg



Zoledronic acid monohydrate (Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ...)

Cat. No.: HY-13777A

Bioactivity: Zoledronic acid monohydrate is a third-generation, nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption, and also has antitumor activity.

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 50 mg, 100 mg



ZSTK474

Cat. No.: HY-50847

Bioactivity: ZSTK474 is an ATP-competitive pan-class I **PI3K** inhibitor with **IC_{50}**s of16 nM, 44 nM, 4.6 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.

Purity: 99.71%
Clinical Data: Phase 1
Size: 10 mg, 50 mg, 100 mg, 200 mg



β-Lapachone

(ARQ-501; NSC-26326)

Cat. No.: HY-13555

Bioactivity: β-Lapachone is a naturally occurring O-naphthoquinone, acts as a **topoisomerase I** inhibitor, and induces apoptosis by inhibiting cell cycle progression.

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



FKBP

FK506-binding protein



AP1867

Cat. No.: HY-114434

Bioactivity: AP1867 is a synthetic FKBP12 ^{F36V}-directed ligand.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



AP20187

(B/B Homodimerizer)

Cat. No.: HY-13992

Bioactivity: AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize **FK506-binding protein** (**FKBP**) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.

Purity: 99.80%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



Everolimus

(RAD001; SDZ-RAD)

Cat. No.: HY-10218

Bioactivity: Everolimus (RAD001) is a potent **mTOR** inhibitor that binds to FKBP-12 to generate an immunosuppressive complex.

Purity: 98.79%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



PROTAC FKBP12-binding moiety 1

Cat. No.: HY-107452

Bioactivity: PROTAC FKBP12-binding moiety 1 is a synthetic ligand for **FKBP** (SLF), which is used in the synthesis of **PROTAC**s.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



Rapamycin

(Sirolimus; AY 22989)

Cat. No.: HY-10219

Bioactivity: Rapamycin (Sirolimus; AY 22989) is a potent and specific **mTOR** inhibitor with an **IC_{50}** of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of **mTORC1** [1]. Rapamycin is...

Purity: 99.93%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g, 5 g



Rimiducid

(AP1903)

Cat. No.: HY-16046

Bioactivity: Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the **FKBP** domains, initiating **Fas** signaling and hence **apoptosis**.

Purity: 99.81%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



SAFit1

Cat. No.: HY-102079

Bioactivity: SAFit1 is a FK506 binding protein 51 (**FKBP51**)-specific inhibitor with a **K_i** of 4±0.3 nM [1] [2].

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg



SAFit2

Cat. No.: HY-102080

Bioactivity: SAFit2 is a novel, selective **FK506-binding protein 51** (**FKBP51**) antagonist with a **K_i** of 6 nM and also enhances **AKT2**-AS160 binding.

Purity: 98.59%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg



Tacrolimus

(FK506; Fujimycin; FR900506)

Cat. No.: HY-13756

Bioactivity: Tacrolimus (FK506; Fujimycin) is a macrocyclic lactone with potent immunosuppressive properties. Tacrolimus binds to **FK506 binding protein (FKBP)** to form a complex and inhibits **calcineurin phosphatase**.

Purity: 98.46%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Tacrolimus monohydrate (FK506 (monohydrate); Fujimycin (monohydrate); FR900506 (monohydrate))

Cat. No.: HY-13756A

Bioactivity: Tacrolimus monohydrate (FK506 monohydrate; Fujimycin monohydrate) binds to **FK506 binding protein** (**FKBP**). This complex inhibits calcineurin phosphatase (PP2B). Tacrolimus monohydrate is a mTOR-independent **autophagy** inducer.

Purity: 98.46%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



LRRK2

Leucine-rich repeat kinase 2



Leucine-rich repeat kinase 2 (LRRK2) is an enzyme that in humans is encoded by the PARK8 gene. LRRK2 is a member of the leucine-rich repeat kinase family. Variants of this gene are associated with an increased risk of Parkinson's disease (PD)and also Crohn's disease (CD).

Leucine-rich repeat kinase 2 (LRRK2) is the gene responsible for autosomal-dominant PD, PARK8, which is originally defined by linkage analysis of a Japanese family. LRRK2 is a complex kinase consisting of LRR, ROC, COR, kinase, and WD40 domains. LRRK2 plays a key role in axonal extension, autophagy, proliferation, and survival of neurons. In addition to neurons, LRRK2 is highly expressed in immune cells such as B cells, macrophages, and microglia. Several studies have demonstrated that LRRK2 is related to inflammatory responses of microglia that could be involved in the development and progression of neurodegeneration.

LRRK2 is a large, multidomain protein containing two catalytic domains: a Ras of complex proteins (Roc) G-domain and a kinase domain. Leucine-rich repeat kinase 2 (LRRK2) represents a promising drug target for treatment and prevention of Parkinson’s disease (PD), because mutations in LRRK2 are the most common cause of Mendelian forms of the disease. PD-associated LRRK2 variants show decreased GTPase and increased kinase activity.

CZC-25146

Cat. No.: HY-15800A

Bioactivity: CZC-25146 is a potent, selective and metabolically stable LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively. IC50 value: 4.76 nM/6.87 nM(wild type/G2019S LRRK2) [1] Target: LRRK2 CZC-25146displayed a very clean profile, it inhibited only...

Purity: 98.24%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 10 mg, 100 mg



CZC-25146 hydrochloride

Cat. No.: HY-15800

Bioactivity: CZC-25146 Hcl is a potent, selective and metabolically stable LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively. IC50 value: 4.76 nM/6.87 nM(wild type/G2019S LRRK2) [1] Target: LRRK2 CZC-25146displayed a very clean profile, it inhibited only...

Purity: >98%

Clinical Data: No Development Reported

Size: 5 mg, 50 mg



CZC-54252

Cat. No.: HY-B0792

Bioactivity: CZC-54252 is a potent inhibitor of LRRK2 with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2 respectively. IC50 value: 1.28 nM/1.85 nM(LRRK2/G2019S LRRK2) [1] Target: LRRK2 inhibitor in vitro: CZC-54252 inhibited the activity of recombinant human wild-type LRRK2 with an IC50 ranging from 1...

Purity: 99.26%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



GNE-7915

Cat. No.: HY-18163

Bioactivity: GNE-7915 is a potent, selective and brain-penetrant inhibitor of **LRRK2** with an **IC_{50}** of 9 nM.

Purity: 99.48%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



GNE-7915 tosylate

Cat. No.: HY-18163A

Bioactivity: GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of **LRRK2** with an **IC_{50}** of 9 nM.

Purity: 98.94%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



GNE-9605

Cat. No.: HY-12282

Bioactivity: GNE-9605 is a highly potent, selective, and brain-penetrant LRRK2 inhibitor with IC50 of 19 nM. IC50 value: Target: LRRK2 GNE-9605 retained excellent predicted human metabolic stability when assayed in human liver microsomes and hepatocytes. In addition, no reversible or time-dependent...

Purity: 99.26%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



GNE0877

Cat. No.: HY-15796

Bioactivity: GNE0877 is a highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitor with an IC50 of 3 nM. IC50 value: 3 nM [1] Target: LRRK2 Invitrogen kinase-selectivity profiling(188 kinases) of aminopyrazole GNE0877 at 0.1 μM (145-fold...

Purity: 98.64%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg



GSK2578215A

Cat. No.: HY-13237

Bioactivity: GSK2578215A is a potent and highly selective **LRRK2** inhibitor, which exhibits **IC_{50}**s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.

Purity: 99.86%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



HG-10-102-01

Cat. No.: HY-13488

Bioactivity: HG-10-102-01 is a potent and selective inhibitor of wild-type LRRK2(IC50=23.3 nM) and the G2019S mutant(IC50=3.2 nM) IC50 Value: 23.3 nM (WT LRRK2); 3.2 nM (LRRK2 G2019S) [1] Target: LRRK2 HG-10-102-01 maintains the ability to potently inhibit the biochemical activity of wild-type and G2019S mutant LRRK2....

Purity: 99.54%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



IKK 16

Cat. No.: HY-13687

Bioactivity: IKK 16 is a selective IκB kinase (**IKK**) inhibitor for **IKK2**, **IKK complex** and **IKK1** with **IC_{50}**s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (**LRRK2**) with an **IC_{50}** of 50 nM.

Purity: 99.78%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



IKK 16 hydrochloride

Cat. No.: HY-13687A

Bioactivity: IKK 16 hydrochloride is a selective IκB kinase (**IKK**) inhibitor for **IKK2**, **IKK complex** and **IKK1** with **IC_{50}**s of 40 nM, 70 nM and 200 nM, respectively [1]. IKK16 also inhibits leucine-rich repeat kinase-2 (**LRRK2**) with an **IC_{50}** of 50 nM [2].

Purity: >98%

Clinical Data: No Development Reported

Size:



JH-II-127

Cat. No.: HY-16936

Bioactivity: JH-II-127 is a highly potent, selective, and brain penetrant LRRK2 inhibitor, with IC50 of 6.6 nM, 2.2 nM ,47.7 nM for LRRK2-wild-type, LRRK2-G2019S, LRRK2-A2016T. IC50 value: 2.2 n(LRRK2-G2019S), 6.6 nM(LRRK2-wild-type), 47.7 nM (LRRK2-A2016T) Target: LRRK2 JH-II-127 is a potent and...

Purity: 98.66%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



LRRK2 inhibitor 1

Cat. No.: HY-111493

Bioactivity: LRRK2 inhibitor 1 is a potent, selective and oral **LRRK2** inhibitor with an **pIC_{50}** of 6.8 nM.

Purity: 99.72%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



LRRK2-IN-1

Cat. No.: HY-10875

Bioactivity: LRRK2-IN-1 is a potent and selective **LRRK2** inhibitor with **IC_{50}** of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.

Purity: 99.38%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



MLi-2

Cat. No.: HY-100411

Bioactivity: MLi-2 is an a potent, highly selective, orally available, brain penetrant inhibitor of **LRRK2** with an **IC_{50}** of 0.76 nM.

Purity: 99.66%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PF-06447475

Cat. No.: HY-12477

Bioactivity: PF-06447475 is a highly potent, selective and brain penetrant **LRRK2** inhibitor with an **IC_{50}** of 3 nM.

Purity: 99.88%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



Mitophagy

Mitochondrial Autophagy



Mitophagy is the selective degradation of mitochondria by autophagy.

Mitochondria are essential organelles that regulate cellular energy homeostasis and cell death. The removal of damaged mitochondria through autophagy, a process called mitophagy, is thus critical for maintaining proper cellular functions. Indeed, mitophagy has been recently proposed to play critical roles in terminal differentiation of red blood cells, paternal mitochondrial degradation, neurodegenerative diseases, and ischemia or drug-induced tissue injury.

Autophagy and mitophagy are important cellular processes that are responsible for breaking down cellular contents, preserving energy and safeguarding against accumulation of damaged and aggregated biomolecules.

3-Methyladenine

(3-MA) Cat. No.: HY-19312

Bioactivity: 3-Methyladenine is a **PI3K** inhibitor. 3-Methyladenine is a widely used inhibitor of **autophagy** via its inhibitory effect on class III PI3K.

Purity: 99.84%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 200 mg, 500 mg



5-Aminolevulinic acid hydrochloride

(ALA; 5-ALA) Cat. No.: HY-N0305

Bioactivity: 5-Aminolevulinic acid HCl is an intermediate in heme biosynthesis in the body and the universal precursor of tetrapyrroles. Target: Others 5-Aminolevulinic acid is a non-fluorescent prodrug that leads to intracellular accumulation of fluorescent porphyrins in malignant gliomas-a...

Purity: 98.0%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 100 mg, 1 g, 5 g, 10 g



ABT-737

Cat. No.: HY-50907

Bioactivity: ABT-737 is a selective and BH3 mimetic **Bcl-xL**, **Bcl-2** and **Bcl-w** inhibitor with **EC_{50}**s of 78.7 nM, 30.3 nM and 197.8 nM, respectively.

Purity: 99.59%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



AICAR

(Acadesine; AICA Riboside) Cat. No.: HY-13417

Bioactivity: AICAR is a cell-permeable AMP-activated protein kinase (**AMPK**) activator.

Purity: 99.92%
Clinical Data: Phase 3
Size: 10mM x 1mL in Water, 50 mg, 100 mg, 200 mg, 500 mg



AICAR phosphate

(Acadesine phosphate; AICA Riboside phosphate) Cat. No.: HY-13417A

Bioactivity: AICAR phosphate is an activator of AMP-activated protein kinase (**AMPK**).

Purity: 98.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in Water, 50 mg, 100 mg, 200 mg, 500 mg



Aspirin

(ASA; Acetylsalicylic Acid) Cat. No.: HY-14654

Bioactivity: Aspirin is a non-selective and irreversible inhibitor of **COX-1** and **COX-2** with **IC_{50}**s of 5 and 210 μg/mL.

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Betulinic acid

(Lupatic acid; Betulic acid) Cat. No.: HY-10529

Bioactivity: Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic **topoisomerase I** inhibitor, with an **IC_{50}** of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties.

Purity: 98.18%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Brefeldin A

(BFA; Cyanein; Decumbin) Cat. No.: HY-16592

Bioactivity: Brefeldin A is a specific inhibitor of **protein trafficking** which blocks the protein transport from the endoplasmic reticulum to the Golgi complex.

Purity: 99.79%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Carbamazepine

(CBZ; NSC 169864) Cat. No.: HY-B0246

Bioactivity: Carbamazepine, a sodium channel blocker, is an anticonvulsant drug. Target: Sodium channel Carbamazepine inhibits the binding of [3H]batrachotoxinin A 20-α-benzoate (BTX-B) to a receptor site of voltage-sensitive sodium channel with IC50 of 131 μM, to decrease the activation of sodium channel ion flux...

Purity: 99.35%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Clioquinol

(Iodochlorhydroxyquin) Cat. No.: HY-14603

Bioactivity: Clioquinol(Iodochlorhydroxyquin) is an antifungal drug and antiprotozoal compound that shows effectivity for Alzheimer's disease treatment and induce cancer cell death.

Purity: 98.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Cresol (Cresol mixture of isomers; Hydroxytoluene; Tricresol; Methylphenol)

Cat. No.: HY-B0969

Bioactivity: Cresol is organic compoundis a widely occurring natural and manufactured group of aromatic organic compounds.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 g



Curcumin (Turmeric yellow; Natural Yellow 3; Diferuloylmethane)

Cat. No.: HY-N0005

Bioactivity: Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (**HATs**) and also shows inhibitory effects on **NF-κB** and...

Purity: 99.66%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



D-Glutamine

Cat. No.: HY-100587

Bioactivity: D-Glutamine is a cell-permeable D type stereoisomer of Glutamine.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 50 mg, 100 mg



Deferoxamine mesylate (Desferrioxamine B mesylate; DFOM)

Cat. No.: HY-B0988

Bioactivity: Deferoxamine mesylate is an iron chelator that binds free iron in a stable complex, preventing it from engaging in chemical reactions.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 500 mg



Dexamethasone (Hexadecadrol; Prednisolone F)

Cat. No.: HY-14648

Bioactivity: Dexamethasone is a **glucocorticoid receptor** agonist.

Purity: 99.86%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Dexamethasone acetate (Dexamethasone 21-acetate)

Cat. No.: HY-14648A

Bioactivity: Dexamethasone acetate is a **glucocorticoid receptor** agonist.

Purity: 97.68%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Doxazosin mesylate (UK 33274 mesylate)

Cat. No.: HY-B0098A

Bioactivity: Doxazosin mesylate(UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. Target: α1-adrenergic receptor Doxazosin (mesylate) is the mesylate salt form of doxazosin, which is a long-lasting inhibitor of α1-adrenoceptors that is widely used to treat...

Purity: 98.60%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 500 mg, 1 g



Doxorubicin (Hydroxydaunorubicin)

Cat. No.: HY-15142A

Bioactivity: Doxorubicin is a cytotoxic anthracycline antibiotic for the treatment of multiple cancers. The possible mechanisms by which doxorubicin acts in the cancer cell are intercalation into DNA and disruption of **topoisomerase-II**-mediated DNA repair.

Purity: >98%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg



Doxorubicin hydrochloride (Hydroxydaunorubicin (hydrochloride))

Cat. No.: HY-15142

Bioactivity: Doxorubicin hydrochloride is a cytotoxic anthracycline antibiotic for the treatment of multiple cancers. The possible mechanisms by which doxorubicin acts in the cancer cell are intercalation into DNA and disruption of **topoisomerase-II**-mediated DNA repair.

Purity: 99.47%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Esmolol hydrochloride

Cat. No.: HY-B1392

Bioactivity: Esmolol Hydrochloride is a beta adrenergic receptor blocker. Target: Adrenergic receptor Esmolol Hydrochloride is the hydrochloride salt form of Esmolol, a short and rapid-acting beta adrenergic antagonist belonging to the class II anti-arrhythmic drugs and devoid of intrinsic sympathomimetic...

Purity: 99.77%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Etoposide

(VP-16; VP-16-213) Cat. No.: HY-13629

Bioactivity: Etoposide (VP-16; VP-16-213), a chemotherapy medication used for the treatments of a number of types of cancer, inhibits **DNA synthesis** by forming a complex with topoisomerase II and DNA. Etoposide arrests cell cycle in G2 and induces apoptos...

Purity: 99.65%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Ginsenoside Rb1

(Gypenoside III) Cat. No.: HY-N0039

Bioactivity: Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits **Na^+, K^+-ATPase** activity with an **IC_{50}** of 6.3±1.0 μM. Ginsenoside also inhibits **IRAK-1** activation and phosphorylation of **NF-κB p65** .

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



GSK2578215A

Cat. No.: HY-13237

Bioactivity: GSK2578215A is a potent and highly selective **LRRK2** inhibitor, which exhibits **IC_{50}**s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.

Purity: 99.86%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Hemin

(Hemin chloride) Cat. No.: HY-19424

Bioactivity: Hemin is an iron-containing porphyrin. Hemin is an **Heme oxygenase (HO)-1** inducer.

Purity: 98.0%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Iohexol

Cat. No.: HY-B0594

Bioactivity: Iohexol is a contrast agent. Target: Others Iohexol is a contrast agent. The osmolality of iohexol ranges from 322 mOsm/kg-approximately 1.1 times that of blood plasma-to 844 mOsm/kg, almost three times that of blood. Despite this difference, iohexol is still considered a low-osmolality...

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Isoniazid

(INH; Isonicotinic acid hydrazide; Isonicotinic hydrazide) Cat. No.: HY-B0329

Bioactivity: Isoniazid is an antibacterial agent used primarily as a tuberculostatic. Target: Antibacterial Isoniazid is a prodrug and must be activated by a bacterial catalase-peroxidase enzyme that in M. tuberculosis is called KatG [1]. KatG couples the isonicotinic acyl with NADH to form isonicotinic...

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg



Ivermectin

(MK-933) Cat. No.: HY-15310

Bioactivity: Ivermectin (MK-933) is a widely used antiparasitic agent in human and veterinary medicine. It is a positive allosteric effector of **$P2X_4$** and the α7 neuronal nicotinic acetylcholine receptor (**nAChRs**).

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 500 mg, 1 g



Kaempferol

(Robigenin; Kempferol) Cat. No.: HY-14590

Bioactivity: Kaempferol inhibits **estrogen receptor α** expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK.

Purity: 99.47%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Luteolin

(Luteolol; Digitoflavone; Luteoline) Cat. No.: HY-N0162

Bioactivity: Luteolin (Luteolol) is a falconoid compound, which exhibits anticancer properties.

Purity: 98.14%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 500 mg



Matrine

(Matridin-15-one; Vegard; α-Matrine) Cat. No.: HY-N0164

Bioactivity: Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus. It has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor and u-receptor agonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Melatonin

(N-Acetyl-5-methoxytryptamine) **Cat. No.:** HY-B0075

Bioactivity: Melatonin is a hormone made by the pineal gland that can activates **melatonin receptor**. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties.

Purity: 98.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Metformin hydrochloride

(1,1-Dimethylbiguanide hydrochloride) **Cat. No.:** HY-17471A

Bioactivity: Metformin (hydrochloride) is an FDA approved first-line drug for the treatment of type 2 diabetes. Metformin decreases hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory-chain complex 1.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 10 g, 50 g



Naringin

(Naringoside) **Cat. No.:** HY-N0153

Bioactivity: Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities.

Purity: 99.79%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 200 mg, 10 g



Olanzapine

(LY170053) **Cat. No.:** HY-14541

Bioactivity: Olanzapine(LY170053) is a high affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist. IC50 Value: Target: 5-HT Receptor Olanzapine is a thienobenzodiazepine that blocks especially the serontonin (5-hydroxytryptamine [5-HT]) 5-HT2A and the dopamine D2 receptors (Ki values are 4 and 11 nM...

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg



Olaparib

(AZD2281; KU0059436) **Cat. No.:** HY-10162

Bioactivity: Olaparib (AZD2281;KU0059436) is a potent and oral **PARP** inhibitor with **IC_{50}**s of 5 and 1 nM for **PARP1** and **PARP2**, respectively.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g



Oxidopamine hydrobromide

(6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide) **Cat. No.:** HY-B1081A

Bioactivity: Oxidopamine (hydrobromide), an antagonist of the **neurotransmitter dopamine**, is a widely used neurotoxin that selectively destroys dopaminergic neurons.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Parthenolide

((-)-Parthenolide) **Cat. No.:** HY-N0141

Bioactivity: Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting **NF-κB** activation; also inhibits **HDAC1** protein without affecting other class I/II HDACs.

Purity: 99.88%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg



Pitavastatin Calcium

(Pitavastatin (hemicalcium); NK-104 (hemicalcium)) **Cat. No.:** HY-B0144

Bioactivity: Pitavastatin Calcium is a potent **hydroxymethylglutaryl-CoA (HMG-CoA) reductase** inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an **IC_{50}** of 5.8 nM in HepG2 cells.

Purity: 99.94%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Polydatin

(Piceid) **Cat. No.:** HY-N0120A

Bioactivity: Polydatin (Piceid), extracted from the roots of Polygonum cuspidatum Sieb, a widely used traditional Chinese remedies, possesses anti-inflammatory activity in several experimental models.

Purity: 98.42%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Quercetin

Cat. No.: HY-18085

Bioactivity: Quercetin, a natural flavonoid, is a stimulator of recombinant **SIRT1** and also a **PI3K** inhibitor with **IC_{50}** of 2.4±0.6 μM, 3.0±0.0 μM and 5.4±0.3 μM for PI3K γ, PI3K δ and PI3K β, respectively.

Purity: 98.0%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 1 g, 5 g



Quinacrine dihydrochloride

(Mepacrine dihydrochloride; SN-390) **Cat. No.:** HY-13735A

Bioactivity: Quinacrine is a fluorescent probe for the conformational transitions of the cholinergic receptor protein. Quinacrine shows activity in the low μM range with a mean IC50 of 2.30 μM In the patient AML cells. IC50 value: 2.30 μM (for AML cells) Target: in vitro: Quinacrine is a fluorescent probe for the...

Purity: 98.05%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg



Ruxolitinib

(INCB018424) **Cat. No.:** HY-50856

Bioactivity: Ruxolitinib is a potent and selective **JAK1/2** inhibitor with **IC_{50}**s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Ruxolitinib phosphate

(INCB018424 phosphate) **Cat. No.:** HY-50858

Bioactivity: Ruxolitinib phosphate is a potent **JAK1/2** inhibitor with **IC_{50}**s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g



Salicylic acid

(2-Hydroxybenzoic acid) **Cat. No.:** HY-B0167

Bioactivity: Salicylic acid inhibits cyclo-oxygenase-2 (**COX-2**) activity independently of transcription factor (NF-κB) activation.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 g, 50 g



Salinomycin

(Procoxacin) **Cat. No.:** HY-15597

Bioactivity: Salinomycin is an anticoccidial drug with potent **anti-bacterial** activity and an novel anticancer agent targeting human cancer stem cells.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

SB 203580

(RWJ 64809) **Cat. No.:** HY-10256

Bioactivity: SB 203580 (RWJ 64809) is a widely used **p38 MAPK** inhibitor with an **IC_{50}** of 0.3-0.5 μM. SB 203580 (RWJ 64809) shows more than 100-fold selectivity over Akt (PKB), LCK, and GSK-3β.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



SB 203580 hydrochloride

(RWJ 64809 hydrochloride) **Cat. No.:** HY-10256A

Bioactivity: SB 203580 hydrochloride (RWJ 64809 hydrochloride) is a widely used **p38 MAPK** inhibitor with an **IC_{50}** of 0.3-0.5 μM. SB 203580 hydrochloride shows more than 100-fold selectivity over Akt (PKB), LCK, and GSK-3β.

Purity: 99.71%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



Simvastatin

(MK 733) **Cat. No.:** HY-17502

Bioactivity: Simvastatin (MK 733) is a competitive inhibitor of **HMG-CoA reductase** with a **K_i** of 0.2 nM.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg



Sunitinib

(SU 11248) **Cat. No.:** HY-10255A

Bioactivity: Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with **IC_{50}**s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.

Purity: 99.66%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Tanespimycin

(17-AAG; NSC 330507; CP 127374) **Cat. No.:** HY-10211

Bioactivity: Tanespimycin (17-AAG) is a potent **HSP90** inhibitor with an **IC_{50}** of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90.

Purity: 99.03%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 100 mg, 200 mg



Torkinib
(PP 242) **Cat. No.:** HY-10474

Bioactivity: Torkinib (PP 242) is a selective and ATP-competitive **mTOR** inhibitor with an **IC_{50}** of 8 nM. PP242 inhibits both **mTORC1** and **mTORC2** with **IC_{50}**s of 30 nM and 58 nM, respectively.

Purity: 95.47%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Tripterin
(Celastrol) **Cat. No.:** HY-13067

Bioactivity: Tripterin (Celastrol) is a **proteasome** inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified **20S proteasome** with **IC_{50}** of 2.5 μM.

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



U0126
(U0126-EtOH) **Cat. No.:** HY-12031

Bioactivity: U0126 is a potent and non-ATP competitive **MEK1** and **MEK2** inhibitor, with **IC_{50}**s of 70 nM and 60 nM, respectively.

Purity: 98.06%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



URB-597
(KDS-4103) **Cat. No.:** HY-10864

Bioactivity: URB597 is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. IC50 value: 4.6 nM [1] Target: FAAH in vitro: URB597 binds in the hydrophobic pocket and catalytic core of FAAH that connects the active site residues to the membrane surface...

Purity: 98.71%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Valproic acid
(VPA; 2-Propylpentanoic Acid) **Cat. No.:** HY-10585

Bioactivity: Valproic acid is an **HDAC** inhibitor, with **IC_{50}** in the range of 0.5 and 2 mM, also inhibits **HDAC1** (**IC_{50}**, 400 μM), and induces proteasomal degradation of **HDAC2**; Valproic acid sodium salt is used in the treatment of epilepsy, bipo...

Purity: 98.67%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g, 5 g, 25 g



Valproic acid sodium salt
(Sodium Valproate) **Cat. No.:** HY-10585A

Bioactivity: Valproic acid sodium salt is an anticonvulsants used to treat epilepsy, bipolar disorder and migraines. Valproic acid inhibits **histone deacetylase 1 (HDAC1)** with an **IC_{50}** of 0.4 mM.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 1 g, 5 g, 25 g



Vorinostat
(SAHA) **Cat. No.:** HY-10221

Bioactivity: Vorinostat is a potent and orally available inhibitor of **HDAC1**, **HDAC2** and **HDAC3 (Class I)**, **HDAC7 (Class II)** and **HDAC11 (Class IV)**, with **ID_{50}** values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively.

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 250 mg, 500 mg, 1 g, 5 g



ULK

Unc-51 like kinase



ULK1, a serine/threonine protein kinase, is an enzyme that in humans is encoded by the ULK1 gene. ULK1 is essential for the initial stages of autophagy. ULK1 is an important protein in autophagy. It is part of the ULK1-complex, which is needed in early steps of autophagosome biogenesis. ULK1 inhibition results in accumulation of stalled early autophagosomal structures, indicating a role for ULK1 in the maturation of autophagosomes as well as initiation.

ULK2 is essential for astrocyte transformation and tumor growth. ULK2 also inhibits the growth of glioma cells, which requires autophagy induction as kinase mutant of ULK2 fails to induce autophagy and inhibit growth. ULK2 and its homologue ULK1 are only down-regulated in all grades of glioma. Thus these results altogether suggest that inhibition of autophagy by ULK1/2 down-regulation is essential for glioma development.

LYN-1604

(LYN1604; LYN 1604)

Cat. No.: HY-101923

Bioactivity: LYN-1604 is a potent UNC-51-like kinase 1 (**ULK1**) agonist with an **EC_{50}** of 18.94 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



LYN-1604 hydrochloride

Cat. No.: HY-101923A

Bioactivity: LYN-1604 hydrochloride is a potent **ULK1** activator with an **EC_{50}** of 18.94 nM.

Purity: 99.80%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



MRT67307

Cat. No.: HY-13018

Bioactivity: MRT67307 is a dual inhibitor of the **IKKε** and **TBK-1** with **IC_{50}**s of 160 and 19 nM, respectively. MRT67307 also inhibits ULK1 and ULK2 with IC $_{50}$s of 45 and 38 nM, respectively.

Purity: 99.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg

MRT68921

Cat. No.: HY-100006

Bioactivity: MRT68921 is the most potent inhibitor of **ULK1** and **ULK2**, with **IC_{50}** values of 2.9 nM and 1.1 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



MRT68921 dihydrochloride

Cat. No.: HY-100006A

Bioactivity: MRT68921 dihydrochloride is the most potent inhibitor of **ULK1** and **ULK2**, with **IC_{50}** values of 2.9 nM and 1.1 nM, respectively.

Purity: 99.38%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



SBI-0206965

Cat. No.: HY-16966

Bioactivity: SBI-0206965 is a potent, selective and cell permeable autophagy kinase **ULK1** inhibitor with **IC_{50}** of 108 nM for ULK1 kinase and 711 nM for the highly related kinase ULK2 .

Purity: 98.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



ULK-101

Cat. No.: HY-114490

Bioactivity: ULK-101 is a potent and selective **ULK1** inhibitor, with **IC_{50}** values of 1.6 nM and 30 nM for ULK1 and ULK2, respectively. ULK-101 suppresses autophagy and sensitizes cancer cells to nutrient stress [1].

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg